<p>3000,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3001,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3002,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3003,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3004,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3005,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3006,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3007,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3008,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3009,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3010,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3011,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3012,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3013,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3014,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3015,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3016,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3017,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3018,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3019,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3020,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3021,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3022,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3023,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3024,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3025,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3026,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3027,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3028,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3029,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3030,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3031,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3032,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3033,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3034,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3035,"ZEBETA should be used with care when myocardial_depressants or inhibitors of AV conduction, such as certain calcium_antagonists (particularly of the phenylalkylamine [ verapamil ] and benzothiazepine [ diltiazem ] classes), or antiarrhythmic_agents , such as disopyramide , are used concurrently."</p>
<p>3036,"Concurrent use of rifampin increases the metabolic clearance of ZEBETA , resulting in a shortened elimination half-life of ZEBETA ."</p>
<p>3037,"Concurrent use of rifampin increases the metabolic clearance of ZEBETA , resulting in a shortened elimination half-life of ZEBETA ."</p>
<p>3038,There was no effect of ZEBETA on prothrombin time in patients on stable doses of warfarin .</p>
<p>3039,"If you are also using a steroid inhaler, take bitolterol first and then wait about # minutes before using the steroid inhaler."</p>
<p>3040,"If you are also using a steroid inhaler, take bitolterol first and then wait about # minutes before using the steroid inhaler."</p>
<p>3041,"This allows bitolterol to open air passages, increasing the effectiveness of the steroid ."</p>
<p>3042,"In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin , warfarin , thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications."</p>
<p>3043,"In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin , warfarin , thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications."</p>
<p>3044,"In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin , warfarin , thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications."</p>
<p>3045,There is no experience with co-administration of Angiomax and plasma expanders such as dextran .</p>
<p>3046,"Among # subjects who received Angiomax in clinical trials and were tested for antibodies, # subjects had treatment-emergent positive bivalirudin antibody tests."</p>
<p>3047,Patients on oral antidiabetic_agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic_medication .</p>
<p>3048,Patients on oral antidiabetic_agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic_medication .</p>
<p>3049,Patients on oral antidiabetic_agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic_medication .</p>
<p>3050,"Hormonal_Contraceptives , Including Oral, Injectable, Transdermal, and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal_contraceptive  Ortho-Novum produced average decreases of norethindrone and ethinyl_estradiol levels of 14% and 31%, respectively."</p>
<p>3051,"Hormonal_Contraceptives , Including Oral, Injectable, Transdermal, and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal_contraceptive  Ortho-Novum produced average decreases of norethindrone and ethinyl_estradiol levels of 14% and 31%, respectively."</p>
<p>3052,"Hormonal_Contraceptives , Including Oral, Injectable, Transdermal, and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal_contraceptive  Ortho-Novum produced average decreases of norethindrone and ethinyl_estradiol levels of 14% and 31%, respectively."</p>
<p>3053,"Hormonal_Contraceptives , Including Oral, Injectable, Transdermal, and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal_contraceptive  Ortho-Novum produced average decreases of norethindrone and ethinyl_estradiol levels of 14% and 31%, respectively."</p>
<p>3054,"Hormonal_Contraceptives , Including Oral, Injectable, Transdermal, and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal_contraceptive  Ortho-Novum produced average decreases of norethindrone and ethinyl_estradiol levels of 14% and 31%, respectively."</p>
<p>3055,"Hormonal_Contraceptives , Including Oral, Injectable, Transdermal, and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal_contraceptive  Ortho-Novum produced average decreases of norethindrone and ethinyl_estradiol levels of 14% and 31%, respectively."</p>
<p>3056,"Hormonal_Contraceptives , Including Oral, Injectable, Transdermal, and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal_contraceptive  Ortho-Novum produced average decreases of norethindrone and ethinyl_estradiol levels of 14% and 31%, respectively."</p>
<p>3057,"Hormonal_Contraceptives , Including Oral, Injectable, Transdermal, and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal_contraceptive  Ortho-Novum produced average decreases of norethindrone and ethinyl_estradiol levels of 14% and 31%, respectively."</p>
<p>3058,"Hormonal_Contraceptives , Including Oral, Injectable, Transdermal, and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal_contraceptive  Ortho-Novum produced average decreases of norethindrone and ethinyl_estradiol levels of 14% and 31%, respectively."</p>
<p>3059,"Hormonal_Contraceptives , Including Oral, Injectable, Transdermal, and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal_contraceptive  Ortho-Novum produced average decreases of norethindrone and ethinyl_estradiol levels of 14% and 31%, respectively."</p>
<p>3060,"Therefore, hormonal_contraceptives , including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered."</p>
<p>3061,Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine_A .</p>
<p>3062,The concomitant administration of bosentan and cyclosporine_A is contraindicated.</p>
<p>3063,Co-administration of bosentan decreased the plasma concentrations of cyclosporine_A (a CYP3A4 substrate) by approximately 50%.</p>
<p>3064,Tacrolimus : Co-administration of tacrolimus and bosentan has not been studied in man.</p>
<p>3065,Tacrolimus : Co-administration of tacrolimus and bosentan has not been studied in man.</p>
<p>3066,Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.</p>
<p>3067,Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.</p>
<p>3068,Caution should be exercised if tacrolimus and bosentan are used together.</p>
<p>3069,"Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic_agents should be considered."</p>
<p>3070,"Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic_agents should be considered."</p>
<p>3071,"Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic_agents should be considered."</p>
<p>3072,Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.</p>
<p>3073,Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic_agents that are predominantly metabolized by CYP2C9 or CYP3A4.</p>
<p>3074,"Ketoconazole : Co-administration of bosentan # mg b,i,d, and ketoconazole , a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold."</p>
<p>3075,"Ketoconazole : Co-administration of bosentan # mg b,i,d, and ketoconazole , a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold."</p>
<p>3076,"Ketoconazole : Co-administration of bosentan # mg b,i,d, and ketoconazole , a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold."</p>
<p>3077,"Ketoconazole : Co-administration of bosentan # mg b,i,d, and ketoconazole , a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold."</p>
<p>3078,"Simvastatin and Other Statins : Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active -hydroxy acid metabolite, by approximately 50%."</p>
<p>3079,"Simvastatin and Other Statins : Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active -hydroxy acid metabolite, by approximately 50%."</p>
<p>3080,"Simvastatin and Other Statins : Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active -hydroxy acid metabolite, by approximately 50%."</p>
<p>3081,"Simvastatin and Other Statins : Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active -hydroxy acid metabolite, by approximately 50%."</p>
<p>3082,"Simvastatin and Other Statins : Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active -hydroxy acid metabolite, by approximately 50%."</p>
<p>3083,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin ."</p>
<p>3084,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin ."</p>
<p>3085,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin ."</p>
<p>3086,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin ."</p>
<p>3087,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin ."</p>
<p>3088,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin ."</p>
<p>3089,Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.</p>
<p>3090,Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.</p>
<p>3091,"Warfarin : Co-administration of bosentan # mg b,i,d, for # days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by # and 38%, respectively."</p>
<p>3092,"Warfarin : Co-administration of bosentan # mg b,i,d, for # days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by # and 38%, respectively."</p>
<p>3093,"Warfarin : Co-administration of bosentan # mg b,i,d, for # days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by # and 38%, respectively."</p>
<p>3094,"Warfarin : Co-administration of bosentan # mg b,i,d, for # days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by # and 38%, respectively."</p>
<p>3095,"Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs, end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan - and placebo-treated patients."</p>
<p>3096,"Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs, end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan - and placebo-treated patients."</p>
<p>3097,"Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs, end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan - and placebo-treated patients."</p>
<p>3098,"Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs, end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan - and placebo-treated patients."</p>
<p>3099,"Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs, end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan - and placebo-treated patients."</p>
<p>3100,"Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs, end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan - and placebo-treated patients."</p>
<p>3101,"Digoxin , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan ."</p>
<p>3102,"Digoxin , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan ."</p>
<p>3103,"Digoxin , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan ."</p>
<p>3104,"Digoxin , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan ."</p>
<p>3105,"Digoxin , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan ."</p>
<p>3106,"Digoxin , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan ."</p>
<p>3107,"Digoxin , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan ."</p>
<p>3108,"Digoxin , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan ."</p>
<p>3109,"Digoxin , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan ."</p>
<p>3110,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e,g,, curare-like_compounds ) should only be performed with caution as the effect of the toxin may be potentiated."</p>
<p>3111,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e,g,, curare-like_compounds ) should only be performed with caution as the effect of the toxin may be potentiated."</p>
<p>3112,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e,g,, curare-like_compounds ) should only be performed with caution as the effect of the toxin may be potentiated."</p>
<p>3113,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e,g,, curare-like_compounds ) should only be performed with caution as the effect of the toxin may be potentiated."</p>
<p>3114,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e,g,, curare-like_compounds ) should only be performed with caution as the effect of the toxin may be potentiated."</p>
<p>3115,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e,g,, curare-like_compounds ) should only be performed with caution as the effect of the toxin may be potentiated."</p>
<p>3116,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e,g,, curare-like_compounds ) should only be performed with caution as the effect of the toxin may be potentiated."</p>
<p>3117,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e,g,, curare-like_compounds ) should only be performed with caution as the effect of the toxin may be potentiated."</p>
<p>3118,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e,g,, curare-like_compounds ) should only be performed with caution as the effect of the toxin may be potentiated."</p>
<p>3119,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e,g,, curare-like_compounds ) should only be performed with caution as the effect of the toxin may be potentiated."</p>
<p>3120,Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium_Tosylate Injection.</p>
<p>3121,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium_Tosylate .</p>
<p>3122,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium_Tosylate .</p>
<p>3123,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium_Tosylate .</p>
<p>3124,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium_Tosylate .</p>
<p>3125,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium_Tosylate .</p>
<p>3126,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium_Tosylate .</p>
<p>3127,"Although there is little published information on concomitant administration of lidocaine and Bretylium_Tosylate , these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy."</p>
<p>3128,"Although specific drug interaction studies have not been conducted with ALPHAGAN_P , the possibility of an additive or potentiating effect with CNS_depressants ( alcohol , barbiturates , opiates , sedatives , or anesthetics ) should be considered."</p>
<p>3129,"Although specific drug interaction studies have not been conducted with ALPHAGAN_P , the possibility of an additive or potentiating effect with CNS_depressants ( alcohol , barbiturates , opiates , sedatives , or anesthetics ) should be considered."</p>
<p>3130,"Although specific drug interaction studies have not been conducted with ALPHAGAN_P , the possibility of an additive or potentiating effect with CNS_depressants ( alcohol , barbiturates , opiates , sedatives , or anesthetics ) should be considered."</p>
<p>3131,"Although specific drug interaction studies have not been conducted with ALPHAGAN_P , the possibility of an additive or potentiating effect with CNS_depressants ( alcohol , barbiturates , opiates , sedatives , or anesthetics ) should be considered."</p>
<p>3132,"Although specific drug interaction studies have not been conducted with ALPHAGAN_P , the possibility of an additive or potentiating effect with CNS_depressants ( alcohol , barbiturates , opiates , sedatives , or anesthetics ) should be considered."</p>
<p>3133,"Although specific drug interaction studies have not been conducted with ALPHAGAN_P , the possibility of an additive or potentiating effect with CNS_depressants ( alcohol , barbiturates , opiates , sedatives , or anesthetics ) should be considered."</p>
<p>3134,"Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac_glycosides is advised."</p>
<p>3135,"Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac_glycosides is advised."</p>
<p>3136,"Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac_glycosides is advised."</p>
<p>3137,"Tricyclic_antidepressants have been reported to blunt the hypotensive effect of systemic clonidine ,It is not known whether the concurrent use of these agents with ALPHAGAN_P in humans can lead to resulting interference with the IOP lowering effect."</p>
<p>3138,"Tricyclic_antidepressants have been reported to blunt the hypotensive effect of systemic clonidine ,It is not known whether the concurrent use of these agents with ALPHAGAN_P in humans can lead to resulting interference with the IOP lowering effect."</p>
<p>3139,"Tricyclic_antidepressants have been reported to blunt the hypotensive effect of systemic clonidine ,It is not known whether the concurrent use of these agents with ALPHAGAN_P in humans can lead to resulting interference with the IOP lowering effect."</p>
<p>3140,AZOPT ( brinzolamide ophthalmic suspension) 1% contains a carbonic_anhydrase_inhibitor .</p>
<p>3141,AZOPT ( brinzolamide ophthalmic suspension) 1% contains a carbonic_anhydrase_inhibitor .</p>
<p>3142,"However, in patients treated with oral carbonic_anhydrase_inhibitors , rare instances of drug interactions have occurred with high-dose salicylate therapy."</p>
<p>3143,"The risk of using bromocriptine_mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine_mesylate ."</p>
<p>3144,"The risk of using bromocriptine_mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine_mesylate ."</p>
<p>3145,"Bromocriptine_mesylate may interact with dopamine_antagonists , butyrophenones , and certain other agents."</p>
<p>3146,"Bromocriptine_mesylate may interact with dopamine_antagonists , butyrophenones , and certain other agents."</p>
<p>3147,"Bromocriptine_mesylate may interact with dopamine_antagonists , butyrophenones , and certain other agents."</p>
<p>3148,"Compounds in these categories result in a decreased efficacy of bromocriptine_mesylate : phenothiazines , haloperidol , metoclopramide , pimozide ."</p>
<p>3149,"Compounds in these categories result in a decreased efficacy of bromocriptine_mesylate : phenothiazines , haloperidol , metoclopramide , pimozide ."</p>
<p>3150,"Compounds in these categories result in a decreased efficacy of bromocriptine_mesylate : phenothiazines , haloperidol , metoclopramide , pimozide ."</p>
<p>3151,"Compounds in these categories result in a decreased efficacy of bromocriptine_mesylate : phenothiazines , haloperidol , metoclopramide , pimozide ."</p>
<p>3152,"Compounds in these categories result in a decreased efficacy of bromocriptine_mesylate : phenothiazines , haloperidol , metoclopramide , pimozide ."</p>
<p>3153,"Compounds in these categories result in a decreased efficacy of bromocriptine_mesylate : phenothiazines , haloperidol , metoclopramide , pimozide ."</p>
<p>3154,"Compounds in these categories result in a decreased efficacy of bromocriptine_mesylate : phenothiazines , haloperidol , metoclopramide , pimozide ."</p>
<p>3155,Concomitant use of bromocriptine_mesylate with other ergot_alkaloids is not recommended.</p>
<p>3156,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3157,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3158,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3159,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3160,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3161,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3162,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3163,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3164,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3165,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3166,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3167,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3168,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3169,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3170,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3171,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3172,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3173,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3174,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3175,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3176,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3177,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3178,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3179,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3180,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3181,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3182,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3183,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3184,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3185,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3186,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3187,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3188,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3189,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3190,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3191,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3192,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3193,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3194,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3195,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3196,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3197,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3198,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3199,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3200,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3201,"This drug may interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>3202,Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide .</p>
<p>3203,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole , intraconazole , ritonavir , indinavir , saquinavir , erythromycin , etc,) is indicated, reduction of the budesonide dose should be considered."</p>
<p>3204,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole , intraconazole , ritonavir , indinavir , saquinavir , erythromycin , etc,) is indicated, reduction of the budesonide dose should be considered."</p>
<p>3205,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole , intraconazole , ritonavir , indinavir , saquinavir , erythromycin , etc,) is indicated, reduction of the budesonide dose should be considered."</p>
<p>3206,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole , intraconazole , ritonavir , indinavir , saquinavir , erythromycin , etc,) is indicated, reduction of the budesonide dose should be considered."</p>
<p>3207,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole , intraconazole , ritonavir , indinavir , saquinavir , erythromycin , etc,) is indicated, reduction of the budesonide dose should be considered."</p>
<p>3208,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole , intraconazole , ritonavir , indinavir , saquinavir , erythromycin , etc,) is indicated, reduction of the budesonide dose should be considered."</p>
<p>3209,"- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside_antibiotics are also being given should be avoided, except in life-threatening conditions."</p>
<p>3210,- Lithium : Lithium should generally not be given with diuretics (such as bumetanide ) because they reduce its renal clearance and add a high risk of lithium toxicity.</p>
<p>3211,- Lithium : Lithium should generally not be given with diuretics (such as bumetanide ) because they reduce its renal clearance and add a high risk of lithium toxicity.</p>
<p>3212,- Lithium : Lithium should generally not be given with diuretics (such as bumetanide ) because they reduce its renal clearance and add a high risk of lithium toxicity.</p>
<p>3213,- Lithium : Lithium should generally not be given with diuretics (such as bumetanide ) because they reduce its renal clearance and add a high risk of lithium toxicity.</p>
<p>3214,- Probenecid : Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide .</p>
<p>3215,This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide .</p>
<p>3216,This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide .</p>
<p>3217,"Thus, probenecid should not be administered concurrently with bumetanide ."</p>
<p>3218,- Indomethacin : Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide -induced increase in plasma renin activity.</p>
<p>3219,- Indomethacin : Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide -induced increase in plasma renin activity.</p>
<p>3220,"- Antihypertensives : Bumetanide may potentiate the effect of various antihypertensive_drugs , necessitating a reduction in the dosage of these drugs."</p>
<p>3221,- Anticoagulants : Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity.</p>
<p>3222,- Anticoagulants : Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity.</p>
<p>3223,- Anticoagulants : Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity.</p>
<p>3224,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>3225,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>3226,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>3227,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>3228,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>3229,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>3230,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>3231,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>3232,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors or tricyclic_antidepressants may produce severe, prolonged hypertension."</p>
<p>3233,"Concurrent administration of vasopressor_drugs and of ergot-type_oxytocic_drugs may cause severe, persistent hypertension or cerebrovascular accidents."</p>
<p>3234,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine .</p>
<p>3235,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine .</p>
<p>3236,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine .</p>
<p>3237,"Because CYP 3A4 inhibitors may increase plasma concentrations of buprenorphine , patients already on CYP 3A4 inhibitors such as azole_antifungals (e,g."</p>
<p>3238,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3239,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3240,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3241,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3242,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3243,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3244,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3245,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3246,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3247,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3248,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3249,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3250,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3251,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3252,"ketoconazole ), macrolide_antibiotics (e,g, erythromycin ), and HIV_protease_inhibitors (e,g, ritonavir , indinavir and saquinavir ) should have their dose of SUBUTEX or SUBOXONE adjusted."</p>
<p>3253,"Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines ."</p>
<p>3254,There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.</p>
<p>3255,"In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets."</p>
<p>3256,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse."</p>
<p>3257,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse."</p>
<p>3258,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse."</p>
<p>3259,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX .</p>
<p>3260,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX .</p>
<p>3261,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX .</p>
<p>3262,"Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e,g,, orphenadrine and cyclophosphamide )."</p>
<p>3263,"Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e,g,, orphenadrine and cyclophosphamide )."</p>
<p>3264,The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in # healthy young male volunteers.</p>
<p>3265,"Following oral administration of two 150-mg sustained-release tablets with and without # mg of cimetidine , the pharmacokinetics of bupropion and hydroxybupropion were unaffected."</p>
<p>3266,"Following oral administration of two 150-mg sustained-release tablets with and without # mg of cimetidine , the pharmacokinetics of bupropion and hydroxybupropion were unaffected."</p>
<p>3267,"However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion ."</p>
<p>3268,"Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics ), beta-blockers , antiarrhythmics , and antipsychotics are metabolized by the CYP2D6 isoenzyme."</p>
<p>3269,"In a study of # male subjects (ages # to # years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as # mg twice daily followed by a single dose of # mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively."</p>
<p>3270,"In a study of # male subjects (ages # to # years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as # mg twice daily followed by a single dose of # mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively."</p>
<p>3271,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3272,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3273,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3274,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3275,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3276,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3277,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3278,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3279,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3280,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3281,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3282,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3283,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3284,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3285,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3286,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3287,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3288,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3289,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3290,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3291,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3292,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3293,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3294,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e,g,, nortriptyline , imipramine , desipramine , paroxetine , fluoxetine , sertraline ), antipsychotics (e,g,, haloperidol , risperidone , thioridazine ), beta-blockers (e,g,, metoprolol ), and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication."</p>
<p>3295,MAO_Inhibitors : Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO_inhibitor  phenelzine .</p>
<p>3296,MAO_Inhibitors : Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO_inhibitor  phenelzine .</p>
<p>3297,MAO_Inhibitors : Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO_inhibitor  phenelzine .</p>
<p>3298,Levodopa and Amantadine : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine .</p>
<p>3299,Levodopa and Amantadine : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine .</p>
<p>3300,Levodopa and Amantadine : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine .</p>
<p>3301,Levodopa and Amantadine : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine .</p>
<p>3302,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases."</p>
<p>3303,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases."</p>
<p>3304,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases."</p>
<p>3305,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e,g,, antipsychotics , other antidepressants , theophylline , systemic steroids , etc,) that lower seizure threshold should be undertaken only with extreme caution."</p>
<p>3306,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e,g,, antipsychotics , other antidepressants , theophylline , systemic steroids , etc,) that lower seizure threshold should be undertaken only with extreme caution."</p>
<p>3307,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e,g,, antipsychotics , other antidepressants , theophylline , systemic steroids , etc,) that lower seizure threshold should be undertaken only with extreme caution."</p>
<p>3308,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e,g,, antipsychotics , other antidepressants , theophylline , systemic steroids , etc,) that lower seizure threshold should be undertaken only with extreme caution."</p>
<p>3309,"Alcohol : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN ."</p>
<p>3310,"Alcohol : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN ."</p>
<p>3311,"Alcohol : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN ."</p>
<p>3312,"The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see a href= bupropz_od,htm#CI CONTRAINDICATIONS)"</p>
<p>3313,"It is recommended that buspirone_hydrochloride not be used concomitantly with MAO_inhibitors Because the effects of concomitant administration of buspirone_HCl with most other psychotropic_drugs have not been studied, the concomitant use of buspirone_HCl with other CNS-active drugs should be approached with caution."</p>
<p>3314,"It is recommended that buspirone_hydrochloride not be used concomitantly with MAO_inhibitors Because the effects of concomitant administration of buspirone_HCl with most other psychotropic_drugs have not been studied, the concomitant use of buspirone_HCl with other CNS-active drugs should be approached with caution."</p>
<p>3315,"It is recommended that buspirone_hydrochloride not be used concomitantly with MAO_inhibitors Because the effects of concomitant administration of buspirone_HCl with most other psychotropic_drugs have not been studied, the concomitant use of buspirone_HCl with other CNS-active drugs should be approached with caution."</p>
<p>3316,"It is recommended that buspirone_hydrochloride not be used concomitantly with MAO_inhibitors Because the effects of concomitant administration of buspirone_HCl with most other psychotropic_drugs have not been studied, the concomitant use of buspirone_HCl with other CNS-active drugs should be approached with caution."</p>
<p>3317,"It is recommended that buspirone_hydrochloride not be used concomitantly with MAO_inhibitors Because the effects of concomitant administration of buspirone_HCl with most other psychotropic_drugs have not been studied, the concomitant use of buspirone_HCl with other CNS-active drugs should be approached with caution."</p>
<p>3318,"It is recommended that buspirone_hydrochloride not be used concomitantly with MAO_inhibitors Because the effects of concomitant administration of buspirone_HCl with most other psychotropic_drugs have not been studied, the concomitant use of buspirone_HCl with other CNS-active drugs should be approached with caution."</p>
<p>3319,"It is recommended that buspirone_hydrochloride not be used concomitantly with MAO_inhibitors Because the effects of concomitant administration of buspirone_HCl with most other psychotropic_drugs have not been studied, the concomitant use of buspirone_HCl with other CNS-active drugs should be approached with caution."</p>
<p>3320,"It is recommended that buspirone_hydrochloride not be used concomitantly with MAO_inhibitors Because the effects of concomitant administration of buspirone_HCl with most other psychotropic_drugs have not been studied, the concomitant use of buspirone_HCl with other CNS-active drugs should be approached with caution."</p>
<p>3321,"It is recommended that buspirone_hydrochloride not be used concomitantly with MAO_inhibitors Because the effects of concomitant administration of buspirone_HCl with most other psychotropic_drugs have not been studied, the concomitant use of buspirone_HCl with other CNS-active drugs should be approached with caution."</p>
<p>3322,There is one report suggesting that the concomitant use of trazodone_hydrochloride ( Desyrel ) and buspirone_HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.</p>
<p>3323,There is one report suggesting that the concomitant use of trazodone_hydrochloride ( Desyrel ) and buspirone_HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.</p>
<p>3324,"In a study in normal volunteers, concomitant administration of buspirone_HCl and haloperidol resulted in increased serum haloperidol concentrations."</p>
<p>3325,"In a study in normal volunteers, concomitant administration of buspirone_HCl and haloperidol resulted in increased serum haloperidol concentrations."</p>
<p>3326,"In vitro, buspirone does not displace tightly bound drugs like phenytoin , propranolol , and warfarin from serum proteins."</p>
<p>3327,"In vitro, buspirone does not displace tightly bound drugs like phenytoin , propranolol , and warfarin from serum proteins."</p>
<p>3328,"In vitro, buspirone does not displace tightly bound drugs like phenytoin , propranolol , and warfarin from serum proteins."</p>
<p>3329,"However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin ."</p>
<p>3330,"In vitro, buspirone may displace less firmly bound drugs like digoxin ."</p>
<p>3331,"Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs  # M min in some patients."</p>
<p>3332,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3333,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3334,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3335,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3336,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3337,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3338,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3339,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3340,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3341,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3342,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3343,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3344,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3345,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3346,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3347,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3348,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3349,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3350,"Fluconazole , and the 5-HT3_antiemetics  ondansetron ( Zofran ) and granisetron ( Kytril ) have all been used with BUSULFEX ."</p>
<p>3351,"Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase."</p>
<p>3352,"Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin , the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin ."</p>
<p>3353,"Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin , the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin ."</p>
<p>3354,"Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin , the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin ."</p>
<p>3355,"Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin , the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin ."</p>
<p>3356,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( # hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues."</p>
<p>3357,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( # hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues."</p>
<p>3358,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( # hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues."</p>
<p>3359,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( # hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues."</p>
<p>3360,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( # hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues."</p>
<p>3361,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( # hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues."</p>
<p>3362,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( # hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues."</p>
<p>3363,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( # hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues."</p>
<p>3364,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3365,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3366,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3367,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3368,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3369,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3370,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3371,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3372,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3373,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3374,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3375,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3376,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3377,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3378,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3379,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3380,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3381,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3382,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3383,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3384,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3385,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3386,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3387,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3388,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3389,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3390,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3391,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3392,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3393,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3394,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3395,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3396,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3397,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3398,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3399,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3400,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3401,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3402,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3403,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3404,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3405,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3406,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3407,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3408,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3409,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3410,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3411,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3412,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3413,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3414,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3415,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3416,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3417,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3418,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3419,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3420,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3421,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3422,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3423,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3424,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3425,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3426,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( blood_thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines), central_nervous_system_(CNS)_depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex_sodium , valproic_acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control)."</p>
<p>3427,The CNS effects of butalbital may be enhanced by monoamine_oxidase_(MAO)_inhibitors .</p>
<p>3428,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3429,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3430,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3431,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3432,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3433,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3434,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3435,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3436,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3437,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3438,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3439,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3440,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3441,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3442,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3443,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3444,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3445,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3446,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3447,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3448,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3449,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3450,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3451,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3452,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3453,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3454,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3455,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3456,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3457,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3458,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3459,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3460,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3461,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3462,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3463,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3464,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3465,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3466,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3467,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3468,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3469,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3470,"Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic_analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS_depressants , causing increased CNS depression."</p>
<p>3471,"Concurrent use of butorphanol with central_nervous_system_depressants (e,g,, alcohol , barbiturates , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects."</p>
<p>3472,"Concurrent use of butorphanol with central_nervous_system_depressants (e,g,, alcohol , barbiturates , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects."</p>
<p>3473,"Concurrent use of butorphanol with central_nervous_system_depressants (e,g,, alcohol , barbiturates , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects."</p>
<p>3474,"Concurrent use of butorphanol with central_nervous_system_depressants (e,g,, alcohol , barbiturates , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects."</p>
<p>3475,"Concurrent use of butorphanol with central_nervous_system_depressants (e,g,, alcohol , barbiturates , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects."</p>
<p>3476,"Concurrent use of butorphanol with central_nervous_system_depressants (e,g,, alcohol , barbiturates , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects."</p>
<p>3477,"Concurrent use of butorphanol with central_nervous_system_depressants (e,g,, alcohol , barbiturates , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects."</p>
<p>3478,"Concurrent use of butorphanol with central_nervous_system_depressants (e,g,, alcohol , barbiturates , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects."</p>
<p>3479,"Concurrent use of butorphanol with central_nervous_system_depressants (e,g,, alcohol , barbiturates , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects."</p>
<p>3480,"Concurrent use of butorphanol with central_nervous_system_depressants (e,g,, alcohol , barbiturates , tranquilizers , and antihistamines ) may result in increased central_nervous_system_depressant effects."</p>
<p>3481,"When used concurrently with such drugs, the dose of butorphanol should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of opioids ."</p>
<p>3482,"In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL_NS were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan ."</p>
<p>3483,"In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL_NS were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan ."</p>
<p>3484,"In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL_NS were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan ."</p>
<p>3485,"However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL_NS was administered # minute after a 20-mg dose of sumatriptan nasal spray."</p>
<p>3486,"However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL_NS was administered # minute after a 20-mg dose of sumatriptan nasal spray."</p>
<p>3487,"However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL_NS was administered # minute after a 20-mg dose of sumatriptan nasal spray."</p>
<p>3488,"When the STADOL_NS was administered # minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%."</p>
<p>3489,"When the STADOL_NS was administered # minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%."</p>
<p>3490,"When the STADOL_NS was administered # minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%."</p>
<p>3491,In neither case were the pharmacokinetics of sumatriptan affected by coadministration with STADOL_NS .</p>
<p>3492,"These results suggest that the analgesic effect of STADOL_NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by # minutes any such reduction in effect should be minimal."</p>
<p>3493,The safety of using STADOL_NS and IMITREX ( sumatriptan ) Nasal Spray during the same episode of migraine has not been established.</p>
<p>3494,The safety of using STADOL_NS and IMITREX ( sumatriptan ) Nasal Spray during the same episode of migraine has not been established.</p>
<p>3495,The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL_NS were not affected by the coadministration of cimetidine (300 mg QID).</p>
<p>3496,The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL_NS were not affected by the coadministration of cimetidine (300 mg QID).</p>
<p>3497,The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL_NS were not affected by the coadministration of cimetidine (300 mg QID).</p>
<p>3498,"Conversely, the administration of STADOL_NS (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine ."</p>
<p>3499,"Conversely, the administration of STADOL_NS (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine ."</p>
<p>3500,"It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs ( erythromycin , etc,), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed."</p>
<p>3501,"The fraction of STADOL_NS absorbed is unaffected by the concomitant administration of a nasal_vasoconstrictor ( oxymetazoline ), but the rate of absorption is decreased."</p>
<p>3502,"The fraction of STADOL_NS absorbed is unaffected by the concomitant administration of a nasal_vasoconstrictor ( oxymetazoline ), but the rate of absorption is decreased."</p>
<p>3503,"Therefore, a slower onset can be anticipated if STADOL_NS is administered concomitantly with, or immediately following, a nasal_vasoconstrictor ."</p>
<p>3504,No information is available about the use of butorphanol concurrently with MAO_inhibitors .</p>
<p>3505,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines , butyrophenones , thioxanthines , or metoclopramide ."</p>
<p>3506,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines , butyrophenones , thioxanthines , or metoclopramide ."</p>
<p>3507,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines , butyrophenones , thioxanthines , or metoclopramide ."</p>
<p>3508,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines , butyrophenones , thioxanthines , or metoclopramide ."</p>
<p>3509,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3510,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3511,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3512,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3513,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3514,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3515,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3516,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3517,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3518,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3519,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3520,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3521,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3522,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3523,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3524,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3525,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3526,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3527,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3528,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e,g,, cimetidine and ketoconazole ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e,g,, phenobarbital and phenytoin )."</p>
<p>3529,Caffeine administered concurrently with ketoprofen reduced the urine volume in # healthy volunteers.</p>
<p>3530,Interconversion between caffeine and theophylline has been reported in preterm neonates.</p>
<p>3531,"Interactions for vitamin_D_analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>3532,"Interactions for vitamin_D_analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>3533,"Interactions for vitamin_D_analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>3534,"Interactions for vitamin_D_analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>3535,"Interactions for vitamin_D_analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>3536,"Interactions for vitamin_D_analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>3537,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3538,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3539,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3540,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3541,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3542,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3543,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3544,"Since blood level of calcitriol /ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously."</p>
<p>3545,Some reports have shown that the concomitant administration of thiazides with vitamin_D causes hypercalcemia.</p>
<p>3546,"Digitalis : Vitamin_D dosage must be determined with care in patients undergoing treatment with digitalis , as hypercalcemia in such patients may precipitate cardiac arrhythmias."</p>
<p>3547,Ketoconazole : Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin_D .</p>
<p>3548,"However, in vivo drug interaction studies of ketoconazole with vitamin_D have not been investigated."</p>
<p>3549,"Corticosteroids : A relationship of functional antagonism exists between vitamin_D_analogues , which promote calcium absorption, and corticosteroids , which inhibit calcium absorption."</p>
<p>3550,"Magnesium : Magnesium -containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin_D by patients on chronic renal dialysis."</p>
<p>3551,"Magnesium : Magnesium -containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin_D by patients on chronic renal dialysis."</p>
<p>3552,"Magnesium : Magnesium -containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin_D by patients on chronic renal dialysis."</p>
<p>3553,"Interactions for vitamin_D_analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>3554,"Interactions for vitamin_D_analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>3555,"Interactions for vitamin_D_analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>3556,"Interactions for vitamin_D_analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>3557,"Interactions for vitamin_D_analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>3558,"Interactions for vitamin_D_analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>3559,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3560,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3561,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3562,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3563,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3564,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3565,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>3566,"Since blood level of calcitriol /ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously."</p>
<p>3567,Thiazides : Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.</p>
<p>3568,Some reports have shown that the concomitant administration of thiazides with vitamin_D causes hypercalcemia.</p>
<p>3569,"Digitalis : Vitamin_D dosage must be determined with care in patients undergoing treatment with digitalis , as hypercalcemia in such patients may precipitate cardiac arrhythmias."</p>
<p>3570,Ketoconazole : Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin_D .</p>
<p>3571,"However, in vivo drug interaction studies of ketoconazole with vitamin_D have not been investigated."</p>
<p>3572,"Corticosteroids : A relationship of functional antagonism exists between vitamin_D_analogues , which promote calcium absorption, and corticosteroids , which inhibit calcium absorption."</p>
<p>3573,"Magnesium : Magnesium -containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin_D by patients on chronic renal dialysis."</p>
<p>3574,"Magnesium : Magnesium -containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin_D by patients on chronic renal dialysis."</p>
<p>3575,"Magnesium : Magnesium -containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin_D by patients on chronic renal dialysis."</p>
<p>3576,"Concomitant use with other calcium -containing medicines (including antacids ) may cause too much calcium in the blood or urine, which may increase the chance of side effects."</p>
<p>3577,"Concomitant use with other calcium -containing medicines (including antacids ) may cause too much calcium in the blood or urine, which may increase the chance of side effects."</p>
<p>3578,"Using calcium_acetate with digitalis_glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat."</p>
<p>3579,"Using calcium_acetate with digitalis_glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat."</p>
<p>3580,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3581,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3582,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3583,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3584,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3585,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3586,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3587,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3588,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3589,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3590,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3591,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3592,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3593,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3594,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3595,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3596,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3597,"No significant drug interactions have been reported in studies of candesartan_cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III)."</p>
<p>3598,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE_inhibitors , and with some angiotensin_II_receptor_antagonists ."</p>
<p>3599,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE_inhibitors , and with some angiotensin_II_receptor_antagonists ."</p>
<p>3600,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE_inhibitors , and with some angiotensin_II_receptor_antagonists ."</p>
<p>3601,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE_inhibitors , and with some angiotensin_II_receptor_antagonists ."</p>
<p>3602,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE_inhibitors , and with some angiotensin_II_receptor_antagonists ."</p>
<p>3603,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE_inhibitors , and with some angiotensin_II_receptor_antagonists ."</p>
<p>3604,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE_inhibitors , and with some angiotensin_II_receptor_antagonists ."</p>
<p>3605,"An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND , so careful monitoring of serum lithium levels is recommended during concomitant use."</p>
<p>3606,"An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND , so careful monitoring of serum lithium levels is recommended during concomitant use."</p>
<p>3607,"An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND , so careful monitoring of serum lithium levels is recommended during concomitant use."</p>
<p>3608,Antacid : The effect of an aluminum_hydroxide - and magnesium_hydroxide -containing antacid ( Maalox )* on the pharmacokinetics of capecitabine was investigated in # cancer patients.</p>
<p>3609,Antacid : The effect of an aluminum_hydroxide - and magnesium_hydroxide -containing antacid ( Maalox )* on the pharmacokinetics of capecitabine was investigated in # cancer patients.</p>
<p>3610,Antacid : The effect of an aluminum_hydroxide - and magnesium_hydroxide -containing antacid ( Maalox )* on the pharmacokinetics of capecitabine was investigated in # cancer patients.</p>
<p>3611,Antacid : The effect of an aluminum_hydroxide - and magnesium_hydroxide -containing antacid ( Maalox )* on the pharmacokinetics of capecitabine was investigated in # cancer patients.</p>
<p>3612,Antacid : The effect of an aluminum_hydroxide - and magnesium_hydroxide -containing antacid ( Maalox )* on the pharmacokinetics of capecitabine was investigated in # cancer patients.</p>
<p>3613,Antacid : The effect of an aluminum_hydroxide - and magnesium_hydroxide -containing antacid ( Maalox )* on the pharmacokinetics of capecitabine was investigated in # cancer patients.</p>
<p>3614,Antacid : The effect of an aluminum_hydroxide - and magnesium_hydroxide -containing antacid ( Maalox )* on the pharmacokinetics of capecitabine was investigated in # cancer patients.</p>
<p>3615,Antacid : The effect of an aluminum_hydroxide - and magnesium_hydroxide -containing antacid ( Maalox )* on the pharmacokinetics of capecitabine was investigated in # cancer patients.</p>
<p>3616,Antacid : The effect of an aluminum_hydroxide - and magnesium_hydroxide -containing antacid ( Maalox )* on the pharmacokinetics of capecitabine was investigated in # cancer patients.</p>
<p>3617,There was a small increase in plasma concentrations of capecitabine and one metabolite ( 5-DFCR );</p>
<p>3618,Coumarin_Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative_anticoagulants such as warfarin and phenprocoumon .</p>
<p>3619,Coumarin_Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative_anticoagulants such as warfarin and phenprocoumon .</p>
<p>3620,Coumarin_Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative_anticoagulants such as warfarin and phenprocoumon .</p>
<p>3621,Coumarin_Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative_anticoagulants such as warfarin and phenprocoumon .</p>
<p>3622,Coumarin_Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative_anticoagulants such as warfarin and phenprocoumon .</p>
<p>3623,Coumarin_Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative_anticoagulants such as warfarin and phenprocoumon .</p>
<p>3624,Coumarin_Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative_anticoagulants such as warfarin and phenprocoumon .</p>
<p>3625,Coumarin_Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative_anticoagulants such as warfarin and phenprocoumon .</p>
<p>3626,Coumarin_Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative_anticoagulants such as warfarin and phenprocoumon .</p>
<p>3627,Coumarin_Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative_anticoagulants such as warfarin and phenprocoumon .</p>
<p>3628,Patients taking coumarin-derivative_anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).</p>
<p>3629,Leucovorin : The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin .</p>
<p>3630,"Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil ."</p>
<p>3631,"Hypotension  Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril ."</p>
<p>3632,"Hypotension  Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril ."</p>
<p>3633,"The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril ( captopril tablets, USP) or initiating therapy with small doses (# or # mg)."</p>
<p>3634,"The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril ( captopril tablets, USP) or initiating therapy with small doses (# or # mg)."</p>
<p>3635,"The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril ( captopril tablets, USP) or initiating therapy with small doses (# or # mg)."</p>
<p>3636,Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients receiving captopril for heart failure are not available;</p>
<p>3637,"therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril ."</p>
<p>3638,"therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril ."</p>
<p>3639,Agents Causing Renin Release Captopril 's effect will be augmented by antihypertensive_agents that cause renin release.</p>
<p>3640,Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics .</p>
<p>3641,"Beta-adrenergic_blocking_drugs add some further antihypertensive effect to captopril , but the overall response is less than additive."</p>
<p>3642,"Potassium-sparing_diuretics such as spironolactone , triamterene , or amiloride , or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."</p>
<p>3643,"Potassium-sparing_diuretics such as spironolactone , triamterene , or amiloride , or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."</p>
<p>3644,"Potassium-sparing_diuretics such as spironolactone , triamterene , or amiloride , or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."</p>
<p>3645,"Potassium-sparing_diuretics such as spironolactone , triamterene , or amiloride , or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."</p>
<p>3646,"Potassium-sparing_diuretics such as spironolactone , triamterene , or amiloride , or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."</p>
<p>3647,"Potassium-sparing_diuretics such as spironolactone , triamterene , or amiloride , or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."</p>
<p>3648,"Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril , especially in cases of low renin hypertension."</p>
<p>3649,Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE_inhibitor therapy.</p>
<p>3650,Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE_inhibitor therapy.</p>
<p>3651,Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE_inhibitor therapy.</p>
<p>3652,Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE_inhibitor therapy.</p>
<p>3653,"If a diuretic is also used, it may increase the risk of lithium toxicity."</p>
<p>3654,Cardiac_Glycosides : In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril - digoxin interaction could be found.</p>
<p>3655,Loop_Diuretics : Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.</p>
<p>3656,Loop_Diuretics : Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.</p>
<p>3657,Allopurinol : In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allopurinol were administered concomitantly for # days.</p>
<p>3658,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3659,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3660,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3661,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3662,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3663,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3664,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3665,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3666,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3667,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3668,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3669,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3670,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3671,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3672,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3673,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3674,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3675,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3676,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3677,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3678,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3679,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3680,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3681,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3682,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3683,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide , azole_antifungals , cimetidine , clarithromycin (1), dalfopristin , danazol , delavirdine , diltiazem , erythromycin (1), fluoxetine , fluvoxamine , grapefruit juice, isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease_inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate (1), verapamil , zileuton ."</p>
<p>3684,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3685,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3686,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3687,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3688,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3689,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3690,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3691,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3692,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3693,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3694,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3695,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3696,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3697,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3698,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3699,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3700,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3701,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3702,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3703,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3704,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3705,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3706,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3707,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3708,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3709,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3710,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin , doxorubicin_HCL , felbamate , rifampin , phenobarbital , Phenytoin (2), primidone , methsuximide , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary."</p>
<p>3711,"Agents with Increased Levels in the Presence of Carbamazepine : EQUETROTM increases the plasma levels of the following agents: Clomipramine_HCl , Phenytoin (6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."</p>
<p>3712,"Agents with Increased Levels in the Presence of Carbamazepine : EQUETROTM increases the plasma levels of the following agents: Clomipramine_HCl , Phenytoin (6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."</p>
<p>3713,"Agents with Increased Levels in the Presence of Carbamazepine : EQUETROTM increases the plasma levels of the following agents: Clomipramine_HCl , Phenytoin (6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."</p>
<p>3714,"Agents with Increased Levels in the Presence of Carbamazepine : EQUETROTM increases the plasma levels of the following agents: Clomipramine_HCl , Phenytoin (6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."</p>
<p>3715,"Agents with Increased Levels in the Presence of Carbamazepine : EQUETROTM increases the plasma levels of the following agents: Clomipramine_HCl , Phenytoin (6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."</p>
<p>3716,"Agents with Increased Levels in the Presence of Carbamazepine : EQUETROTM increases the plasma levels of the following agents: Clomipramine_HCl , Phenytoin (6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary."</p>
<p>3717,Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.</p>
<p>3718,Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.</p>
<p>3719,"Given the anticonvulsant properties of carbamazepine , EQUETROTM may reduce the thyroid function as has been reported with other anticonvulsants ."</p>
<p>3720,"Given the anticonvulsant properties of carbamazepine , EQUETROTM may reduce the thyroid function as has been reported with other anticonvulsants ."</p>
<p>3721,"Given the anticonvulsant properties of carbamazepine , EQUETROTM may reduce the thyroid function as has been reported with other anticonvulsants ."</p>
<p>3722,"Additionally, anti-malarial_drugs , such as chloroquine and mefloquine , may antagonize the activity of carbamazepine ."</p>
<p>3723,"Additionally, anti-malarial_drugs , such as chloroquine and mefloquine , may antagonize the activity of carbamazepine ."</p>
<p>3724,"Additionally, anti-malarial_drugs , such as chloroquine and mefloquine , may antagonize the activity of carbamazepine ."</p>
<p>3725,"Additionally, anti-malarial_drugs , such as chloroquine and mefloquine , may antagonize the activity of carbamazepine ."</p>
<p>3726,"Additionally, anti-malarial_drugs , such as chloroquine and mefloquine , may antagonize the activity of carbamazepine ."</p>
<p>3727,"Additionally, anti-malarial_drugs , such as chloroquine and mefloquine , may antagonize the activity of carbamazepine ."</p>
<p>3728,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally_acting_drugs and alcohol ."</p>
<p>3729,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally_acting_drugs and alcohol ."</p>
<p>3730,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally_acting_drugs and alcohol ."</p>
<p>3731,Geocillin ( carbenicillin_indanyl_sodium ) blood levels may be increased and prolonged by concurrent administration of probenecid .</p>
<p>3732,Geocillin ( carbenicillin_indanyl_sodium ) blood levels may be increased and prolonged by concurrent administration of probenecid .</p>
<p>3733,Caution should be exercised when the following drugs are administered concomitantly with LODOSYN ( Carbidopa ) given with levodopa or carbidopa - levodopa combination products.</p>
<p>3734,Caution should be exercised when the following drugs are administered concomitantly with LODOSYN ( Carbidopa ) given with levodopa or carbidopa - levodopa combination products.</p>
<p>3735,Caution should be exercised when the following drugs are administered concomitantly with LODOSYN ( Carbidopa ) given with levodopa or carbidopa - levodopa combination products.</p>
<p>3736,Caution should be exercised when the following drugs are administered concomitantly with LODOSYN ( Carbidopa ) given with levodopa or carbidopa - levodopa combination products.</p>
<p>3737,Caution should be exercised when the following drugs are administered concomitantly with LODOSYN ( Carbidopa ) given with levodopa or carbidopa - levodopa combination products.</p>
<p>3738,Caution should be exercised when the following drugs are administered concomitantly with LODOSYN ( Carbidopa ) given with levodopa or carbidopa - levodopa combination products.</p>
<p>3739,Caution should be exercised when the following drugs are administered concomitantly with LODOSYN ( Carbidopa ) given with levodopa or carbidopa - levodopa combination products.</p>
<p>3740,"Dopamine_D2_receptor_antagonists (e,g,, phenothiazines , butyrophenones , risperidone ) and isoniazid may reduce the therapeutic effects of levodopa ."</p>
<p>3741,"Dopamine_D2_receptor_antagonists (e,g,, phenothiazines , butyrophenones , risperidone ) and isoniazid may reduce the therapeutic effects of levodopa ."</p>
<p>3742,"Dopamine_D2_receptor_antagonists (e,g,, phenothiazines , butyrophenones , risperidone ) and isoniazid may reduce the therapeutic effects of levodopa ."</p>
<p>3743,"Dopamine_D2_receptor_antagonists (e,g,, phenothiazines , butyrophenones , risperidone ) and isoniazid may reduce the therapeutic effects of levodopa ."</p>
<p>3744,"Dopamine_D2_receptor_antagonists (e,g,, phenothiazines , butyrophenones , risperidone ) and isoniazid may reduce the therapeutic effects of levodopa ."</p>
<p>3745,"Dopamine_D2_receptor_antagonists (e,g,, phenothiazines , butyrophenones , risperidone ) and isoniazid may reduce the therapeutic effects of levodopa ."</p>
<p>3746,"Dopamine_D2_receptor_antagonists (e,g,, phenothiazines , butyrophenones , risperidone ) and isoniazid may reduce the therapeutic effects of levodopa ."</p>
<p>3747,"Dopamine_D2_receptor_antagonists (e,g,, phenothiazines , butyrophenones , risperidone ) and isoniazid may reduce the therapeutic effects of levodopa ."</p>
<p>3748,"Dopamine_D2_receptor_antagonists (e,g,, phenothiazines , butyrophenones , risperidone ) and isoniazid may reduce the therapeutic effects of levodopa ."</p>
<p>3749,"In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine ."</p>
<p>3750,"In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine ."</p>
<p>3751,"In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine ."</p>
<p>3752,Patients taking these drugs with LODOSYN and levodopa or carbidopa - levodopa combination products should be carefully observed for loss of therapeutic response.</p>
<p>3753,Patients taking these drugs with LODOSYN and levodopa or carbidopa - levodopa combination products should be carefully observed for loss of therapeutic response.</p>
<p>3754,Patients taking these drugs with LODOSYN and levodopa or carbidopa - levodopa combination products should be carefully observed for loss of therapeutic response.</p>
<p>3755,Patients taking these drugs with LODOSYN and levodopa or carbidopa - levodopa combination products should be carefully observed for loss of therapeutic response.</p>
<p>3756,Patients taking these drugs with LODOSYN and levodopa or carbidopa - levodopa combination products should be carefully observed for loss of therapeutic response.</p>
<p>3757,Iron salts may reduce the bioavailability of carbidopa and levodopa .</p>
<p>3758,Iron salts may reduce the bioavailability of carbidopa and levodopa .</p>
<p>3759,Iron salts may reduce the bioavailability of carbidopa and levodopa .</p>
<p>3760,"Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties."</p>
<p>3761,"Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties."</p>
<p>3762,"Iodine or iodine excess may decrease the effect of Carbimazole , and an iodine deficiency can increase the effect of Carbimazole ."</p>
<p>3763,"Iodine or iodine excess may decrease the effect of Carbimazole , and an iodine deficiency can increase the effect of Carbimazole ."</p>
<p>3764,"Iodine or iodine excess may decrease the effect of Carbimazole , and an iodine deficiency can increase the effect of Carbimazole ."</p>
<p>3765,"Iodine or iodine excess may decrease the effect of Carbimazole , and an iodine deficiency can increase the effect of Carbimazole ."</p>
<p>3766,"Iodine or iodine excess may decrease the effect of Carbimazole , and an iodine deficiency can increase the effect of Carbimazole ."</p>
<p>3767,"Iodine or iodine excess may decrease the effect of Carbimazole , and an iodine deficiency can increase the effect of Carbimazole ."</p>
<p>3768,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid_agents .</p>
<p>3769,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid_agents .</p>
<p>3770,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid_agents .</p>
<p>3771,"Antithyroid_agents may decrease thyroidal uptake of sodium_iodide_I131 , a rebound in uptake may occur up to # days after sudden withdrawal of Carbimazole ."</p>
<p>3772,"Antithyroid_agents may decrease thyroidal uptake of sodium_iodide_I131 , a rebound in uptake may occur up to # days after sudden withdrawal of Carbimazole ."</p>
<p>3773,"Antithyroid_agents may decrease thyroidal uptake of sodium_iodide_I131 , a rebound in uptake may occur up to # days after sudden withdrawal of Carbimazole ."</p>
<p>3774,"Antihistamines may enhance the effects of tricyclic_antidepressants , barbiturates , alcohol , and other CNS_depressants ."</p>
<p>3775,"Antihistamines may enhance the effects of tricyclic_antidepressants , barbiturates , alcohol , and other CNS_depressants ."</p>
<p>3776,"Antihistamines may enhance the effects of tricyclic_antidepressants , barbiturates , alcohol , and other CNS_depressants ."</p>
<p>3777,"Antihistamines may enhance the effects of tricyclic_antidepressants , barbiturates , alcohol , and other CNS_depressants ."</p>
<p>3778,"Antihistamines may enhance the effects of tricyclic_antidepressants , barbiturates , alcohol , and other CNS_depressants ."</p>
<p>3779,"Antihistamines may enhance the effects of tricyclic_antidepressants , barbiturates , alcohol , and other CNS_depressants ."</p>
<p>3780,"Antihistamines may enhance the effects of tricyclic_antidepressants , barbiturates , alcohol , and other CNS_depressants ."</p>
<p>3781,MAO_inhibitors prolong and intensify the anticholinergic effects of antihistamines .</p>
<p>3782,"Sympathomimetic_amines may reduce the antihypertensive effects of reserpine , veratrum_alkaloids , methyldopa and mecamylamine ."</p>
<p>3783,"Sympathomimetic_amines may reduce the antihypertensive effects of reserpine , veratrum_alkaloids , methyldopa and mecamylamine ."</p>
<p>3784,"Sympathomimetic_amines may reduce the antihypertensive effects of reserpine , veratrum_alkaloids , methyldopa and mecamylamine ."</p>
<p>3785,"Sympathomimetic_amines may reduce the antihypertensive effects of reserpine , veratrum_alkaloids , methyldopa and mecamylamine ."</p>
<p>3786,Effects of sympathomimetics are increased with MAO_inhibitors and beta_adrenergic_blockers .</p>
<p>3787,Effects of sympathomimetics are increased with MAO_inhibitors and beta_adrenergic_blockers .</p>
<p>3788,Effects of sympathomimetics are increased with MAO_inhibitors and beta_adrenergic_blockers .</p>
<p>3789,HEMABATE may augment the activity of other oxytocic_agents .</p>
<p>3790,Ocupress should be used with caution in patients who are receiving a beta-adrenergic_blocking_agent orally because of the potential for additive effects on systemic beta-blockade.</p>
<p>3791,"Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine , because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension."</p>
<p>3792,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3793,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3794,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3795,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3796,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3797,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3798,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3799,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3800,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3801,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3802,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3803,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3804,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3805,"poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."</p>
<p>3806,"Catecholamine-depleting Agents: Patients taking both agents_with_b-blocking_properties and a drug that can deplete catecholamines (e,g,, reserpine and monoamine_oxidase_inhibitors ) should be observed closely for signs of hypotension and/or severe bradycardia."</p>
<p>3807,"Catecholamine-depleting Agents: Patients taking both agents_with_b-blocking_properties and a drug that can deplete catecholamines (e,g,, reserpine and monoamine_oxidase_inhibitors ) should be observed closely for signs of hypotension and/or severe bradycardia."</p>
<p>3808,Clonidine : Concomitant administration of clonidine with agents_with_b-blocking_properties may potentiate blood-pressure- and heart-rate-lowering effects.</p>
<p>3809,Clonidine : Concomitant administration of clonidine with agents_with_b-blocking_properties may potentiate blood-pressure- and heart-rate-lowering effects.</p>
<p>3810,"When concomitant treatment with agents_with_b-blocking_properties and clonidine is to be terminated, the b-blocking_agent should be discontinued first."</p>
<p>3811,"When concomitant treatment with agents_with_b-blocking_properties and clonidine is to be terminated, the b-blocking_agent should be discontinued first."</p>
<p>3812,"When concomitant treatment with agents_with_b-blocking_properties and clonidine is to be terminated, the b-blocking_agent should be discontinued first."</p>
<p>3813,Cyclosporine : Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in # renal transplant patients suffering from chronic vascular rejection.</p>
<p>3814,"Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate."</p>
<p>3815,"Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate."</p>
<p>3816,Digoxin : Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.</p>
<p>3817,Digoxin : Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.</p>
<p>3818,Both digoxin and COREG slow AV conduction.</p>
<p>3819,"Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG ."</p>
<p>3820,Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.</p>
<p>3821,Calcium_Channel_Blockers : Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem .</p>
<p>3822,"As with other agents_with_b-blocking_properties , if COREG is to be administered orally with calcium_channel_blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored."</p>
<p>3823,"As with other agents_with_b-blocking_properties , if COREG is to be administered orally with calcium_channel_blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored."</p>
<p>3824,"As with other agents_with_b-blocking_properties , if COREG is to be administered orally with calcium_channel_blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored."</p>
<p>3825,"As with other agents_with_b-blocking_properties , if COREG is to be administered orally with calcium_channel_blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored."</p>
<p>3826,"As with other agents_with_b-blocking_properties , if COREG is to be administered orally with calcium_channel_blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored."</p>
<p>3827,"As with other agents_with_b-blocking_properties , if COREG is to be administered orally with calcium_channel_blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored."</p>
<p>3828,"As with other agents_with_b-blocking_properties , if COREG is to be administered orally with calcium_channel_blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored."</p>
<p>3829,"As with other agents_with_b-blocking_properties , if COREG is to be administered orally with calcium_channel_blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored."</p>
<p>3830,"As with other agents_with_b-blocking_properties , if COREG is to be administered orally with calcium_channel_blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored."</p>
<p>3831,"As with other agents_with_b-blocking_properties , if COREG is to be administered orally with calcium_channel_blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored."</p>
<p>3832,Insulin or Oral Hypoglycemics : Agents_with_b-blocking_properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics .</p>
<p>3833,Insulin or Oral Hypoglycemics : Agents_with_b-blocking_properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics .</p>
<p>3834,Insulin or Oral Hypoglycemics : Agents_with_b-blocking_properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics .</p>
<p>3835,Insulin or Oral Hypoglycemics : Agents_with_b-blocking_properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics .</p>
<p>3836,"Therefore, in patients taking insulin or oral hypoglycemics , regular monitoring of blood glucose is recommended."</p>
<p>3837,"Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole , amphotericin_B , mycophenolate , nelfinavir , or tacrolimus ."</p>
<p>3838,"Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole , amphotericin_B , mycophenolate , nelfinavir , or tacrolimus ."</p>
<p>3839,"Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole , amphotericin_B , mycophenolate , nelfinavir , or tacrolimus ."</p>
<p>3840,"Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole , amphotericin_B , mycophenolate , nelfinavir , or tacrolimus ."</p>
<p>3841,"Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole , amphotericin_B , mycophenolate , nelfinavir , or tacrolimus ."</p>
<p>3842,"CANCIDAS has no effect on the pharmacokinetics of itraconazole , amphotericin_B , or the active metabolite of mycophenolate."</p>
<p>3843,"CANCIDAS has no effect on the pharmacokinetics of itraconazole , amphotericin_B , or the active metabolite of mycophenolate."</p>
<p>3844,"CANCIDAS has no effect on the pharmacokinetics of itraconazole , amphotericin_B , or the active metabolite of mycophenolate."</p>
<p>3845,"CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of # mg/kg # hours apart) was administered on the 10th day of CANCIDAS # mg daily, as compared to results from a control period in which tacrolimus was administered alone."</p>
<p>3846,"CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of # mg/kg # hours apart) was administered on the 10th day of CANCIDAS # mg daily, as compared to results from a control period in which tacrolimus was administered alone."</p>
<p>3847,"CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of # mg/kg # hours apart) was administered on the 10th day of CANCIDAS # mg daily, as compared to results from a control period in which tacrolimus was administered alone."</p>
<p>3848,"CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of # mg/kg # hours apart) was administered on the 10th day of CANCIDAS # mg daily, as compared to results from a control period in which tacrolimus was administered alone."</p>
<p>3849,"CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of # mg/kg # hours apart) was administered on the 10th day of CANCIDAS # mg daily, as compared to results from a control period in which tacrolimus was administered alone."</p>
<p>3850,"CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of # mg/kg # hours apart) was administered on the 10th day of CANCIDAS # mg daily, as compared to results from a control period in which tacrolimus was administered alone."</p>
<p>3851,"In two clinical studies, cyclosporine (one # mg/kg dose or two # mg/kg doses) increased the AUC of caspofungin by approximately 35%."</p>
<p>3852,CANCIDAS did not increase the plasma levels of cyclosporine .</p>
<p>3853,There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.</p>
<p>3854,A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.</p>
<p>3855,Patients on rifampin should receive # mg of CANCIDAS daily.</p>
<p>3856,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations."</p>
<p>3857,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations."</p>
<p>3858,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations."</p>
<p>3859,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations."</p>
<p>3860,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations."</p>
<p>3861,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations."</p>
<p>3862,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations."</p>
<p>3863,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations."</p>
<p>3864,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations."</p>
<p>3865,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations."</p>
<p>3866,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations."</p>
<p>3867,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of # mg of CANCIDAS should be considered"</p>
<p>3868,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of # mg of CANCIDAS should be considered"</p>
<p>3869,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of # mg of CANCIDAS should be considered"</p>
<p>3870,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of # mg of CANCIDAS should be considered"</p>
<p>3871,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of # mg of CANCIDAS should be considered"</p>
<p>3872,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of # mg of CANCIDAS should be considered"</p>
<p>3873,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of # mg of CANCIDAS should be considered"</p>
<p>3874,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of # mg of CANCIDAS should be considered"</p>
<p>3875,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of # mg of CANCIDAS should be considered"</p>
<p>3876,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of # mg of CANCIDAS should be considered"</p>
<p>3877,"Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels."</p>
<p>3878,"Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels."</p>
<p>3879,Antacids ( aluminum - or magnesium -containing): Concomitant administration of 300-mg cefdinir capsules with # mL Maalox_TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.</p>
<p>3880,Antacids ( aluminum - or magnesium -containing): Concomitant administration of 300-mg cefdinir capsules with # mL Maalox_TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.</p>
<p>3881,Antacids ( aluminum - or magnesium -containing): Concomitant administration of 300-mg cefdinir capsules with # mL Maalox_TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.</p>
<p>3882,Antacids ( aluminum - or magnesium -containing): Concomitant administration of 300-mg cefdinir capsules with # mL Maalox_TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.</p>
<p>3883,Antacids ( aluminum - or magnesium -containing): Concomitant administration of 300-mg cefdinir capsules with # mL Maalox_TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.</p>
<p>3884,Antacids ( aluminum - or magnesium -containing): Concomitant administration of 300-mg cefdinir capsules with # mL Maalox_TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.</p>
<p>3885,Antacids ( aluminum - or magnesium -containing): Concomitant administration of 300-mg cefdinir capsules with # mL Maalox_TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.</p>
<p>3886,There are no significant effects on cefdinir pharmacokinetics if the antacid is administered # hours before or # hours after cefdinir .</p>
<p>3887,There are no significant effects on cefdinir pharmacokinetics if the antacid is administered # hours before or # hours after cefdinir .</p>
<p>3888,"If antacids are required during OMNICEF therapy, OMNICEF should be taken at least # hours before or after the antacid ."</p>
<p>3889,"If antacids are required during OMNICEF therapy, OMNICEF should be taken at least # hours before or after the antacid ."</p>
<p>3890,"If antacids are required during OMNICEF therapy, OMNICEF should be taken at least # hours before or after the antacid ."</p>
<p>3891,"If antacids are required during OMNICEF therapy, OMNICEF should be taken at least # hours before or after the antacid ."</p>
<p>3892,"Probenecid : As with other b-lactam_antibiotics , probenecid inhibits the renal excretion of cefdinir , resulting in an approximate doubling in A,C, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life."</p>
<p>3893,"Probenecid : As with other b-lactam_antibiotics , probenecid inhibits the renal excretion of cefdinir , resulting in an approximate doubling in A,C, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life."</p>
<p>3894,"Probenecid : As with other b-lactam_antibiotics , probenecid inhibits the renal excretion of cefdinir , resulting in an approximate doubling in A,C, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life."</p>
<p>3895,"Probenecid : As with other b-lactam_antibiotics , probenecid inhibits the renal excretion of cefdinir , resulting in an approximate doubling in A,C, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life."</p>
<p>3896,"Probenecid : As with other b-lactam_antibiotics , probenecid inhibits the renal excretion of cefdinir , resulting in an approximate doubling in A,C, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life."</p>
<p>3897,"Probenecid : As with other b-lactam_antibiotics , probenecid inhibits the renal excretion of cefdinir , resulting in an approximate doubling in A,C, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life."</p>
<p>3898,"Probenecid : As with other b-lactam_antibiotics , probenecid inhibits the renal excretion of cefdinir , resulting in an approximate doubling in A,C, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life."</p>
<p>3899,"Probenecid : As with other b-lactam_antibiotics , probenecid inhibits the renal excretion of cefdinir , resulting in an approximate doubling in A,C, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life."</p>
<p>3900,"Iron_Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron_supplement containing # mg of elemental iron (as FeSO4) or vitamins supplemented with # mg of elemental iron reduced extent of absorption by 80% and 31%, respectively."</p>
<p>3901,"Iron_Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron_supplement containing # mg of elemental iron (as FeSO4) or vitamins supplemented with # mg of elemental iron reduced extent of absorption by 80% and 31%, respectively."</p>
<p>3902,"Iron_Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron_supplement containing # mg of elemental iron (as FeSO4) or vitamins supplemented with # mg of elemental iron reduced extent of absorption by 80% and 31%, respectively."</p>
<p>3903,"Iron_Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron_supplement containing # mg of elemental iron (as FeSO4) or vitamins supplemented with # mg of elemental iron reduced extent of absorption by 80% and 31%, respectively."</p>
<p>3904,"Iron_Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron_supplement containing # mg of elemental iron (as FeSO4) or vitamins supplemented with # mg of elemental iron reduced extent of absorption by 80% and 31%, respectively."</p>
<p>3905,"Iron_Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron_supplement containing # mg of elemental iron (as FeSO4) or vitamins supplemented with # mg of elemental iron reduced extent of absorption by 80% and 31%, respectively."</p>
<p>3906,"Iron_Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron_supplement containing # mg of elemental iron (as FeSO4) or vitamins supplemented with # mg of elemental iron reduced extent of absorption by 80% and 31%, respectively."</p>
<p>3907,"Iron_Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron_supplement containing # mg of elemental iron (as FeSO4) or vitamins supplemented with # mg of elemental iron reduced extent of absorption by 80% and 31%, respectively."</p>
<p>3908,"Iron_Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron_supplement containing # mg of elemental iron (as FeSO4) or vitamins supplemented with # mg of elemental iron reduced extent of absorption by 80% and 31%, respectively."</p>
<p>3909,"Iron_Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron_supplement containing # mg of elemental iron (as FeSO4) or vitamins supplemented with # mg of elemental iron reduced extent of absorption by 80% and 31%, respectively."</p>
<p>3910,"Iron_Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron_supplement containing # mg of elemental iron (as FeSO4) or vitamins supplemented with # mg of elemental iron reduced extent of absorption by 80% and 31%, respectively."</p>
<p>3911,"If iron_supplements are required during OMNICEF therapy, OMNICEF should be taken at least # hours before or after the supplement."</p>
<p>3912,"If iron_supplements are required during OMNICEF therapy, OMNICEF should be taken at least # hours before or after the supplement."</p>
<p>3913,The effect of foods highly fortified with elemental iron (primarily iron -fortified breakfast cereals) on cefdinir absorption has not been studied.</p>
<p>3914,The effect of foods highly fortified with elemental iron (primarily iron -fortified breakfast cereals) on cefdinir absorption has not been studied.</p>
<p>3915,Concomitantly administered iron -fortified infant formula (# mg elemental iron /6 oz) has no significant effect on cefdinir pharmacokinetics.</p>
<p>3916,Concomitantly administered iron -fortified infant formula (# mg elemental iron /6 oz) has no significant effect on cefdinir pharmacokinetics.</p>
<p>3917,"Therefore, OMNICEF for Oral Suspension can be administered with iron -fortified infant formula."</p>
<p>3918,The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.</p>
<p>3919,"Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside , but not with those using nitroferricyanide ."</p>
<p>3920,"Oral Contraceptives Multiple doses of cefditoren_pivoxil had no effect on the pharmacokinetics of ethinyl_estradiol , the estrogenic component in most oral contraceptives ."</p>
<p>3921,"Oral Contraceptives Multiple doses of cefditoren_pivoxil had no effect on the pharmacokinetics of ethinyl_estradiol , the estrogenic component in most oral contraceptives ."</p>
<p>3922,"Oral Contraceptives Multiple doses of cefditoren_pivoxil had no effect on the pharmacokinetics of ethinyl_estradiol , the estrogenic component in most oral contraceptives ."</p>
<p>3923,"Oral Contraceptives Multiple doses of cefditoren_pivoxil had no effect on the pharmacokinetics of ethinyl_estradiol , the estrogenic component in most oral contraceptives ."</p>
<p>3924,"Oral Contraceptives Multiple doses of cefditoren_pivoxil had no effect on the pharmacokinetics of ethinyl_estradiol , the estrogenic component in most oral contraceptives ."</p>
<p>3925,"Although the clinical significance is not known, it is not recommended that cefditoren_pivoxil be taken concomitantly with antacids ."</p>
<p>3926,"H2-Receptor_Antagonists : Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single # mg dose of cefditoren_pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC."</p>
<p>3927,"H2-Receptor_Antagonists : Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single # mg dose of cefditoren_pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC."</p>
<p>3928,"H2-Receptor_Antagonists : Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single # mg dose of cefditoren_pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC."</p>
<p>3929,"Although the clinical significance is not known, it is not recommended that cefditoren_pivoxil be taken concomitantly with H2_receptor_antagonists ."</p>
<p>3930,"Probenecid : As with other b-lactam_antibiotics , co-administration of probenecid with cefditoren_pivoxil resulted in an increase in the plasma exposure of cefditoren , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."</p>
<p>3931,"Probenecid : As with other b-lactam_antibiotics , co-administration of probenecid with cefditoren_pivoxil resulted in an increase in the plasma exposure of cefditoren , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."</p>
<p>3932,"Probenecid : As with other b-lactam_antibiotics , co-administration of probenecid with cefditoren_pivoxil resulted in an increase in the plasma exposure of cefditoren , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."</p>
<p>3933,"Probenecid : As with other b-lactam_antibiotics , co-administration of probenecid with cefditoren_pivoxil resulted in an increase in the plasma exposure of cefditoren , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."</p>
<p>3934,"Probenecid : As with other b-lactam_antibiotics , co-administration of probenecid with cefditoren_pivoxil resulted in an increase in the plasma exposure of cefditoren , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."</p>
<p>3935,"Probenecid : As with other b-lactam_antibiotics , co-administration of probenecid with cefditoren_pivoxil resulted in an increase in the plasma exposure of cefditoren , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."</p>
<p>3936,"Probenecid : As with other b-lactam_antibiotics , co-administration of probenecid with cefditoren_pivoxil resulted in an increase in the plasma exposure of cefditoren , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."</p>
<p>3937,"Probenecid : As with other b-lactam_antibiotics , co-administration of probenecid with cefditoren_pivoxil resulted in an increase in the plasma exposure of cefditoren , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."</p>
<p>3938,Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside_antibiotics .</p>
<p>3939,Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside_antibiotics .</p>
<p>3940,Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside_antibiotics .</p>
<p>3941,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide .</p>
<p>3942,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide .</p>
<p>3943,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide .</p>
<p>3944,Carbamazepine : Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.</p>
<p>3945,Carbamazepine : Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.</p>
<p>3946,"Warfarin and Anticoagulants : Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly."</p>
<p>3947,"Warfarin and Anticoagulants : Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly."</p>
<p>3948,"Warfarin and Anticoagulants : Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly."</p>
<p>3949,Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide .</p>
<p>3950,Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside_antibiotics .</p>
<p>3951,"Drug/Laboratory Test Interactions Cephalosporins , including cefotaxime_sodium , are known to occasionally induce a positive direct Coombs test."</p>
<p>3952,"If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated."</p>
<p>3953,"As with other cephalosporins , high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels by Jaffe reaction and produce false increases in the levels of creatinine reported."</p>
<p>3954,Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside_antibiotics .</p>
<p>3955,"Drug/Laboratory Test Interactions As with cephalothin , high concentrations of cefoxitin ( # micrograms/mL) may interfere with measurement of serum and urine creatinine levels by the Jaff reaction, and produce false increases of modest degree in the levels of creatinine reported."</p>
<p>3956,Nephrotoxicity has been reported following concomitant administration of aminoglycoside_antibiotics and cephalosporin_antibiotics .</p>
<p>3957,Concomitant administration of probenecid doubled the AUC for cefprozil .</p>
<p>3958,The bioavailability of the capsule formulation of cefprozil was not affected when administered # minutes following an antacid .</p>
<p>3959,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside_antibiotics or potent diuretics such as furosemide .</p>
<p>3960,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside_antibiotics or potent diuretics such as furosemide .</p>
<p>3961,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside_antibiotics or potent diuretics such as furosemide .</p>
<p>3962,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside_antibiotics or potent diuretics such as furosemide .</p>
<p>3963,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside_antibiotics or potent diuretics such as furosemide .</p>
<p>3964,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside_antibiotics or potent diuretics such as furosemide .</p>
<p>3965,"Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycosidic_antibiotics ."</p>
<p>3966,"Chloramphenicol has been shown to be antagonistic to beta-lactam_antibiotics , including ceftazidime , based on in vitro studies and time kill curves with enteric gram-negative bacilli."</p>
<p>3967,"Chloramphenicol has been shown to be antagonistic to beta-lactam_antibiotics , including ceftazidime , based on in vitro studies and time kill curves with enteric gram-negative bacilli."</p>
<p>3968,"Chloramphenicol has been shown to be antagonistic to beta-lactam_antibiotics , including ceftazidime , based on in vitro studies and time kill curves with enteric gram-negative bacilli."</p>
<p>3969,"With the morning dose of ceftibuten on day 6, each volunteer received a single intravenous infusion of theophylline (4 mg/kg)."</p>
<p>3970,The effect of ceftibuten on the pharmacokinetics of theophylline administered orally has not been investigated.</p>
<p>3971,Antacids or H_2_-receptor_antagonists : The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in # healthy adult volunteers.</p>
<p>3972,A single dose of liquid antacid did not affect the C max or AUC of ceftibuten ;</p>
<p>3973,"however, # mg of ranitidine q12h for # days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%."</p>
<p>3974,"however, # mg of ranitidine q12h for # days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%."</p>
<p>3975,"Although the occurrence has not been reported with Cefizox , nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides ."</p>
<p>3976,"Although the occurrence has not been reported with Cefizox , nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides ."</p>
<p>3977,"Although the occurrence has not been reported with Cefizox , nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides ."</p>
<p>3978,Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium .</p>
<p>3979,Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium .</p>
<p>3980,Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium .</p>
<p>3981,Experience with nonsteroidal_anti-inflammatory_drugs ( NSAIDs ) suggests the potential for interactions with furosemide and ACE_inhibitors .</p>
<p>3982,Experience with nonsteroidal_anti-inflammatory_drugs ( NSAIDs ) suggests the potential for interactions with furosemide and ACE_inhibitors .</p>
<p>3983,Experience with nonsteroidal_anti-inflammatory_drugs ( NSAIDs ) suggests the potential for interactions with furosemide and ACE_inhibitors .</p>
<p>3984,Experience with nonsteroidal_anti-inflammatory_drugs ( NSAIDs ) suggests the potential for interactions with furosemide and ACE_inhibitors .</p>
<p>3985,Experience with nonsteroidal_anti-inflammatory_drugs ( NSAIDs ) suggests the potential for interactions with furosemide and ACE_inhibitors .</p>
<p>3986,"The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide , ketoconazole , methotrexate , phenytoin , tolbutamide , and warfarin have been studied in vivo and clinically important interactions have not been found."</p>
<p>3987,"The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide , ketoconazole , methotrexate , phenytoin , tolbutamide , and warfarin have been studied in vivo and clinically important interactions have not been found."</p>
<p>3988,"The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide , ketoconazole , methotrexate , phenytoin , tolbutamide , and warfarin have been studied in vivo and clinically important interactions have not been found."</p>
<p>3989,"The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide , ketoconazole , methotrexate , phenytoin , tolbutamide , and warfarin have been studied in vivo and clinically important interactions have not been found."</p>
<p>3990,"The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide , ketoconazole , methotrexate , phenytoin , tolbutamide , and warfarin have been studied in vivo and clinically important interactions have not been found."</p>
<p>3991,"The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide , ketoconazole , methotrexate , phenytoin , tolbutamide , and warfarin have been studied in vivo and clinically important interactions have not been found."</p>
<p>3992,"The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide , ketoconazole , methotrexate , phenytoin , tolbutamide , and warfarin have been studied in vivo and clinically important interactions have not been found."</p>
<p>3993,"The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide , ketoconazole , methotrexate , phenytoin , tolbutamide , and warfarin have been studied in vivo and clinically important interactions have not been found."</p>
<p>3994,"The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide , ketoconazole , methotrexate , phenytoin , tolbutamide , and warfarin have been studied in vivo and clinically important interactions have not been found."</p>
<p>3995,"The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide , ketoconazole , methotrexate , phenytoin , tolbutamide , and warfarin have been studied in vivo and clinically important interactions have not been found."</p>
<p>3996,"The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide , ketoconazole , methotrexate , phenytoin , tolbutamide , and warfarin have been studied in vivo and clinically important interactions have not been found."</p>
<p>3997,ACE_inhibitors : Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin_Converting_Enzyme_(ACE)_inhibitors .</p>
<p>3998,This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors .</p>
<p>3999,"Furosemide : Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>4000,"Furosemide : Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>4001,"Furosemide : Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>4002,"Furosemide : Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>4003,"Furosemide : Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."</p>
<p>4004,Aspirin : CELEBREX can be used with low dose aspirin .</p>
<p>4005,"However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone."</p>
<p>4006,"However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone."</p>
<p>4007,"Because of its lack of platelet effects, CELEBREX is not a substitute for aspirin for cardiovascular prophylaxis."</p>
<p>4008,Fluconazole : Concomitant administration of fluconazole at # mg QD resulted in a two-fold increase in celecoxib plasma concentration.</p>
<p>4009,Fluconazole : Concomitant administration of fluconazole at # mg QD resulted in a two-fold increase in celecoxib plasma concentration.</p>
<p>4010,This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).</p>
<p>4011,CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole .</p>
<p>4012,"Lithium : In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium # mg BID with CELEBREX # mg BID as compared to subjects receiving lithium alone."</p>
<p>4013,"Lithium : In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium # mg BID with CELEBREX # mg BID as compared to subjects receiving lithium alone."</p>
<p>4014,"Lithium : In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium # mg BID with CELEBREX # mg BID as compared to subjects receiving lithium alone."</p>
<p>4015,Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.</p>
<p>4016,"Methotrexate : In an interaction study of rheumatoid arthritis patients taking methotrexate , CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate ."</p>
<p>4017,"Methotrexate : In an interaction study of rheumatoid arthritis patients taking methotrexate , CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate ."</p>
<p>4018,Warfarin : The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin .</p>
<p>4019,Warfarin : The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin .</p>
<p>4020,"In these subjects, celecoxib did not alter the anticoagulant effect of warfarin as determined by prothrombin time."</p>
<p>4021,"However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications."</p>
<p>4022,"Metformin : In healthy subjects given single # mg doses of cephalexin and metformin , plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%."</p>
<p>4023,"Metformin : In healthy subjects given single # mg doses of cephalexin and metformin , plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%."</p>
<p>4024,"Metformin : In healthy subjects given single # mg doses of cephalexin and metformin , plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%."</p>
<p>4025,No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.</p>
<p>4026,"Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems."</p>
<p>4027,"Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin ."</p>
<p>4028,"Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin ."</p>
<p>4029,"Probenecid : As with other b-lactams , the renal excretion of cephalexin is inhibited by probenecid ."</p>
<p>4030,"Probenecid : As with other b-lactams , the renal excretion of cephalexin is inhibited by probenecid ."</p>
<p>4031,"Probenecid : As with other b-lactams , the renal excretion of cephalexin is inhibited by probenecid ."</p>
<p>4032,"Probenecid : As with other b-lactams , the renal excretion of cephalexin is inhibited by probenecid ."</p>
<p>4033,"Probenecid : As with other b-lactams , the renal excretion of cephalexin is inhibited by probenecid ."</p>
<p>4034,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4035,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4036,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4037,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4038,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4039,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4040,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4041,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4042,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4043,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4044,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4045,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4046,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4047,"Immunosuppressive_Drugs , Fibric_Acid_Derivatives , Niacin ( Nicotinic_Acid , Erythromycin , Azole_Antifungals : Skeletal Muscle."</p>
<p>4048,ANTACID ( Magnesium-Aluminum_Hydroxide ): Cerivastatin plasma concentrations were not affected by co-administration of antacid .</p>
<p>4049,CIMETlDINE : Cerivastatin plasma concentrations were not affected by co-administration of cimetidine .</p>
<p>4050,CHOLESTYRAMINE : The influence of the bile-acid sequestering agent cholestyramine on the pharmacokinetics of cerivastatin_sodium was evaluated in # healthy males in # separate randomized crossover studies.</p>
<p>4051,"In the first study, concomitant administration of # mg cerivastatin_sodium and # g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin_sodium alone."</p>
<p>4052,"In the first study, concomitant administration of # mg cerivastatin_sodium and # g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin_sodium alone."</p>
<p>4053,"However, in the second study, administration of # g cholestyramine # hour before the evening meal and # mg cerivastatin_sodium approximately # hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin_sodium alone."</p>
<p>4054,"However, in the second study, administration of # g cholestyramine # hour before the evening meal and # mg cerivastatin_sodium approximately # hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin_sodium alone."</p>
<p>4055,"However, in the second study, administration of # g cholestyramine # hour before the evening meal and # mg cerivastatin_sodium approximately # hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin_sodium alone."</p>
<p>4056,"Therefore, it would be expected that a dosing schedule of cerivastatin_sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin_sodium ."</p>
<p>4057,"Therefore, it would be expected that a dosing schedule of cerivastatin_sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin_sodium ."</p>
<p>4058,DIGOXIN : Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of # mg cerivastatin_sodium .</p>
<p>4059,DIGOXIN : Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of # mg cerivastatin_sodium .</p>
<p>4060,Cerivastatin plasma concentrations were also not affected by co-administration of digoxin .</p>
<p>4061,WARFARIN : Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.</p>
<p>4062,WARFARIN : Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.</p>
<p>4063,The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of # mg cerivastatin_sodium .</p>
<p>4064,Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin_sodium .</p>
<p>4065,Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin_sodium .</p>
<p>4066,"ERYTHROMYCIN : In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after # days with co-administration of erythromycin , a known inhibitor of cytochrome P450 3A4."</p>
<p>4067,"ERYTHROMYCIN : In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after # days with co-administration of erythromycin , a known inhibitor of cytochrome P450 3A4."</p>
<p>4068,"OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin_sodium was used concomitantly with angiotensin-_converting_enzyme_(ACE)_inhibitors , betablockers , calcium-channel_blockers , diuretics , and nonsteroidal_anti-inflammatory_drugs ( NSAIDs ) without evidence of clinically significant adverse interactions."</p>
<p>4069,"OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin_sodium was used concomitantly with angiotensin-_converting_enzyme_(ACE)_inhibitors , betablockers , calcium-channel_blockers , diuretics , and nonsteroidal_anti-inflammatory_drugs ( NSAIDs ) without evidence of clinically significant adverse interactions."</p>
<p>4070,"OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin_sodium was used concomitantly with angiotensin-_converting_enzyme_(ACE)_inhibitors , betablockers , calcium-channel_blockers , diuretics , and nonsteroidal_anti-inflammatory_drugs ( NSAIDs ) without evidence of clinically significant adverse interactions."</p>
<p>4071,"OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin_sodium was used concomitantly with angiotensin-_converting_enzyme_(ACE)_inhibitors , betablockers , calcium-channel_blockers , diuretics , and nonsteroidal_anti-inflammatory_drugs ( NSAIDs ) without evidence of clinically significant adverse interactions."</p>
<p>4072,"OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin_sodium was used concomitantly with angiotensin-_converting_enzyme_(ACE)_inhibitors , betablockers , calcium-channel_blockers , diuretics , and nonsteroidal_anti-inflammatory_drugs ( NSAIDs ) without evidence of clinically significant adverse interactions."</p>
<p>4073,"OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin_sodium was used concomitantly with angiotensin-_converting_enzyme_(ACE)_inhibitors , betablockers , calcium-channel_blockers , diuretics , and nonsteroidal_anti-inflammatory_drugs ( NSAIDs ) without evidence of clinically significant adverse interactions."</p>
<p>4074,"Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine , antipyrine , ketoconazole , erythromycin and azithromycin ."</p>
<p>4075,"Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine , antipyrine , ketoconazole , erythromycin and azithromycin ."</p>
<p>4076,"Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine , antipyrine , ketoconazole , erythromycin and azithromycin ."</p>
<p>4077,"Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine , antipyrine , ketoconazole , erythromycin and azithromycin ."</p>
<p>4078,"Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine , antipyrine , ketoconazole , erythromycin and azithromycin ."</p>
<p>4079,"In a multiple dose study of theophylline (400 mg once daily for # days) and cetirizine (20 mg once daily for # days), a 16% decrease in the clearance of cetirizine was observed."</p>
<p>4080,"In a multiple dose study of theophylline (400 mg once daily for # days) and cetirizine (20 mg once daily for # days), a 16% decrease in the clearance of cetirizine was observed."</p>
<p>4081,The disposition of theophylline was not altered by concomitant cetirizine administration.</p>
<p>4082,"Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin , pseudoephedrine , ketoconazole , or erythromycin ."</p>
<p>4083,"Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin , pseudoephedrine , ketoconazole , or erythromycin ."</p>
<p>4084,"Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin , pseudoephedrine , ketoconazole , or erythromycin ."</p>
<p>4085,"Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin , pseudoephedrine , ketoconazole , or erythromycin ."</p>
<p>4086,There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline ;</p>
<p>4087,A drug interaction study was performed in which ERBITUX was administered in combination with irinotecan .</p>
<p>4088,There was no evidence of any pharmacokinetic interactions between ERBITUX and irinotecan .</p>
<p>4089,"Cevimeline should be administered with caution to patients taking beta_adrenergic_antagonists , because of the possibility of conduction disturbances."</p>
<p>4090,"Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide ."</p>
<p>4091,The concomitant use of alcohol or other central_nervous_system_depressants may have an additive effect.</p>
<p>4092,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension."</p>
<p>4093,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension."</p>
<p>4094,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension."</p>
<p>4095,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension."</p>
<p>4096,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension."</p>
<p>4097,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension."</p>
<p>4098,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension."</p>
<p>4099,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension."</p>
<p>4100,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension."</p>
<p>4101,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension."</p>
<p>4102,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension."</p>
<p>4103,"The administration of local anesthetic_solutions containing epinephrine or norepinephrine to patients receiving monoamine_oxidase_inhibitors , tricyclic_antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension."</p>
<p>4104,"Concurrent administration of vasopressor_drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type_oxytocic_drugs may cause severe, persistent hypertension or cerebrovascular accidents."</p>
<p>4105,"Therefore, chloroprocaine should not be used in any condition in which a sulfonamide_drug is being employed."</p>
<p>4106,Antacids and kaolin : Antacids and kaolin can reduce absorption of chloroquine ;</p>
<p>4107,Antacids and kaolin : Antacids and kaolin can reduce absorption of chloroquine ;</p>
<p>4108,Antacids and kaolin : Antacids and kaolin can reduce absorption of chloroquine ;</p>
<p>4109,Antacids and kaolin : Antacids and kaolin can reduce absorption of chloroquine ;</p>
<p>4110,"Cimetidine : Cimetidine can inhibit the metabolism of chloroquine , increasing its plasma level."</p>
<p>4111,"Ampicillin : In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin ."</p>
<p>4112,"Cyclosporin : After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported."</p>
<p>4113,"Cyclosporin : After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported."</p>
<p>4114,"Therefore, close monitoring of serum cyclosporin level is recommended and, if necessary, chloroquine should be discontinued."</p>
<p>4115,- Antidiabetic_drugs : (Oral agents and insulin ) Dosage adjustment of the antidiabetic_drug may be required</p>
<p>4116,- Antidiabetic_drugs : (Oral agents and insulin ) Dosage adjustment of the antidiabetic_drug may be required</p>
<p>4117,- Cholestyramine and colestipol  resins : Cholestyramine and colestipol  resins have the potential of binding thiazide_diuretics and reducing diuretic absorption from the gastrointestinal tract</p>
<p>4118,- Cholestyramine and colestipol  resins : Cholestyramine and colestipol  resins have the potential of binding thiazide_diuretics and reducing diuretic absorption from the gastrointestinal tract</p>
<p>4119,- Cholestyramine and colestipol  resins : Cholestyramine and colestipol  resins have the potential of binding thiazide_diuretics and reducing diuretic absorption from the gastrointestinal tract</p>
<p>4120,- Cholestyramine and colestipol  resins : Cholestyramine and colestipol  resins have the potential of binding thiazide_diuretics and reducing diuretic absorption from the gastrointestinal tract</p>
<p>4121,- Cholestyramine and colestipol  resins : Cholestyramine and colestipol  resins have the potential of binding thiazide_diuretics and reducing diuretic absorption from the gastrointestinal tract</p>
<p>4122,- Cholestyramine and colestipol  resins : Cholestyramine and colestipol  resins have the potential of binding thiazide_diuretics and reducing diuretic absorption from the gastrointestinal tract</p>
<p>4123,- Cholestyramine and colestipol  resins : Cholestyramine and colestipol  resins have the potential of binding thiazide_diuretics and reducing diuretic absorption from the gastrointestinal tract</p>
<p>4124,- Cholestyramine and colestipol  resins : Cholestyramine and colestipol  resins have the potential of binding thiazide_diuretics and reducing diuretic absorption from the gastrointestinal tract</p>
<p>4125,- Cholestyramine and colestipol  resins : Cholestyramine and colestipol  resins have the potential of binding thiazide_diuretics and reducing diuretic absorption from the gastrointestinal tract</p>
<p>4126,- Cholestyramine and colestipol  resins : Cholestyramine and colestipol  resins have the potential of binding thiazide_diuretics and reducing diuretic absorption from the gastrointestinal tract</p>
<p>4127,- Cholestyramine and colestipol  resins : Cholestyramine and colestipol  resins have the potential of binding thiazide_diuretics and reducing diuretic absorption from the gastrointestinal tract</p>
<p>4128,- Cholestyramine and colestipol  resins : Cholestyramine and colestipol  resins have the potential of binding thiazide_diuretics and reducing diuretic absorption from the gastrointestinal tract</p>
<p>4129,"- Corticosteroids , ACTH : Intensified electrolyte depletion, particularly hypokalemia"</p>
<p>4130,"- Skeletal_muscle_relaxants , nondepolarizing (e,g,, tubocurarine ): Possible increased responsiveness to the muscle_relaxant"</p>
<p>4131,Diuretic_agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.</p>
<p>4132,Diuretic_agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.</p>
<p>4133,Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide</p>
<p>4134,"- Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>4135,"- Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>4136,"- Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>4137,"- Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>4138,"- Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>4139,"- Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>4140,"- Non-steroidal_Anti-inflammatory_Drugs : In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."</p>
<p>4141,"Therefore, when chlorothiazide and non-steroidal_anti-inflammatory_agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained"</p>
<p>4142,"Therefore, when chlorothiazide and non-steroidal_anti-inflammatory_agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained"</p>
<p>4143,"Therefore, when chlorothiazide and non-steroidal_anti-inflammatory_agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained"</p>
<p>4144,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4145,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4146,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4147,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4148,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4149,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4150,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4151,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4152,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4153,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4154,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4155,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4156,"Chlorotrianisene may interact with antidepressants , aspirin , barbiturates , bromocriptine , calcium supplements, corticosteroids , corticotropin , cyclosporine , dantrolene , nicotine , somatropin , tamoxifen , and warfarin ."</p>
<p>4157,"Increased toxicity (CNS depression): CNS_depressants , MAO_inhibitors , tricyclic_antidepressants , phenothiazines ."</p>
<p>4158,"Increased toxicity (CNS depression): CNS_depressants , MAO_inhibitors , tricyclic_antidepressants , phenothiazines ."</p>
<p>4159,"Increased toxicity (CNS depression): CNS_depressants , MAO_inhibitors , tricyclic_antidepressants , phenothiazines ."</p>
<p>4160,"Increased toxicity (CNS depression): CNS_depressants , MAO_inhibitors , tricyclic_antidepressants , phenothiazines ."</p>
<p>4161,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia."</p>
<p>4162,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia."</p>
<p>4163,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia."</p>
<p>4164,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia."</p>
<p>4165,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia."</p>
<p>4166,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia."</p>
<p>4167,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia."</p>
<p>4168,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia."</p>
<p>4169,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia."</p>
<p>4170,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia."</p>
<p>4171,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia."</p>
<p>4172,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic_drug (eg, chlorpromazine ), an antiparkinsonian_drug (eg, trihexyphenidyl ), and/or a tricyclic_antidepressant (eg, amitriptyline )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia."</p>
<p>4173,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4174,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4175,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4176,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4177,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4178,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4179,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4180,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4181,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4182,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4183,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4184,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4185,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4186,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4187,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4188,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4189,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4190,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4191,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4192,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4193,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4194,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4195,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4196,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4197,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4198,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4199,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4200,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4201,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4202,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4203,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4204,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4205,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4206,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4207,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4208,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4209,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4210,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4211,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4212,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4213,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4214,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4215,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4216,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4217,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4218,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4219,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4220,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4221,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4222,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4223,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4224,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4225,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4226,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4227,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4228,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4229,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4230,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4231,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4232,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4233,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4234,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4235,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4236,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4237,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4238,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4239,"Interactions may also occur with the following: anti-depressants / anti-anxiety_drugs , drugs used to treat an overactive thyroid, beta-blockers (e,g,, propranolol ), sparfloxacin , grepafloxacin , guanethidine , guanadrel , metrizamide , cabergoline , lithium , narcotic pain medication (e,g,, codeine ), drugs used to aid sleep, drowsiness-causing antihistamines (e,g,, diphenhydramine ), any other drugs that may make you drowsy."</p>
<p>4240,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4241,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4242,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4243,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4244,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4245,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4246,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4247,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4248,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4249,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4250,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4251,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4252,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4253,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4254,"The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal_anti-inflammatory_agents and other drugs that are highly protein bound, salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine_oxidase_inhibitors , and beta_adrenergic_blocking_agents ."</p>
<p>4255,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products, estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>4256,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products, estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>4257,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products, estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel_blocking_drugs , and isoniazid ."</p>
<p>4258,"Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide , barbiturates should be employed with caution."</p>
<p>4259,"Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide , barbiturates should be employed with caution."</p>
<p>4260,"In some patients, a disulfiram -like reaction may be produced by the ingestion of alcohol ."</p>
<p>4261,A potential interaction between oral miconazole and oral hypoglycemic_agents leading to severe hypoglycemia has been reported.</p>
<p>4262,Chlorprothixene may increase the plasma-level of concomitantly given lithium .</p>
<p>4263,"If chlorprothixene is given concomitantly with opioids , the opioid dose should be reduced (by approx, 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively."</p>
<p>4264,"If chlorprothixene is given concomitantly with opioids , the opioid dose should be reduced (by approx, 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively."</p>
<p>4265,"If chlorprothixene is given concomitantly with opioids , the opioid dose should be reduced (by approx, 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively."</p>
<p>4266,"If chlorprothixene is given concomitantly with opioids , the opioid dose should be reduced (by approx, 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively."</p>
<p>4267,"If chlorprothixene is given concomitantly with opioids , the opioid dose should be reduced (by approx, 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively."</p>
<p>4268,"If chlorprothixene is given concomitantly with opioids , the opioid dose should be reduced (by approx, 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively."</p>
<p>4269,Avoid the concomitant use of chlorprothixene and tramadol ( Ultram ).</p>
<p>4270,Avoid the concomitant use of chlorprothixene and tramadol ( Ultram ).</p>
<p>4271,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates ."</p>
<p>4272,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates ."</p>
<p>4273,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates ."</p>
<p>4274,"Exert particular caution in combining chlorprothixene with other anticholinergic_drugs ( tricyclic_antidepressants and antiparkinsonian_agents ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma."</p>
<p>4275,"Exert particular caution in combining chlorprothixene with other anticholinergic_drugs ( tricyclic_antidepressants and antiparkinsonian_agents ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma."</p>
<p>4276,"Exert particular caution in combining chlorprothixene with other anticholinergic_drugs ( tricyclic_antidepressants and antiparkinsonian_agents ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma."</p>
<p>4277,Chlorthalidone may add to or potentiate the action of other antihypertensive_drugs .</p>
<p>4278,Chlorthalidone and related drugs may increase the responsiveness to tubocurarine .</p>
<p>4279,Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine .</p>
<p>4280,The concomitant use of alcohol or other central_nervous_system_depressants may have an additive effect.</p>
<p>4281,"Interactions for vitamin_D analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>4282,"Interactions for vitamin_D analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>4283,"Interactions for vitamin_D analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>4284,"Interactions for vitamin_D analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>4285,"Interactions for vitamin_D analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>4286,"Interactions for vitamin_D analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>4287,"Interactions for vitamin_D analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>4288,"Interactions for vitamin_D analogues ( Vitamin_D2 , Vitamin_D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat_soluble_vitamins ;"</p>
<p>4289,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>4290,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>4291,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>4292,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>4293,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>4294,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>4295,"Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin_D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism."</p>
<p>4296,"Since blood level of calcitriol /ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously."</p>
<p>4297,Some reports have shown that the concomitant administration of thiazides with vitamin_D causes hypercalcemia.</p>
<p>4298,"Digitalis : Vitamin_D dosage must be determined with care in patients undergoing treatment with digitalis , as hypercalcemia in such patients may precipitate cardiac arrhythmias."</p>
<p>4299,Ketoconazole : Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin_D .</p>
<p>4300,"However, in vivo drug interaction studies of ketoconazole with vitamin_D have not been investigated."</p>
<p>4301,"Corticosteroids : A relationship of functional antagonism exists between vitamin_D analogues, which promote calcium absorption, and corticosteroids , which inhibit calcium absorption."</p>
<p>4302,"Magnesium : Magnesium -containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin_D by patients on chronic renal dialysis."</p>
<p>4303,"Magnesium : Magnesium -containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin_D by patients on chronic renal dialysis."</p>
<p>4304,"Magnesium : Magnesium -containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin_D by patients on chronic renal dialysis."</p>
<p>4305,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4306,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4307,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4308,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4309,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4310,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4311,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4312,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4313,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4314,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4315,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4316,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4317,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4318,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4319,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4320,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4321,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4322,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4323,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4324,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4325,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4326,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4327,"Cholestyramine  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone , warfarin , thiazide_diuretics (acidic) or propranolol (basic), as well as tetracycline  penicillin_G , phenobarbital , thyroid and thyroxine preparations, estrogens and progestins , and digitalis ."</p>
<p>4328,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4329,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4330,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4331,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4332,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4333,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4334,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4335,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4336,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4337,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4338,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4339,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4340,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4341,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4342,"Cholestyramine  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  resin ."</p>
<p>4343,"Because cholestyramine binds bile acids, cholestyramine  resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat_soluble_vitamins such as A, D, E, and K."</p>
<p>4344,"Because cholestyramine binds bile acids, cholestyramine  resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat_soluble_vitamins such as A, D, E, and K."</p>
<p>4345,"Because cholestyramine binds bile acids, cholestyramine  resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat_soluble_vitamins such as A, D, E, and K."</p>
<p>4346,"Because cholestyramine binds bile acids, cholestyramine  resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat_soluble_vitamins such as A, D, E, and K."</p>
<p>4347,"Because cholestyramine binds bile acids, cholestyramine  resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat_soluble_vitamins such as A, D, E, and K."</p>
<p>4348,"When cholestyramine  resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble_vitamins should be considered."</p>
<p>4349,"When cholestyramine  resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble_vitamins should be considered."</p>
<p>4350,"When cholestyramine  resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble_vitamins should be considered."</p>
<p>4351,"SINCE CHOLESTYRAMINE  RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST # HOUR BEFORE OR # TO # HOURS AFTER CHOLESTYRAMINE  RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION."</p>
<p>4352,"SINCE CHOLESTYRAMINE  RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST # HOUR BEFORE OR # TO # HOURS AFTER CHOLESTYRAMINE  RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION."</p>
<p>4353,"SINCE CHOLESTYRAMINE  RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST # HOUR BEFORE OR # TO # HOURS AFTER CHOLESTYRAMINE  RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION."</p>
<p>4354,"SINCE CHOLESTYRAMINE  RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST # HOUR BEFORE OR # TO # HOURS AFTER CHOLESTYRAMINE  RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION."</p>
<p>4355,"In vitro studies demonstrated that the plasma protein binding of des-ciclesonide was not affected by warfarin or salicylic_acid , indicating no potential for protein binding-based drug interactions."</p>
<p>4356,"In vitro studies demonstrated that the plasma protein binding of des-ciclesonide was not affected by warfarin or salicylic_acid , indicating no potential for protein binding-based drug interactions."</p>
<p>4357,"In vitro studies demonstrated that the plasma protein binding of des-ciclesonide was not affected by warfarin or salicylic_acid , indicating no potential for protein binding-based drug interactions."</p>
<p>4358,"In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin , an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin ."</p>
<p>4359,"In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin , an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin ."</p>
<p>4360,"In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin , an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin ."</p>
<p>4361,"In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin , an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin ."</p>
<p>4362,"In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole , a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately #-fold at steady state, while levels of ciclesonide remained unchanged."</p>
<p>4363,"In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole , a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately #-fold at steady state, while levels of ciclesonide remained unchanged."</p>
<p>4364,"In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole , a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately #-fold at steady state, while levels of ciclesonide remained unchanged."</p>
<p>4365,"Therefore, ketoconazole should be administered with caution with intranasal ciclesonide ."</p>
<p>4366,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4367,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4368,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4369,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4370,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4371,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4372,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4373,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4374,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4375,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4376,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4377,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4378,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4379,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e,g,, acetaminophen , acyclovir , angiotensin-converting_enzyme_inhibitors , aminosalicylic_acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , furosemide , nonsteroidal_anti-inflammatory agents, theophylline , and zidovudine )."</p>
<p>4380,Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.</p>
<p>4381,Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.</p>
<p>4382,Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.</p>
<p>4383,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e,g,, intravenous aminoglycosides (e,g,, tobramycin , gentamicin , and amikacin ), amphotericin_B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal_anti-inflammatory_agents ] is contraindicated."</p>
<p>4384,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e,g,, intravenous aminoglycosides (e,g,, tobramycin , gentamicin , and amikacin ), amphotericin_B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal_anti-inflammatory_agents ] is contraindicated."</p>
<p>4385,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e,g,, intravenous aminoglycosides (e,g,, tobramycin , gentamicin , and amikacin ), amphotericin_B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal_anti-inflammatory_agents ] is contraindicated."</p>
<p>4386,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e,g,, intravenous aminoglycosides (e,g,, tobramycin , gentamicin , and amikacin ), amphotericin_B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal_anti-inflammatory_agents ] is contraindicated."</p>
<p>4387,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e,g,, intravenous aminoglycosides (e,g,, tobramycin , gentamicin , and amikacin ), amphotericin_B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal_anti-inflammatory_agents ] is contraindicated."</p>
<p>4388,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e,g,, intravenous aminoglycosides (e,g,, tobramycin , gentamicin , and amikacin ), amphotericin_B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal_anti-inflammatory_agents ] is contraindicated."</p>
<p>4389,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e,g,, intravenous aminoglycosides (e,g,, tobramycin , gentamicin , and amikacin ), amphotericin_B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal_anti-inflammatory_agents ] is contraindicated."</p>
<p>4390,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e,g,, intravenous aminoglycosides (e,g,, tobramycin , gentamicin , and amikacin ), amphotericin_B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal_anti-inflammatory_agents ] is contraindicated."</p>
<p>4391,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e,g,, intravenous aminoglycosides (e,g,, tobramycin , gentamicin , and amikacin ), amphotericin_B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal_anti-inflammatory_agents ] is contraindicated."</p>
<p>4392,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C,P,A, such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole ."</p>
<p>4393,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C,P,A, such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole ."</p>
<p>4394,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C,P,A, such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole ."</p>
<p>4395,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C,P,A, such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole ."</p>
<p>4396,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C,P,A, such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole ."</p>
<p>4397,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C,P,A, such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole ."</p>
<p>4398,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C,P,A, such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole ."</p>
<p>4399,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C,P,A, such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole ."</p>
<p>4400,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C,P,A, such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole ."</p>
<p>4401,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.</p>
<p>4402,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.</p>
<p>4403,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.</p>
<p>4404,"Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem , an inhibitor of C,P,A,."</p>
<p>4405,"Pletal does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin , a drug with metabolism very sensitive to C,P,A, inhibition."</p>
<p>4406,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4407,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4408,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4409,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4410,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4411,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4412,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4413,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4414,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4415,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4416,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4417,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4418,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4419,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4420,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4421,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4422,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4423,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4424,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4425,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4426,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4427,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4428,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4429,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4430,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4431,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4432,"Tagamet , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type_anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic_antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs."</p>
<p>4433,"therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly."</p>
<p>4434,"However, a crossover study in healthy subjects receiving either Tagamet # mg q,i,d, or # mg h,s, concomitantly with a # mg b,i,d, dosage of theophylline ( Theo-Dur , Key Pharmaceuticals, Inc,) demonstrated less alteration in steady-state theophylline peak serum levels with the # mg h,s, regimen, particularly in subjects aged # years and older."</p>
<p>4435,"However, a crossover study in healthy subjects receiving either Tagamet # mg q,i,d, or # mg h,s, concomitantly with a # mg b,i,d, dosage of theophylline ( Theo-Dur , Key Pharmaceuticals, Inc,) demonstrated less alteration in steady-state theophylline peak serum levels with the # mg h,s, regimen, particularly in subjects aged # years and older."</p>
<p>4436,"However, a crossover study in healthy subjects receiving either Tagamet # mg q,i,d, or # mg h,s, concomitantly with a # mg b,i,d, dosage of theophylline ( Theo-Dur , Key Pharmaceuticals, Inc,) demonstrated less alteration in steady-state theophylline peak serum levels with the # mg h,s, regimen, particularly in subjects aged # years and older."</p>
<p>4437,"However, a crossover study in healthy subjects receiving either Tagamet # mg q,i,d, or # mg h,s, concomitantly with a # mg b,i,d, dosage of theophylline ( Theo-Dur , Key Pharmaceuticals, Inc,) demonstrated less alteration in steady-state theophylline peak serum levels with the # mg h,s, regimen, particularly in subjects aged # years and older."</p>
<p>4438,Amitriptyline : Concurrent administration of # mg or # mg cinacalcet with # mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.</p>
<p>4439,Amitriptyline : Concurrent administration of # mg or # mg cinacalcet with # mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.</p>
<p>4440,Amitriptyline : Concurrent administration of # mg or # mg cinacalcet with # mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.</p>
<p>4441,Amitriptyline : Concurrent administration of # mg or # mg cinacalcet with # mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.</p>
<p>4442,Amitriptyline : Concurrent administration of # mg or # mg cinacalcet with # mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.</p>
<p>4443,Amitriptyline : Concurrent administration of # mg or # mg cinacalcet with # mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.</p>
<p>4444,Amitriptyline : Concurrent administration of # mg or # mg cinacalcet with # mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.</p>
<p>4445,"Co-administration of ketoconazole , a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single # mg dose of Sensipar by # fold."</p>
<p>4446,"Co-administration of ketoconazole , a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single # mg dose of Sensipar by # fold."</p>
<p>4447,"Co-administration of ketoconazole , a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single # mg dose of Sensipar by # fold."</p>
<p>4448,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e,g,, ketoconazole , erythromycin , itraconazole ;"</p>
<p>4449,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e,g,, ketoconazole , erythromycin , itraconazole ;"</p>
<p>4450,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e,g,, ketoconazole , erythromycin , itraconazole ;"</p>
<p>4451,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e,g,, ketoconazole , erythromycin , itraconazole ;"</p>
<p>4452,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e,g,, ketoconazole , erythromycin , itraconazole ;"</p>
<p>4453,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e,g,, ketoconazole , erythromycin , itraconazole ;"</p>
<p>4454,Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones .</p>
<p>4455,There have been reports of theophylline -related side-effects in patients on concomitant theophylline - quinolone therapy.</p>
<p>4456,There have been reports of theophylline -related side-effects in patients on concomitant theophylline - quinolone therapy.</p>
<p>4457,Quinolones have also been shown to interfere with the metabolism of caffeine .</p>
<p>4458,"Although this interaction has not been reported with cinoxacin , caution should be exercised when cinoxacin is given concomitantly with caffeine -containing products."</p>
<p>4459,"Although this interaction has not been reported with cinoxacin , caution should be exercised when cinoxacin is given concomitantly with caffeine -containing products."</p>
<p>4460,"Antacids or sucralfate substantially interfere with the absorption of some quinolones , resulting in low urine levels."</p>
<p>4461,"Antacids or sucralfate substantially interfere with the absorption of some quinolones , resulting in low urine levels."</p>
<p>4462,"Antacids or sucralfate substantially interfere with the absorption of some quinolones , resulting in low urine levels."</p>
<p>4463,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4464,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4465,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4466,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4467,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4468,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4469,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4470,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4471,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4472,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4473,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4474,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4475,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4476,"Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels."</p>
<p>4477,"Quinolones , including cinoxacin , may enhance the effects of oral anticoagulants , such as warfarin or its derivatives."</p>
<p>4478,"Quinolones , including cinoxacin , may enhance the effects of oral anticoagulants , such as warfarin or its derivatives."</p>
<p>4479,"Quinolones , including cinoxacin , may enhance the effects of oral anticoagulants , such as warfarin or its derivatives."</p>
<p>4480,"Quinolones , including cinoxacin , may enhance the effects of oral anticoagulants , such as warfarin or its derivatives."</p>
<p>4481,"Quinolones , including cinoxacin , may enhance the effects of oral anticoagulants , such as warfarin or its derivatives."</p>
<p>4482,"Quinolones , including cinoxacin , may enhance the effects of oral anticoagulants , such as warfarin or its derivatives."</p>
<p>4483,Seizures have been reported in patients taking another quinolone_class_antimicrobial and the nonsteroidal_anti-inflammatory_drug  fenbufen concurrently.</p>
<p>4484,Seizures have been reported in patients taking another quinolone_class_antimicrobial and the nonsteroidal_anti-inflammatory_drug  fenbufen concurrently.</p>
<p>4485,Seizures have been reported in patients taking another quinolone_class_antimicrobial and the nonsteroidal_anti-inflammatory_drug  fenbufen concurrently.</p>
<p>4486,Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal_anti-inflammatory_agents are administered concomitantly.</p>
<p>4487,Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine .</p>
<p>4488,Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine .</p>
<p>4489,"Some quinolones , including ciprofloxacin , have also been shown to interfere with the metabolism of caffeine ."</p>
<p>4490,"Some quinolones , including ciprofloxacin , have also been shown to interfere with the metabolism of caffeine ."</p>
<p>4491,"Some quinolones , including ciprofloxacin , have also been shown to interfere with the metabolism of caffeine ."</p>
<p>4492,"Some quinolones , including ciprofloxacin , have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly."</p>
<p>4493,"Some quinolones , including ciprofloxacin , have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly."</p>
<p>4494,"Some quinolones , including ciprofloxacin , have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly."</p>
<p>4495,"Glyburide : The concomitant administration of ciprofloxacin with the sulfonylurea  glyburide has, on rare occasions, resulted in severe hypoglycemia."</p>
<p>4496,"Glyburide : The concomitant administration of ciprofloxacin with the sulfonylurea  glyburide has, on rare occasions, resulted in severe hypoglycemia."</p>
<p>4497,"Glyburide : The concomitant administration of ciprofloxacin with the sulfonylurea  glyburide has, on rare occasions, resulted in severe hypoglycemia."</p>
<p>4498,Histamine_H2-receptor_antagonists : Histamine_H2-receptor_antagonists appear to have no significant effect on the bioavailability of ciprofloxacin .</p>
<p>4499,"Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin , potentially leading to increased plasma levels of methotrexate ."</p>
<p>4500,"Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin , potentially leading to increased plasma levels of methotrexate ."</p>
<p>4501,"Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin , potentially leading to increased plasma levels of methotrexate ."</p>
<p>4502,"Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated."</p>
<p>4503,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4504,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4505,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4506,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4507,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4508,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4509,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4510,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4511,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4512,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4513,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4514,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4515,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4516,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4517,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4518,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4519,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4520,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4521,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4522,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4523,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4524,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4525,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4526,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4527,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4528,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4529,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4530,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4531,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4532,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4533,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4534,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4535,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4536,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4537,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4538,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4539,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4540,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4541,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4542,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4543,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4544,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4545,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum  antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired."</p>
<p>4546,"This time window is different than for other oral formulations of ciprofloxacin , which are usually administered # hours before or # hours after antacids ."</p>
<p>4547,Omeprazole : The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin_XR was given alone or when Proquin_XR was given # hours after omeprazole at the dose that maximally suppresses gastric acid secretion.</p>
<p>4548,Omeprazole : The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin_XR was given alone or when Proquin_XR was given # hours after omeprazole at the dose that maximally suppresses gastric acid secretion.</p>
<p>4549,Omeprazole : The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin_XR was given alone or when Proquin_XR was given # hours after omeprazole at the dose that maximally suppresses gastric acid secretion.</p>
<p>4550,Omeprazole : The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin_XR was given alone or when Proquin_XR was given # hours after omeprazole at the dose that maximally suppresses gastric acid secretion.</p>
<p>4551,Omeprazole : The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin_XR was given alone or when Proquin_XR was given # hours after omeprazole at the dose that maximally suppresses gastric acid secretion.</p>
<p>4552,"Omeprazole should be taken as directed and Proquin_XR should be taken with a main meal of the day, preferably the evening meal,."</p>
<p>4553,Phenytoin : Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin .</p>
<p>4554,Phenytoin : Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin .</p>
<p>4555,Probenecid : Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.</p>
<p>4556,Probenecid : Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.</p>
<p>4557,"Theophylline : As with some other quinolones , concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life."</p>
<p>4558,"Theophylline : As with some other quinolones , concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life."</p>
<p>4559,"Theophylline : As with some other quinolones , concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life."</p>
<p>4560,"Theophylline : As with some other quinolones , concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life."</p>
<p>4561,"Theophylline : As with some other quinolones , concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life."</p>
<p>4562,Warfarin : Quinolones have been reported to enhance the effects of the oral anticoagulant  warfarin or its derivatives.</p>
<p>4563,Warfarin : Quinolones have been reported to enhance the effects of the oral anticoagulant  warfarin or its derivatives.</p>
<p>4564,Warfarin : Quinolones have been reported to enhance the effects of the oral anticoagulant  warfarin or its derivatives.</p>
<p>4565,"Antibiotics : In vitro and/or in vivo data show that clarithromycin , erythromycin , and troleandomycin markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4566,"Antibiotics : In vitro and/or in vivo data show that clarithromycin , erythromycin , and troleandomycin markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4567,"Antibiotics : In vitro and/or in vivo data show that clarithromycin , erythromycin , and troleandomycin markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4568,"Antibiotics : In vitro and/or in vivo data show that clarithromycin , erythromycin , and troleandomycin markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4569,"Antibiotics : In vitro and/or in vivo data show that clarithromycin , erythromycin , and troleandomycin markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4570,"Antibiotics : In vitro and/or in vivo data show that clarithromycin , erythromycin , and troleandomycin markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4571,"Anticholinergics : Concurrent administration of certain anticholinergic_compounds , such as belladonna_alkaloids and dicyclomine , would be expected to compromise the beneficial effects of cisapride ."</p>
<p>4572,"Anticholinergics : Concurrent administration of certain anticholinergic_compounds , such as belladonna_alkaloids and dicyclomine , would be expected to compromise the beneficial effects of cisapride ."</p>
<p>4573,"Anticholinergics : Concurrent administration of certain anticholinergic_compounds , such as belladonna_alkaloids and dicyclomine , would be expected to compromise the beneficial effects of cisapride ."</p>
<p>4574,"Anticholinergics : Concurrent administration of certain anticholinergic_compounds , such as belladonna_alkaloids and dicyclomine , would be expected to compromise the beneficial effects of cisapride ."</p>
<p>4575,"Anticholinergics : Concurrent administration of certain anticholinergic_compounds , such as belladonna_alkaloids and dicyclomine , would be expected to compromise the beneficial effects of cisapride ."</p>
<p>4576,"Anticholinergics : Concurrent administration of certain anticholinergic_compounds , such as belladonna_alkaloids and dicyclomine , would be expected to compromise the beneficial effects of cisapride ."</p>
<p>4577,"Anticholinergics : Concurrent administration of certain anticholinergic_compounds , such as belladonna_alkaloids and dicyclomine , would be expected to compromise the beneficial effects of cisapride ."</p>
<p>4578,"Anticholinergics : Concurrent administration of certain anticholinergic_compounds , such as belladonna_alkaloids and dicyclomine , would be expected to compromise the beneficial effects of cisapride ."</p>
<p>4579,"Anticholinergics : Concurrent administration of certain anticholinergic_compounds , such as belladonna_alkaloids and dicyclomine , would be expected to compromise the beneficial effects of cisapride ."</p>
<p>4580,"Anticholinergics : Concurrent administration of certain anticholinergic_compounds , such as belladonna_alkaloids and dicyclomine , would be expected to compromise the beneficial effects of cisapride ."</p>
<p>4581,"It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary."</p>
<p>4582,"Antidepressants : In vitro data indicate that nefazodone inhibits the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4583,"Antidepressants : In vitro data indicate that nefazodone inhibits the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4584,"Antifungals : In vitro and/or in vivo data indicate that fluconazole , itraconazole , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4585,"Antifungals : In vitro and/or in vivo data indicate that fluconazole , itraconazole , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4586,"Antifungals : In vitro and/or in vivo data indicate that fluconazole , itraconazole , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4587,"Antifungals : In vitro and/or in vivo data indicate that fluconazole , itraconazole , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4588,"Antifungals : In vitro and/or in vivo data indicate that fluconazole , itraconazole , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4589,"Antifungals : In vitro and/or in vivo data indicate that fluconazole , itraconazole , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4590,"Antifungals : In vitro and/or in vivo data indicate that fluconazole , itraconazole , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4591,"Antifungals : In vitro and/or in vivo data indicate that fluconazole , itraconazole , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4592,"Antifungals : In vitro and/or in vivo data indicate that fluconazole , itraconazole , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG."</p>
<p>4593,"Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride , resulting in a mean eight-fold increase in AUC of cisapride ."</p>
<p>4594,"Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride , resulting in a mean eight-fold increase in AUC of cisapride ."</p>
<p>4595,A study in # normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.</p>
<p>4596,"H2_Receptor_Antagonists : Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride , there is no effect on cisapride absorption when it is coadministered with ranitidine ."</p>
<p>4597,"H2_Receptor_Antagonists : Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride , there is no effect on cisapride absorption when it is coadministered with ranitidine ."</p>
<p>4598,"H2_Receptor_Antagonists : Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride , there is no effect on cisapride absorption when it is coadministered with ranitidine ."</p>
<p>4599,"H2_Receptor_Antagonists : Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride , there is no effect on cisapride absorption when it is coadministered with ranitidine ."</p>
<p>4600,"H2_Receptor_Antagonists : Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride , there is no effect on cisapride absorption when it is coadministered with ranitidine ."</p>
<p>4601,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride .</p>
<p>4602,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride .</p>
<p>4603,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride .</p>
<p>4604,Protease_Inhibitors : In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.</p>
<p>4605,Protease_Inhibitors : In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.</p>
<p>4606,Protease_Inhibitors : In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.</p>
<p>4607,Protease_Inhibitors : In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.</p>
<p>4608,Protease_Inhibitors : In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.</p>
<p>4609,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics , including those of Class IA (such as quinidine and procainamide ) and Class III (such as sotalol );"</p>
<p>4610,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics , including those of Class IA (such as quinidine and procainamide ) and Class III (such as sotalol );"</p>
<p>4611,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics , including those of Class IA (such as quinidine and procainamide ) and Class III (such as sotalol );"</p>
<p>4612,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics , including those of Class IA (such as quinidine and procainamide ) and Class III (such as sotalol );"</p>
<p>4613,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics , including those of Class IA (such as quinidine and procainamide ) and Class III (such as sotalol );"</p>
<p>4614,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics , including those of Class IA (such as quinidine and procainamide ) and Class III (such as sotalol );"</p>
<p>4615,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics , including those of Class IA (such as quinidine and procainamide ) and Class III (such as sotalol );"</p>
<p>4616,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics , including those of Class IA (such as quinidine and procainamide ) and Class III (such as sotalol );"</p>
<p>4617,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics , including those of Class IA (such as quinidine and procainamide ) and Class III (such as sotalol );"</p>
<p>4618,Administration of #-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced 95% neuromuscular block.</p>
<p>4619,The time to onset of maximum block following NIMBEX is approximately # minutes faster with prior administration of succinylcholine .</p>
<p>4620,Prior administration of succinylcholine had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of NIMBEX .</p>
<p>4621,Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.</p>
<p>4622,Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.</p>
<p>4623,Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.</p>
<p>4624,Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.</p>
<p>4625,The use of NIMBEX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.</p>
<p>4626,The use of NIMBEX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.</p>
<p>4627,"Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium , pancuronium , or atracurium were administered following varying degrees of recovery from single doses or infusions of NIMBEX ."</p>
<p>4628,"Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium , pancuronium , or atracurium were administered following varying degrees of recovery from single doses or infusions of NIMBEX ."</p>
<p>4629,"Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium , pancuronium , or atracurium were administered following varying degrees of recovery from single doses or infusions of NIMBEX ."</p>
<p>4630,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4631,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4632,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4633,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4634,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4635,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4636,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4637,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4638,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4639,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4640,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4641,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4642,Isoflurane or enflurane administered with nitrous_oxide / oxygen to achieve # MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX .</p>
<p>4643,"Fifteen to # minutes of exposure to # MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents."</p>
<p>4644,"Fifteen to # minutes of exposure to # MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents."</p>
<p>4645,"Fifteen to # minutes of exposure to # MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents."</p>
<p>4646,"Fifteen to # minutes of exposure to # MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents."</p>
<p>4647,"Fifteen to # minutes of exposure to # MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents."</p>
<p>4648,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary."</p>
<p>4649,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary."</p>
<p>4650,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary."</p>
<p>4651,In clinical studies propofol had no effect on the duration of action or dosing requirements for NIMBEX .</p>
<p>4652,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4653,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4654,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4655,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4656,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4657,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4658,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4659,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4660,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4661,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4662,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4663,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4664,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4665,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4666,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4667,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4668,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4669,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4670,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4671,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4672,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4673,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4674,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4675,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4676,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4677,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4678,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4679,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4680,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4681,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4682,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4683,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4684,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing_agents such as NIMBEX include certain antibiotics (e, g,, aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium_colistemethate ), magnesium salts, lithium , local anesthetics , procainamide , and quinidine ."</p>
<p>4685,Resistance to the neuromuscular blocking action of nondepolarizing_neuromuscular_blocking_agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .</p>
<p>4686,Resistance to the neuromuscular blocking action of nondepolarizing_neuromuscular_blocking_agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .</p>
<p>4687,Resistance to the neuromuscular blocking action of nondepolarizing_neuromuscular_blocking_agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .</p>
<p>4688,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher."</p>
<p>4689,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher."</p>
<p>4690,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher."</p>
<p>4691,Plasma levels of anticonvulsant_agents may become subtherapeutic during cisplatin therapy.</p>
<p>4692,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4693,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4694,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4695,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4696,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4697,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4698,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4699,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4700,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4701,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4702,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4703,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4704,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4705,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4706,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4707,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4708,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4709,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4710,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4711,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4712,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4713,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4714,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4715,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4716,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4717,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4718,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4719,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4720,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4721,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4722,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4723,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4724,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4725,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4726,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4727,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4728,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4729,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4730,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4731,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4732,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4733,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4734,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4735,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4736,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4737,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4738,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4739,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4740,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4741,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4742,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4743,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4744,"Central_nervous_system_depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications, muscle_relaxants , narcotics , sedatives , sleeping pills and tranquilizers"</p>
<p>4745,The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.</p>
<p>4746,The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.</p>
<p>4747,It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.</p>
<p>4748,"In controlled clinical trials of AUGMENTIN_XR , # patients received concomitant allopurinol and AUGMENTIN_XR ."</p>
<p>4749,"In controlled clinical trials of AUGMENTIN_XR , # patients received concomitant allopurinol and AUGMENTIN_XR ."</p>
<p>4750,"However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN_XR and allopurinol use."</p>
<p>4751,"In common with other broad-spectrum_antibiotics , AUGMENTIN_XR may reduce the efficacy of oral contraceptives"</p>
<p>4752,"In common with other broad-spectrum_antibiotics , AUGMENTIN_XR may reduce the efficacy of oral contraceptives"</p>
<p>4753,"In common with other broad-spectrum_antibiotics , AUGMENTIN_XR may reduce the efficacy of oral contraceptives"</p>
<p>4754,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS_depressants including barbiturates , tranquilizers , and alcohol ."</p>
<p>4755,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS_depressants including barbiturates , tranquilizers , and alcohol ."</p>
<p>4756,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS_depressants including barbiturates , tranquilizers , and alcohol ."</p>
<p>4757,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS_depressants including barbiturates , tranquilizers , and alcohol ."</p>
<p>4758,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS_depressants including barbiturates , tranquilizers , and alcohol ."</p>
<p>4759,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS_depressants including barbiturates , tranquilizers , and alcohol ."</p>
<p>4760,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS_depressants including barbiturates , tranquilizers , and alcohol ."</p>
<p>4761,Patients receiving antihistamines should be advised against the concurrent use of other CNS_depressant_drugs .</p>
<p>4762,Monoamine_oxidase_(MAO)_inhibitors prolong and intensify the anticholinergic effects of antihistamines .</p>
<p>4763,"Amantadine , tricyclic_antidepressants , and MAOIs may increase anticholinergic effect of clidinium ."</p>
<p>4764,"Amantadine , tricyclic_antidepressants , and MAOIs may increase anticholinergic effect of clidinium ."</p>
<p>4765,"Amantadine , tricyclic_antidepressants , and MAOIs may increase anticholinergic effect of clidinium ."</p>
<p>4766,"Clidinium may decrease the effect of phenothiazines , levodopa , and ketoconazole ."</p>
<p>4767,"Clidinium may decrease the effect of phenothiazines , levodopa , and ketoconazole ."</p>
<p>4768,"Clidinium may decrease the effect of phenothiazines , levodopa , and ketoconazole ."</p>
<p>4769,Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular_blocking_agents .</p>
<p>4770,Antagonism has been demonstrated between clindamycin and erythromycin in vitro.</p>
<p>4771,Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.</p>
<p>4772,"If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine , it is still advisable to continue treatment with both drugs."</p>
<p>4773,Caution should be exercised when anticoagulants are given in conjunction with Atromid-S .</p>
<p>4774,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.</p>
<p>4775,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.</p>
<p>4776,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.</p>
<p>4777,The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.</p>
<p>4778,Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.</p>
<p>4779,"For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure."</p>
<p>4780,"While it is not known whether this interaction occurs with fibrates other than gemfibrozil , myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate ."</p>
<p>4781,"While it is not known whether this interaction occurs with fibrates other than gemfibrozil , myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate ."</p>
<p>4782,"While it is not known whether this interaction occurs with fibrates other than gemfibrozil , myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate ."</p>
<p>4783,"While it is not known whether this interaction occurs with fibrates other than gemfibrozil , myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate ."</p>
<p>4784,"While it is not known whether this interaction occurs with fibrates other than gemfibrozil , myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate ."</p>
<p>4785,"Therefore, the combined use of lovastatin with fibrates should generally be avoided."</p>
<p>4786,Anafranil should not be used with MAO_inhibitors .</p>
<p>4787,Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic_drugs .</p>
<p>4788,Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic_drugs .</p>
<p>4789,Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic_drugs .</p>
<p>4790,"Several tricyclic_antidepressants have been reported to block the pharmacologic effects of guanethidine , clonidine , or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic_antidepressants ."</p>
<p>4791,"Several tricyclic_antidepressants have been reported to block the pharmacologic effects of guanethidine , clonidine , or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic_antidepressants ."</p>
<p>4792,"Several tricyclic_antidepressants have been reported to block the pharmacologic effects of guanethidine , clonidine , or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic_antidepressants ."</p>
<p>4793,"Several tricyclic_antidepressants have been reported to block the pharmacologic effects of guanethidine , clonidine , or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic_antidepressants ."</p>
<p>4794,"Several tricyclic_antidepressants have been reported to block the pharmacologic effects of guanethidine , clonidine , or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic_antidepressants ."</p>
<p>4795,"Several tricyclic_antidepressants have been reported to block the pharmacologic effects of guanethidine , clonidine , or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic_antidepressants ."</p>
<p>4796,"Several tricyclic_antidepressants have been reported to block the pharmacologic effects of guanethidine , clonidine , or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic_antidepressants ."</p>
<p>4797,"Several tricyclic_antidepressants have been reported to block the pharmacologic effects of guanethidine , clonidine , or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic_antidepressants ."</p>
<p>4798,"Several tricyclic_antidepressants have been reported to block the pharmacologic effects of guanethidine , clonidine , or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic_antidepressants ."</p>
<p>4799,The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol ;</p>
<p>4800,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4801,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4802,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4803,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4804,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4805,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4806,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4807,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4808,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4809,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4810,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4811,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4812,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4813,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4814,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4815,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4816,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4817,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4818,"plasma levels of several closely related tricyclic_antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e,g,, cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers (e,g,, barbiturates , phenytoin ), and such an effect may be anticipated with CMI as well."</p>
<p>4819,"Administration of CMI has been reported to increase the plasma levels of phenobarbital , if given concomitantly."</p>
<p>4820,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."</p>
<p>4821,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."</p>
<p>4822,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."</p>
<p>4823,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."</p>
<p>4824,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."</p>
<p>4825,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , paroxetine , and fluvoxamine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>4826,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , paroxetine , and fluvoxamine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>4827,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , paroxetine , and fluvoxamine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>4828,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , paroxetine , and fluvoxamine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>4829,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , paroxetine , and fluvoxamine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>4830,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , paroxetine , and fluvoxamine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>4831,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , paroxetine , and fluvoxamine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>4832,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , paroxetine , and fluvoxamine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>4833,"Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCA metabolism."</p>
<p>4834,The extent to which SSRI - TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.</p>
<p>4835,The extent to which SSRI - TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.</p>
<p>4836,"Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other."</p>
<p>4837,"Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine , given the long half-life of the parent and active metabolite (at least # weeks may be necessary)."</p>
<p>4838,Concomitant use of agents in the tricyclic_antidepressant_class (which includes Anafranil ) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic_antidepressant_agent or the other drug.</p>
<p>4839,Concomitant use of agents in the tricyclic_antidepressant_class (which includes Anafranil ) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic_antidepressant_agent or the other drug.</p>
<p>4840,It is desirable to monitor TCA plasma levels whenever an agent of the tricyclic_antidepressant_class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).</p>
<p>4841,It is desirable to monitor TCA plasma levels whenever an agent of the tricyclic_antidepressant_class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).</p>
<p>4842,It is desirable to monitor TCA plasma levels whenever an agent of the tricyclic_antidepressant_class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).</p>
<p>4843,"Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e,g,, warfarin , digoxin ) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects."</p>
<p>4844,"Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e,g,, warfarin , digoxin ) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects."</p>
<p>4845,"Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e,g,, warfarin , digoxin ) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects."</p>
<p>4846,"Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e,g,, warfarin , digoxin ) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects."</p>
<p>4847,"Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin , carbamazepine , or phenobarbital ."</p>
<p>4848,"Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin , carbamazepine , or phenobarbital ."</p>
<p>4849,"Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin , carbamazepine , or phenobarbital ."</p>
<p>4850,"Effect of Other Drugs on the Pharmacokinetics of Clonazepam : Literature reports suggest that ranitidine , an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics."</p>
<p>4851,"In a study in which the # mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic_agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone."</p>
<p>4852,"In a study in which the # mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic_agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone."</p>
<p>4853,"In a study in which the # mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic_agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone."</p>
<p>4854,"In a study in which the # mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic_agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone."</p>
<p>4855,"In a study in which the # mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic_agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone."</p>
<p>4856,"In a study in which the # mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic_agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone."</p>
<p>4857,"In a study in which the # mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic_agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone."</p>
<p>4858,"In a study in which the # mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic_agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone."</p>
<p>4859,"In a study in which the # mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic_agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone."</p>
<p>4860,"In a study in which the # mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic_agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone."</p>
<p>4861,"In a study in which the # mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic_agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone."</p>
<p>4862,Fluoxetine does not affect the pharmacokinetics of clonazepam .</p>
<p>4863,"Cytochrome P-450 inducers, such as phenytoin , carbamazepine and phenobarbital , induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels."</p>
<p>4864,"Cytochrome P-450 inducers, such as phenytoin , carbamazepine and phenobarbital , induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels."</p>
<p>4865,"Cytochrome P-450 inducers, such as phenytoin , carbamazepine and phenobarbital , induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels."</p>
<p>4866,"Cytochrome P-450 inducers, such as phenytoin , carbamazepine and phenobarbital , induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels."</p>
<p>4867,"Cytochrome P-450 inducers, such as phenytoin , carbamazepine and phenobarbital , induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels."</p>
<p>4868,"Cytochrome P-450 inducers, such as phenytoin , carbamazepine and phenobarbital , induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels."</p>
<p>4869,"Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal_agents , should be used cautiously in patients receiving clonazepam ."</p>
<p>4870,"Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal_agents , should be used cautiously in patients receiving clonazepam ."</p>
<p>4871,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4872,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4873,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4874,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4875,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4876,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4877,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4878,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4879,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4880,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4881,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4882,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4883,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4884,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4885,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4886,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4887,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4888,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4889,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4890,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4891,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4892,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4893,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4894,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4895,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4896,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4897,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4898,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4899,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4900,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4901,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4902,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4903,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4904,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4905,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4906,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4907,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4908,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4909,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4910,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4911,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4912,"Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine_class of drugs may be potentiated by alcohol , narcotics , barbiturates , nonbarbiturate_hypnotics , antianxiety_agents , the phenothiazines_classes_of_antipsychotic_agents , thioxanthene_classes_of_antipsychotic_agents and butyrophenone_classes_of_antipsychotic_agents , monoamine_oxidase_inhibitors and the tricyclic_antidepressants , and by other anticonvulsant_drugs ."</p>
<p>4913,"Tablet If a patient receiving clonidine_hydrochloride is also taking tricyclic_antidepressants , the effect of clonidine may be reduced, thus necessitating an increase in dosage."</p>
<p>4914,"Tablet If a patient receiving clonidine_hydrochloride is also taking tricyclic_antidepressants , the effect of clonidine may be reduced, thus necessitating an increase in dosage."</p>
<p>4915,"Clonidine_hydrochloride may enhance the CNS-depressive effects of alcohol , barbiturates or other sedatives ."</p>
<p>4916,"Clonidine_hydrochloride may enhance the CNS-depressive effects of alcohol , barbiturates or other sedatives ."</p>
<p>4917,"Clonidine_hydrochloride may enhance the CNS-depressive effects of alcohol , barbiturates or other sedatives ."</p>
<p>4918,"Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating_drugs ."</p>
<p>4919,"Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating_drugs ."</p>
<p>4920,"Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating_drugs ."</p>
<p>4921,"Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating_drugs ."</p>
<p>4922,"Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating_drugs ."</p>
<p>4923,"Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating_drugs ."</p>
<p>4924,"Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating_drugs ."</p>
<p>4925,"Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating_drugs ."</p>
<p>4926,"Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating_drugs ."</p>
<p>4927,"Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating_drugs ."</p>
<p>4928,"Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating_drugs ."</p>
<p>4929,Narcotic_analgesics may potentiate the hypotensive effects of clonidine .</p>
<p>4930,Tricyclic_antidepressants may antagonize the hypotensive effects of clonidine .</p>
<p>4931,The effects of tricyclic_antidepressants on clonidine s analgesic actions are not known.</p>
<p>4932,Beta_blockers may exacerbate the hypertensive response seen with clonidine withdrawl.</p>
<p>4933,"Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e,g,, digitalis , calcium_channel_blockers , and beta-blockers ."</p>
<p>4934,"Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e,g,, digitalis , calcium_channel_blockers , and beta-blockers ."</p>
<p>4935,"Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e,g,, digitalis , calcium_channel_blockers , and beta-blockers ."</p>
<p>4936,There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine .</p>
<p>4937,"Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics , including both sensory and motor blockade."</p>
<p>4938,"Animal experience indicates that clorazepate_dipotassium prolongs the sleeping time after hexobarbital or after ethyl_alcohol , increases the inhibitory effects of chlorpromazine , but does not exhibit monoamine oxidase inhibition."</p>
<p>4939,"Animal experience indicates that clorazepate_dipotassium prolongs the sleeping time after hexobarbital or after ethyl_alcohol , increases the inhibitory effects of chlorpromazine , but does not exhibit monoamine oxidase inhibition."</p>
<p>4940,"Animal experience indicates that clorazepate_dipotassium prolongs the sleeping time after hexobarbital or after ethyl_alcohol , increases the inhibitory effects of chlorpromazine , but does not exhibit monoamine oxidase inhibition."</p>
<p>4941,"Animal experience indicates that clorazepate_dipotassium prolongs the sleeping time after hexobarbital or after ethyl_alcohol , increases the inhibitory effects of chlorpromazine , but does not exhibit monoamine oxidase inhibition."</p>
<p>4942,"Animal experience indicates that clorazepate_dipotassium prolongs the sleeping time after hexobarbital or after ethyl_alcohol , increases the inhibitory effects of chlorpromazine , but does not exhibit monoamine oxidase inhibition."</p>
<p>4943,"Animal experience indicates that clorazepate_dipotassium prolongs the sleeping time after hexobarbital or after ethyl_alcohol , increases the inhibitory effects of chlorpromazine , but does not exhibit monoamine oxidase inhibition."</p>
<p>4944,"The actions of the benzodiazepines may be potentiated by barbiturates , narcotics , phenothiazines , monoamine_oxidase_inhibitors or other antidepressants ."</p>
<p>4945,"The actions of the benzodiazepines may be potentiated by barbiturates , narcotics , phenothiazines , monoamine_oxidase_inhibitors or other antidepressants ."</p>
<p>4946,"The actions of the benzodiazepines may be potentiated by barbiturates , narcotics , phenothiazines , monoamine_oxidase_inhibitors or other antidepressants ."</p>
<p>4947,"The actions of the benzodiazepines may be potentiated by barbiturates , narcotics , phenothiazines , monoamine_oxidase_inhibitors or other antidepressants ."</p>
<p>4948,"The actions of the benzodiazepines may be potentiated by barbiturates , narcotics , phenothiazines , monoamine_oxidase_inhibitors or other antidepressants ."</p>
<p>4949,"In bioavailability studies with normal subjects, the concurrent administration of antacids at therapeutic levels did not significantly influence the bioavailability of TRANXENE tablets."</p>
<p>4950,"Given the primary CNS effects of Clozapine , caution is advised in using it concomitantly with other CNS-active drugs or alcohol ."</p>
<p>4951,similar events have been reported in patients taking other psychotropic_drugs or even Clozapine by itself.</p>
<p>4952,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics , caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic_drug ."</p>
<p>4953,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics , caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic_drug ."</p>
<p>4954,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics , caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic_drug ."</p>
<p>4955,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics , caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic_drug ."</p>
<p>4956,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics , caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic_drug ."</p>
<p>4957,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics , caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic_drug ."</p>
<p>4958,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics , caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic_drug ."</p>
<p>4959,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics , caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic_drug ."</p>
<p>4960,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics , caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic_drug ."</p>
<p>4961,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics , caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic_drug ."</p>
<p>4962,Clozapine may potentiate the hypotensive effects of antihypertensive_drugs and the anticholinergic effects of atropine -type drugs.</p>
<p>4963,Clozapine may potentiate the hypotensive effects of antihypertensive_drugs and the anticholinergic effects of atropine -type drugs.</p>
<p>4964,Clozapine may potentiate the hypotensive effects of antihypertensive_drugs and the anticholinergic effects of atropine -type drugs.</p>
<p>4965,"Phenytoin , nicotine , and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose."</p>
<p>4966,"Phenytoin , nicotine , and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose."</p>
<p>4967,"Phenytoin , nicotine , and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose."</p>
<p>4968,"Phenytoin , nicotine , and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose."</p>
<p>4969,"Phenytoin , nicotine , and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose."</p>
<p>4970,"Phenytoin , nicotine , and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose."</p>
<p>4971,"Cimetidine , caffeine , and erythromycin may increase plasma levels of Clozapine , potentially resulting in adverse effects."</p>
<p>4972,"Cimetidine , caffeine , and erythromycin may increase plasma levels of Clozapine , potentially resulting in adverse effects."</p>
<p>4973,"Cimetidine , caffeine , and erythromycin may increase plasma levels of Clozapine , potentially resulting in adverse effects."</p>
<p>4974,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels."</p>
<p>4975,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels."</p>
<p>4976,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels."</p>
<p>4977,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels."</p>
<p>4978,"In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in # and # patients, respectively."</p>
<p>4979,"In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in # and # patients, respectively."</p>
<p>4980,"In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in # and # patients, respectively."</p>
<p>4981,"After # days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine_N-oxide , were elevated with fluvoxamine by about three-fold compared to baseline concentrations."</p>
<p>4982,"After # days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine_N-oxide , were elevated with fluvoxamine by about three-fold compared to baseline concentrations."</p>
<p>4983,"After # days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine_N-oxide , were elevated with fluvoxamine by about three-fold compared to baseline concentrations."</p>
<p>4984,"After # days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine_N-oxide , were elevated with fluvoxamine by about three-fold compared to baseline concentrations."</p>
<p>4985,Paroxetine produced only minor changes in the levels of clozapine and its metabolites.</p>
<p>4986,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine , fluoxetine , and sertraline ."</p>
<p>4987,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine , fluoxetine , and sertraline ."</p>
<p>4988,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine , fluoxetine , and sertraline ."</p>
<p>4989,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine , fluoxetine , and sertraline ."</p>
<p>4990,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine , fluoxetine , and sertraline ."</p>
<p>4991,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine , fluoxetine , and sertraline ."</p>
<p>4992,"Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine ."</p>
<p>4993,"Such individuals are referred to as poor metabolizers of drugs such as debrisoquin , dextromethorphan , the tricyclic_antidepressants , and clozapine ."</p>
<p>4994,"Such individuals are referred to as poor metabolizers of drugs such as debrisoquin , dextromethorphan , the tricyclic_antidepressants , and clozapine ."</p>
<p>4995,"Such individuals are referred to as poor metabolizers of drugs such as debrisoquin , dextromethorphan , the tricyclic_antidepressants , and clozapine ."</p>
<p>4996,"Such individuals are referred to as poor metabolizers of drugs such as debrisoquin , dextromethorphan , the tricyclic_antidepressants , and clozapine ."</p>
<p>4997,"Such individuals are referred to as poor metabolizers of drugs such as debrisoquin , dextromethorphan , the tricyclic_antidepressants , and clozapine ."</p>
<p>4998,"Such individuals are referred to as poor metabolizers of drugs such as debrisoquin , dextromethorphan , the tricyclic_antidepressants , and clozapine ."</p>
<p>4999,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5000,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5001,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5002,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5003,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5004,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5005,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5006,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5007,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5008,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5009,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5010,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5011,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5012,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5013,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants , phenothiazines , carbamazepine , and Type_1C_antiarrhythmics (e,g,, propafenone , flecainide and encainide ), or that inhibit this enzyme (e,g,, quinidine ), should be approached with caution."</p>
<p>5014,The risk of a potential interaction between NovoSeven and coagulation_factor concentrates has not been adequately evaluated in preclinical or clinical studies.</p>
<p>5015,"Although the specific drug interaction was not studied in a clinical trial, there have been more than # episodes of concomitant use of antifibrinolytic therapies (i,e,, tranexamic_acid , aminocaproic_acid ) and NovoSeven ."</p>
<p>5016,"Although the specific drug interaction was not studied in a clinical trial, there have been more than # episodes of concomitant use of antifibrinolytic therapies (i,e,, tranexamic_acid , aminocaproic_acid ) and NovoSeven ."</p>
<p>5017,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5018,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5019,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5020,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5021,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5022,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5023,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5024,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5025,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5026,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5027,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5028,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5029,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5030,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5031,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5032,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5033,"Codeine in combination with other narcotic_analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , or other CNS_depressants (including alcohol ) has additive depressant effects."</p>
<p>5034,Colchicine is inhibited by acidifying_agents .</p>
<p>5035,The action of colchicine is potentiated by alkalinizing_agents .</p>
<p>5036,Colchicine may increase sensitivity to the CNS_depressants .</p>
<p>5037,Response to sympathomimetic_agents may be enhanced by colchicine .</p>
<p>5038,"WelChol  was found to have no significant effect on the bioavailability of digoxin , lovastatin , metoprolol , quinidine , valproic_acid , and warfarin ."</p>
<p>5039,"WelChol  was found to have no significant effect on the bioavailability of digoxin , lovastatin , metoprolol , quinidine , valproic_acid , and warfarin ."</p>
<p>5040,"WelChol  was found to have no significant effect on the bioavailability of digoxin , lovastatin , metoprolol , quinidine , valproic_acid , and warfarin ."</p>
<p>5041,"WelChol  was found to have no significant effect on the bioavailability of digoxin , lovastatin , metoprolol , quinidine , valproic_acid , and warfarin ."</p>
<p>5042,"WelChol  was found to have no significant effect on the bioavailability of digoxin , lovastatin , metoprolol , quinidine , valproic_acid , and warfarin ."</p>
<p>5043,"WelChol  was found to have no significant effect on the bioavailability of digoxin , lovastatin , metoprolol , quinidine , valproic_acid , and warfarin ."</p>
<p>5044,"WelChol  decreased the Cmax and AUC of sustained-release verapamil ( Calan_SR ) by approximately 31% and 11%, respectively."</p>
<p>5045,"WelChol  decreased the Cmax and AUC of sustained-release verapamil ( Calan_SR ) by approximately 31% and 11%, respectively."</p>
<p>5046,"In clinical studies, coadministration of WelChol  with atorvastatin , lovastatin , or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA_reductase_inhibitor ."</p>
<p>5047,"In clinical studies, coadministration of WelChol  with atorvastatin , lovastatin , or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA_reductase_inhibitor ."</p>
<p>5048,"In clinical studies, coadministration of WelChol  with atorvastatin , lovastatin , or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA_reductase_inhibitor ."</p>
<p>5049,"In clinical studies, coadministration of WelChol  with atorvastatin , lovastatin , or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA_reductase_inhibitor ."</p>
<p>5050,"In clinical studies, coadministration of WelChol  with atorvastatin , lovastatin , or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA_reductase_inhibitor ."</p>
<p>5051,"In clinical studies, coadministration of WelChol  with atorvastatin , lovastatin , or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA_reductase_inhibitor ."</p>
<p>5052,"In clinical studies, coadministration of WelChol  with atorvastatin , lovastatin , or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA_reductase_inhibitor ."</p>
<p>5053,"Since colestipol_hydrochloride is an anion_exchange_resin , it may have a strong affinity for anions other than the bile acids."</p>
<p>5054,Repeated doses of colestipol_hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.</p>
<p>5055,Repeated doses of colestipol_hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.</p>
<p>5056,"However, in a follow-up study in normal subjects, single-dose administration of colestipol_hydrochloride and propranolol and twice-a-day administration for # days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption;"</p>
<p>5057,"Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen."</p>
<p>5058,Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol_hydrochloride .</p>
<p>5059,"The absorption of tetracycline , furosemide , penicillin_G , hydrochlorothiazide , and gemfibrozil was significantly decreased when given simultaneously with colestipol_hydrochloride ;"</p>
<p>5060,"The absorption of tetracycline , furosemide , penicillin_G , hydrochlorothiazide , and gemfibrozil was significantly decreased when given simultaneously with colestipol_hydrochloride ;"</p>
<p>5061,"The absorption of tetracycline , furosemide , penicillin_G , hydrochlorothiazide , and gemfibrozil was significantly decreased when given simultaneously with colestipol_hydrochloride ;"</p>
<p>5062,"The absorption of tetracycline , furosemide , penicillin_G , hydrochlorothiazide , and gemfibrozil was significantly decreased when given simultaneously with colestipol_hydrochloride ;"</p>
<p>5063,"The absorption of tetracycline , furosemide , penicillin_G , hydrochlorothiazide , and gemfibrozil was significantly decreased when given simultaneously with colestipol_hydrochloride ;"</p>
<p>5064,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5065,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5066,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5067,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5068,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5069,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5070,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5071,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5072,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5073,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5074,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5075,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5076,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5077,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5078,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5079,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5080,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5081,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5082,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5083,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5084,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5085,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5086,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5087,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5088,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5089,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5090,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5091,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5092,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5093,"No depressant effect on blood levels in humans was noted when colestipol_hydrochloride was administered with any of the following drugs: aspirin , clindamycin , clofibrate , methyldopa , nicotinic_acid ( niacin ), tolbutamide , phenytoin or warfarin ."</p>
<p>5094,Particular caution should be observed with digitalis_preparations since there are conflicting results for the effect of colestipol_hydrochloride on the availability of digoxin and digitoxin .</p>
<p>5095,Particular caution should be observed with digitalis_preparations since there are conflicting results for the effect of colestipol_hydrochloride on the availability of digoxin and digitoxin .</p>
<p>5096,Particular caution should be observed with digitalis_preparations since there are conflicting results for the effect of colestipol_hydrochloride on the availability of digoxin and digitoxin .</p>
<p>5097,Particular caution should be observed with digitalis_preparations since there are conflicting results for the effect of colestipol_hydrochloride on the availability of digoxin and digitoxin .</p>
<p>5098,Particular caution should be observed with digitalis_preparations since there are conflicting results for the effect of colestipol_hydrochloride on the availability of digoxin and digitoxin .</p>
<p>5099,Particular caution should be observed with digitalis_preparations since there are conflicting results for the effect of colestipol_hydrochloride on the availability of digoxin and digitoxin .</p>
<p>5100,Discontinuing colestipol_hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol_hydrochloride .</p>
<p>5101,Discontinuing colestipol_hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol_hydrochloride .</p>
<p>5102,Bile_acid_binding_resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone .</p>
<p>5103,Bile_acid_binding_resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone .</p>
<p>5104,Bile_acid_binding_resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone .</p>
<p>5105,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5106,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5107,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5108,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5109,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5110,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5111,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5112,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5113,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5114,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5115,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5116,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5117,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5118,"Curariform_muscle_relaxants (eg, tubocurarine ) and other drugs, including ether, succinylcholine , gallamine , decamethonium and sodium_citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin_M Parenteral."</p>
<p>5119,Sodium_cephalothin may enhance the nephrotoxicity of Coly-Mycin_M Parenteral.</p>
<p>5120,The concomitant use of sodium_cephalothin and Coly-Mycin_M Parenteral should be avoided.</p>
<p>5121,"Digoxin : Coadministration of digoxin , a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values."</p>
<p>5122,"Digoxin : Coadministration of digoxin , a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values."</p>
<p>5123,"Digoxin : Coadministration of digoxin , a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values."</p>
<p>5124,"Therefore, if digoxin is administered with VAPRISOL , the clinician should be alert to the possibility of increases in digoxin levels."</p>
<p>5125,"Therefore, if digoxin is administered with VAPRISOL , the clinician should be alert to the possibility of increases in digoxin levels."</p>
<p>5126,"Other binding proteins may be elevated in serum, (i,e,, corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex_steroids , respectively."</p>
<p>5127,Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.</p>
<p>5128,"Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response."</p>
<p>5129,"Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response."</p>
<p>5130,"Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response."</p>
<p>5131,"Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response."</p>
<p>5132,"Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response."</p>
<p>5133,"Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response."</p>
<p>5134,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.</p>
<p>5135,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.</p>
<p>5136,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.</p>
<p>5137,Corticosteroids may increase the clearance of chronic high dose aspirin .</p>
<p>5138,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.</p>
<p>5139,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.</p>
<p>5140,Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.</p>
<p>5141,The effect of corticosteroids on oral anticoagulants is variable.</p>
<p>5142,There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids .</p>
<p>5143,Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.</p>
<p>5144,Drug Interaction During Pregnancy: Cromolyn_sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.</p>
<p>5145,The addition of # mg/kg/day of cromolyn_sodium (approximately # times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to # mg/kg/day of isoproterenol (approximately # times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.</p>
<p>5146,"Persons taking most antibiotics , methotrexate and pyrimethamine invalidate folic_acid and vitamin_B12 diagnostic blood assays."</p>
<p>5147,"Persons taking most antibiotics , methotrexate and pyrimethamine invalidate folic_acid and vitamin_B12 diagnostic blood assays."</p>
<p>5148,"Persons taking most antibiotics , methotrexate and pyrimethamine invalidate folic_acid and vitamin_B12 diagnostic blood assays."</p>
<p>5149,"Persons taking most antibiotics , methotrexate and pyrimethamine invalidate folic_acid and vitamin_B12 diagnostic blood assays."</p>
<p>5150,"Persons taking most antibiotics , methotrexate and pyrimethamine invalidate folic_acid and vitamin_B12 diagnostic blood assays."</p>
<p>5151,"Persons taking most antibiotics , methotrexate and pyrimethamine invalidate folic_acid and vitamin_B12 diagnostic blood assays."</p>
<p>5152,"Persons taking most antibiotics , methotrexate and pyrimethamine invalidate folic_acid and vitamin_B12 diagnostic blood assays."</p>
<p>5153,"Persons taking most antibiotics , methotrexate and pyrimethamine invalidate folic_acid and vitamin_B12 diagnostic blood assays."</p>
<p>5154,Colchicine  para-aminosalicylic_acid and heavy alcohol intake for longer than # weeks may produce malabsorption of vitamin_B12 .</p>
<p>5155,Colchicine  para-aminosalicylic_acid and heavy alcohol intake for longer than # weeks may produce malabsorption of vitamin_B12 .</p>
<p>5156,Colchicine  para-aminosalicylic_acid and heavy alcohol intake for longer than # weeks may produce malabsorption of vitamin_B12 .</p>
<p>5157,Colchicine  para-aminosalicylic_acid and heavy alcohol intake for longer than # weeks may produce malabsorption of vitamin_B12 .</p>
<p>5158,Colchicine  para-aminosalicylic_acid and heavy alcohol intake for longer than # weeks may produce malabsorption of vitamin_B12 .</p>
<p>5159,Colchicine  para-aminosalicylic_acid and heavy alcohol intake for longer than # weeks may produce malabsorption of vitamin_B12 .</p>
<p>5160,FLEXERIL may have life-threatening interactions with MAO_inhibitors .</p>
<p>5161,"FLEXERIL may enhance the effects of alcohol , barbiturates , and other CNS_depressants ."</p>
<p>5162,"FLEXERIL may enhance the effects of alcohol , barbiturates , and other CNS_depressants ."</p>
<p>5163,"FLEXERIL may enhance the effects of alcohol , barbiturates , and other CNS_depressants ."</p>
<p>5164,"FLEXERIL may enhance the effects of alcohol , barbiturates , and other CNS_depressants ."</p>
<p>5165,"FLEXERIL may enhance the effects of alcohol , barbiturates , and other CNS_depressants ."</p>
<p>5166,"FLEXERIL may enhance the effects of alcohol , barbiturates , and other CNS_depressants ."</p>
<p>5167,Tricyclic_antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.</p>
<p>5168,Tricyclic_antidepressants may enhance the seizure risk in patients taking tramadol</p>
<p>5169,Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine ;</p>
<p>5170,Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine ;</p>
<p>5171,Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine ;</p>
<p>5172,The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital .</p>
<p>5173,"Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine_chloride ."</p>
<p>5174,May interact with wthionamide ( Trecator-SC ) and isoniazid ( Nydrazid ).</p>
<p>5175,May interact with wthionamide ( Trecator-SC ) and isoniazid ( Nydrazid ).</p>
<p>5176,MAO_inhibitors prolong and intensify the anticholinergic effects of antihistamines .</p>
<p>5177,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5178,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5179,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5180,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5181,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5182,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5183,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5184,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5185,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5186,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5187,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5188,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5189,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5190,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5191,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5192,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5193,"Antihistamines may have additive effects with alcohol and other CNS_depressants , e,g,, hypnotics , sedatives , tranquilizers , antianxiety_agents ."</p>
<p>5194,Drug/laboratory test Interactions Dactinomycin may interfere with bioassay procedures for the determination of antibacterial_drug levels.</p>
<p>5195,"However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism."</p>
<p>5196,"However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism."</p>
<p>5197,"However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism."</p>
<p>5198,Binding to plasma proteins is reduced by warfarin and clotibrate and increased by tolbutamide .</p>
<p>5199,The combination of therapeutic doses of intravenous dantrolene_sodium and verapamil in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.</p>
<p>5200,The combination of therapeutic doses of intravenous dantrolene_sodium and verapamil in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.</p>
<p>5201,The combination of therapeutic doses of intravenous dantrolene_sodium and verapamil in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.</p>
<p>5202,"It is recommended that the combination of intravenous dantrolene_sodium and calcium_channel_blockers , such as verapamil , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established."</p>
<p>5203,"It is recommended that the combination of intravenous dantrolene_sodium and calcium_channel_blockers , such as verapamil , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established."</p>
<p>5204,"It is recommended that the combination of intravenous dantrolene_sodium and calcium_channel_blockers , such as verapamil , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established."</p>
<p>5205,Administration of dantrolene may potentiate vecuronium -induced neuromuscular block.</p>
<p>5206,"A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim / sulfamethoxazole ( TMP / SMX )."</p>
<p>5207,"A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim / sulfamethoxazole ( TMP / SMX )."</p>
<p>5208,"A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim / sulfamethoxazole ( TMP / SMX )."</p>
<p>5209,"A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim / sulfamethoxazole ( TMP / SMX )."</p>
<p>5210,"A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim / sulfamethoxazole ( TMP / SMX )."</p>
<p>5211,"A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim / sulfamethoxazole ( TMP / SMX )."</p>
<p>5212,"During co-administration, systemic levels of TMP and SMX were essentially unchanged."</p>
<p>5213,"Notably, systemic exposure (AUC0-12) of dapsone_hydroxylamine ( DHA ) was more than doubled in the presence of TMP / SMX ."</p>
<p>5214,"Notably, systemic exposure (AUC0-12) of dapsone_hydroxylamine ( DHA ) was more than doubled in the presence of TMP / SMX ."</p>
<p>5215,"Notably, systemic exposure (AUC0-12) of dapsone_hydroxylamine ( DHA ) was more than doubled in the presence of TMP / SMX ."</p>
<p>5216,"Notably, systemic exposure (AUC0-12) of dapsone_hydroxylamine ( DHA ) was more than doubled in the presence of TMP / SMX ."</p>
<p>5217,"Certain concomitant medications (such as rifampin , anticonvulsants , St."</p>
<p>5218,"With oral dapsone treatment, folic_acid_antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions"</p>
<p>5219,"With oral dapsone treatment, folic_acid_antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions"</p>
<p>5220,"With oral dapsone treatment, folic_acid_antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions"</p>
<p>5221,"Warfarin : Concomitant administration of daptomycin (6 mg/kg once every # hours for # days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered."</p>
<p>5222,"Warfarin : Concomitant administration of daptomycin (6 mg/kg once every # hours for # days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered."</p>
<p>5223,"HMG-CoA_Reductase_Inhibitors : Inhibitors_of_HMG-CoA_reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK."</p>
<p>5224,There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which # healthy subjects on stable simvastatin therapy were treated concurrently with daptomycin (4 mg/kg once every # hours) for # days.</p>
<p>5225,"Experience with co-administration of HMG-CoA_reductase_inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA_reductase_inhibitors in patients receiving Fentanyl ."</p>
<p>5226,"Experience with co-administration of HMG-CoA_reductase_inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA_reductase_inhibitors in patients receiving Fentanyl ."</p>
<p>5227,"Experience with co-administration of HMG-CoA_reductase_inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA_reductase_inhibitors in patients receiving Fentanyl ."</p>
<p>5228,"Experience with co-administration of HMG-CoA_reductase_inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA_reductase_inhibitors in patients receiving Fentanyl ."</p>
<p>5229,"The daily dose of ENABLEX should not exceed # mg when coadministered with potent CYP3A4 inhibitors (e,g,, ketoconazole , itraconazole , ritonavir , nelfinavir , clarithromycin and nefazadone) ."</p>
<p>5230,"The daily dose of ENABLEX should not exceed # mg when coadministered with potent CYP3A4 inhibitors (e,g,, ketoconazole , itraconazole , ritonavir , nelfinavir , clarithromycin and nefazadone) ."</p>
<p>5231,"The daily dose of ENABLEX should not exceed # mg when coadministered with potent CYP3A4 inhibitors (e,g,, ketoconazole , itraconazole , ritonavir , nelfinavir , clarithromycin and nefazadone) ."</p>
<p>5232,"The daily dose of ENABLEX should not exceed # mg when coadministered with potent CYP3A4 inhibitors (e,g,, ketoconazole , itraconazole , ritonavir , nelfinavir , clarithromycin and nefazadone) ."</p>
<p>5233,"The daily dose of ENABLEX should not exceed # mg when coadministered with potent CYP3A4 inhibitors (e,g,, ketoconazole , itraconazole , ritonavir , nelfinavir , clarithromycin and nefazadone) ."</p>
<p>5234,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide , thioridazine and tricyclic_antidepressants (see CLINICAL PHARMACOLOGY)."</p>
<p>5235,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide , thioridazine and tricyclic_antidepressants (see CLINICAL PHARMACOLOGY)."</p>
<p>5236,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide , thioridazine and tricyclic_antidepressants (see CLINICAL PHARMACOLOGY)."</p>
<p>5237,"The concomitant use of ENABLEX with other anticholinergic_agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects."</p>
<p>5238,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5239,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5240,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5241,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5242,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5243,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5244,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5245,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5246,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5247,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5248,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5249,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5250,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5251,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5252,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5253,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5254,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5255,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5256,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5257,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5258,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5259,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5260,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nefazodone , nelfinavir , saquinavir , telithromycin ) may increase exposure to dasatinib and should be avoided."</p>
<p>5261,Simultaneous administration of SPRYCEL with antacids should be avoided.</p>
<p>5262,"If antacid therapy is needed, the antacid dose should be administered at least # hours prior to or # hours after the dose of SPRYCEL ."</p>
<p>5263,"H2_Blockers / Proton_Pump_Inhibitors : Long-term suppression of gastric acid secretion by H2_blockers or proton_pump_inhibitors (eg, famotidine and omeprazole ) is likely to reduce dasatinib exposure."</p>
<p>5264,"H2_Blockers / Proton_Pump_Inhibitors : Long-term suppression of gastric acid secretion by H2_blockers or proton_pump_inhibitors (eg, famotidine and omeprazole ) is likely to reduce dasatinib exposure."</p>
<p>5265,"H2_Blockers / Proton_Pump_Inhibitors : Long-term suppression of gastric acid secretion by H2_blockers or proton_pump_inhibitors (eg, famotidine and omeprazole ) is likely to reduce dasatinib exposure."</p>
<p>5266,"H2_Blockers / Proton_Pump_Inhibitors : Long-term suppression of gastric acid secretion by H2_blockers or proton_pump_inhibitors (eg, famotidine and omeprazole ) is likely to reduce dasatinib exposure."</p>
<p>5267,"H2_Blockers / Proton_Pump_Inhibitors : Long-term suppression of gastric acid secretion by H2_blockers or proton_pump_inhibitors (eg, famotidine and omeprazole ) is likely to reduce dasatinib exposure."</p>
<p>5268,"H2_Blockers / Proton_Pump_Inhibitors : Long-term suppression of gastric acid secretion by H2_blockers or proton_pump_inhibitors (eg, famotidine and omeprazole ) is likely to reduce dasatinib exposure."</p>
<p>5269,"H2_Blockers / Proton_Pump_Inhibitors : Long-term suppression of gastric acid secretion by H2_blockers or proton_pump_inhibitors (eg, famotidine and omeprazole ) is likely to reduce dasatinib exposure."</p>
<p>5270,"H2_Blockers / Proton_Pump_Inhibitors : Long-term suppression of gastric acid secretion by H2_blockers or proton_pump_inhibitors (eg, famotidine and omeprazole ) is likely to reduce dasatinib exposure."</p>
<p>5271,The concomitant use of H2_blockers or proton_pump_inhibitors with SPRYCEL is not recommended.</p>
<p>5272,The concomitant use of H2_blockers or proton_pump_inhibitors with SPRYCEL is not recommended.</p>
<p>5273,The concomitant use of H2_blockers or proton_pump_inhibitors with SPRYCEL is not recommended.</p>
<p>5274,The use of antacids should be considered in place of H2_blockers or proton_pump_inhibitors in patients receiving SPRYCEL therapy.</p>
<p>5275,The use of antacids should be considered in place of H2_blockers or proton_pump_inhibitors in patients receiving SPRYCEL therapy.</p>
<p>5276,The use of antacids should be considered in place of H2_blockers or proton_pump_inhibitors in patients receiving SPRYCEL therapy.</p>
<p>5277,The use of antacids should be considered in place of H2_blockers or proton_pump_inhibitors in patients receiving SPRYCEL therapy.</p>
<p>5278,The use of antacids should be considered in place of H2_blockers or proton_pump_inhibitors in patients receiving SPRYCEL therapy.</p>
<p>5279,The use of antacids should be considered in place of H2_blockers or proton_pump_inhibitors in patients receiving SPRYCEL therapy.</p>
<p>5280,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5281,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5282,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5283,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5284,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5285,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5286,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5287,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5288,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5289,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5290,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5291,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5292,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil , astemizole , terfenadine , cisapride , cyclosporine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , or ergot_alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution in patients receiving SPRYCEL ."</p>
<p>5293,Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.</p>
<p>5294,Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine .</p>
<p>5295,Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine .</p>
<p>5296,Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.</p>
<p>5297,"In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium_carbonate , and terbutaline ."</p>
<p>5298,"In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium_carbonate , and terbutaline ."</p>
<p>5299,"In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium_carbonate , and terbutaline ."</p>
<p>5300,"In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium_carbonate , and terbutaline ."</p>
<p>5301,"In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium_carbonate , and terbutaline ."</p>
<p>5302,"In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium_carbonate , and terbutaline ."</p>
<p>5303,"In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium_carbonate , and terbutaline ."</p>
<p>5304,"In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium_carbonate , and terbutaline ."</p>
<p>5305,"In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium_carbonate , and terbutaline ."</p>
<p>5306,"In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium_carbonate , and terbutaline ."</p>
<p>5307,"In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium_carbonate , and terbutaline ."</p>
<p>5308,"In addition, neuromuscular blocking action is enhanced by general anesthetics , local anesthetics like lidocaine , procaine , beta-blockers , metaclopramide , lithium_carbonate , and terbutaline ."</p>
<p>5309,The concomitant administration of Exjade and aluminum -containing antacid_preparations has not been formally studied.</p>
<p>5310,The concomitant administration of Exjade and aluminum -containing antacid_preparations has not been formally studied.</p>
<p>5311,The concomitant administration of Exjade and aluminum -containing antacid_preparations has not been formally studied.</p>
<p>5312,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5313,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5314,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5315,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5316,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5317,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5318,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5319,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5320,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5321,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5322,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5323,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5324,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5325,"Although deferasirox has a lower affinity for aluminum than for iron , Exjade should not be taken with aluminum -containing antacid_preparations ."</p>
<p>5326,"In healthy volunteers, Exjade had no effect on the pharmacokinetics of digoxin ."</p>
<p>5327,The effect of digoxin on Exjade pharmacokinetics has not been studied.</p>
<p>5328,The concomitant administration of Exjade and vitamin_C has not been formally studied.</p>
<p>5329,The interaction of Exjade with hydroxyurea has not been formally studied.</p>
<p>5330,No inhibition of deferasirox metabolism by hydroxyurea is expected based on the results of an in vitro study.</p>
<p>5331,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5332,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5333,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5334,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5335,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5336,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5337,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5338,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5339,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5340,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5341,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5342,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5343,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5344,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5345,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5346,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5347,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5348,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5349,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5350,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5351,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5352,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5353,"Antiacid, clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir, Ketoconazole , Phenytoin , Phenobarbitol, carbamazepine , Rifabutin , Rifampin , Ritanovir, Saquinavir ."</p>
<p>5354,Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase_agents .</p>
<p>5355,Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase_agents .</p>
<p>5356,Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase_agents .</p>
<p>5357,"Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage."</p>
<p>5358,"Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage."</p>
<p>5359,"Since bacteriostatic drugs, such as the tetracycline_class of antibiotics , may interfere with the bactericidal action of penicillins , it is not advisable to administer these drugs concomitantly."</p>
<p>5360,"Since bacteriostatic drugs, such as the tetracycline_class of antibiotics , may interfere with the bactericidal action of penicillins , it is not advisable to administer these drugs concomitantly."</p>
<p>5361,"Since bacteriostatic drugs, such as the tetracycline_class of antibiotics , may interfere with the bactericidal action of penicillins , it is not advisable to administer these drugs concomitantly."</p>
<p>5362,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.</p>
<p>5363,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.</p>
<p>5364,Taking a rauwolfia_alkaloid while you are taking or within # weeks of taking MAO_inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.</p>
<p>5365,"Like isoflurane , desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine."</p>
<p>5366,"Like isoflurane , desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine."</p>
<p>5367,"Like isoflurane , desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine."</p>
<p>5368,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type 1C antiarrhythrnics propatenone and flecainide )."</p>
<p>5369,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type 1C antiarrhythrnics propatenone and flecainide )."</p>
<p>5370,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type 1C antiarrhythrnics propatenone and flecainide )."</p>
<p>5371,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , seriraline, and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>5372,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , seriraline, and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>5373,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , seriraline, and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>5374,"While all the selective_serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , seriraline, and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."</p>
<p>5375,The extent to which SSRI - TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.</p>
<p>5376,The extent to which SSRI - TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.</p>
<p>5377,"Nevertheless, caution is indicated in the co-administration of T,A, with any of the SSRIs and also in switching from one class to the other."</p>
<p>5378,Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic_drugs .</p>
<p>5379,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5380,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5381,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5382,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5383,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5384,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5385,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5386,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5387,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5388,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5389,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5390,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5391,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5392,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5393,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5394,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5395,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5396,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5397,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5398,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5399,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5400,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5401,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5402,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5403,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5404,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5405,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5406,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5407,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5408,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5409,"If desipramine_hydrochloride is to be combined with other psychotropic_agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e,g,, chlordiazepoxide or diazepam ) are additive."</p>
<p>5410,Both the sedative and anticholinergic effects of the major_tranquilizers are also additive to those of desipramine .</p>
<p>5411,Concurrent administration of cimetidine and tricyclic_antidepressants can produce clinically significant increases in the plasma levels of the tricyclic_antidepressants .</p>
<p>5412,Concurrent administration of cimetidine and tricyclic_antidepressants can produce clinically significant increases in the plasma levels of the tricyclic_antidepressants .</p>
<p>5413,"Conversely, decreases in plasma levels of the tricyclic_antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic_antidepressant 6."</p>
<p>5414,"Conversely, decreases in plasma levels of the tricyclic_antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic_antidepressant 6."</p>
<p>5415,There have been greater than two-fold increases of previously stable plasma levels of tricyclic_antidepressants when fluoxetine has been administered in combination with these agents.</p>
<p>5416,"In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine # mg (# times the daily dose) once daily was coadministered with erythromycin # mg every # hours or ketoconazole # mg every # hours for # days."</p>
<p>5417,"In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine # mg (# times the daily dose) once daily was coadministered with erythromycin # mg every # hours or ketoconazole # mg every # hours for # days."</p>
<p>5418,"In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine # mg (# times the daily dose) once daily was coadministered with erythromycin # mg every # hours or ketoconazole # mg every # hours for # days."</p>
<p>5419,"In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of # mg has been coadministered with azithromycin # mg followed by # mg once daily for # days (n=18) or with fluoxetine # mg once daily for # days after a # day pretreatment period with fluoxetine (n=18) or with cimetidine # mg every # hours for # days (n=18) under steady state conditions to normal healthy male and female volunteers."</p>
<p>5420,"In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of # mg has been coadministered with azithromycin # mg followed by # mg once daily for # days (n=18) or with fluoxetine # mg once daily for # days after a # day pretreatment period with fluoxetine (n=18) or with cimetidine # mg every # hours for # days (n=18) under steady state conditions to normal healthy male and female volunteers."</p>
<p>5421,"In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of # mg has been coadministered with azithromycin # mg followed by # mg once daily for # days (n=18) or with fluoxetine # mg once daily for # days after a # day pretreatment period with fluoxetine (n=18) or with cimetidine # mg every # hours for # days (n=18) under steady state conditions to normal healthy male and female volunteers."</p>
<p>5422,"In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of # mg has been coadministered with azithromycin # mg followed by # mg once daily for # days (n=18) or with fluoxetine # mg once daily for # days after a # day pretreatment period with fluoxetine (n=18) or with cimetidine # mg every # hours for # days (n=18) under steady state conditions to normal healthy male and female volunteers."</p>
<p>5423,"In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of # mg has been coadministered with azithromycin # mg followed by # mg once daily for # days (n=18) or with fluoxetine # mg once daily for # days after a # day pretreatment period with fluoxetine (n=18) or with cimetidine # mg every # hours for # days (n=18) under steady state conditions to normal healthy male and female volunteers."</p>
<p>5424,"In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of # mg has been coadministered with azithromycin # mg followed by # mg once daily for # days (n=18) or with fluoxetine # mg once daily for # days after a # day pretreatment period with fluoxetine (n=18) or with cimetidine # mg every # hours for # days (n=18) under steady state conditions to normal healthy male and female volunteers."</p>
<p>5425,"In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of # mg has been coadministered with azithromycin # mg followed by # mg once daily for # days (n=18) or with fluoxetine # mg once daily for # days after a # day pretreatment period with fluoxetine (n=18) or with cimetidine # mg every # hours for # days (n=18) under steady state conditions to normal healthy male and female volunteers."</p>
<p>5426,"In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of # mg has been coadministered with azithromycin # mg followed by # mg once daily for # days (n=18) or with fluoxetine # mg once daily for # days after a # day pretreatment period with fluoxetine (n=18) or with cimetidine # mg every # hours for # days (n=18) under steady state conditions to normal healthy male and female volunteers."</p>
<p>5427,"In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of # mg has been coadministered with azithromycin # mg followed by # mg once daily for # days (n=18) or with fluoxetine # mg once daily for # days after a # day pretreatment period with fluoxetine (n=18) or with cimetidine # mg every # hours for # days (n=18) under steady state conditions to normal healthy male and female volunteers."</p>
<p>5428,"A similar association, though less marked, has been suggested with barbiturates , phenyl-butazone, phenytoin_sodium , carbamazepine and possibly with griseofulvin , ampicillin , and tetracyclines (72)"</p>
<p>5429,"A similar association, though less marked, has been suggested with barbiturates , phenyl-butazone, phenytoin_sodium , carbamazepine and possibly with griseofulvin , ampicillin , and tetracyclines (72)"</p>
<p>5430,"A similar association, though less marked, has been suggested with barbiturates , phenyl-butazone, phenytoin_sodium , carbamazepine and possibly with griseofulvin , ampicillin , and tetracyclines (72)"</p>
<p>5431,"A similar association, though less marked, has been suggested with barbiturates , phenyl-butazone, phenytoin_sodium , carbamazepine and possibly with griseofulvin , ampicillin , and tetracyclines (72)"</p>
<p>5432,"A similar association, though less marked, has been suggested with barbiturates , phenyl-butazone, phenytoin_sodium , carbamazepine and possibly with griseofulvin , ampicillin , and tetracyclines (72)"</p>
<p>5433,"A similar association, though less marked, has been suggested with barbiturates , phenyl-butazone, phenytoin_sodium , carbamazepine and possibly with griseofulvin , ampicillin , and tetracyclines (72)"</p>
<p>5434,"A similar association, though less marked, has been suggested with barbiturates , phenyl-butazone, phenytoin_sodium , carbamazepine and possibly with griseofulvin , ampicillin , and tetracyclines (72)"</p>
<p>5435,"A similar association, though less marked, has been suggested with barbiturates , phenyl-butazone, phenytoin_sodium , carbamazepine and possibly with griseofulvin , ampicillin , and tetracyclines (72)"</p>
<p>5436,"A similar association, though less marked, has been suggested with barbiturates , phenyl-butazone, phenytoin_sodium , carbamazepine and possibly with griseofulvin , ampicillin , and tetracyclines (72)"</p>
<p>5437,Aminoglutethimide : Aminoglutethimide may diminish adrenal suppression by corticosteroids .</p>
<p>5438,"Amphotericin_B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e,g,, amphotericin_B , diuretics ), patients should be observed closely for development of hypokalemia."</p>
<p>5439,"Amphotericin_B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e,g,, amphotericin_B , diuretics ), patients should be observed closely for development of hypokalemia."</p>
<p>5440,"In addition, there have been cases reported in which concomitant use of amphotericin_B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."</p>
<p>5441,Antibiotics : Macrolide_antibiotics have been reported to cause a significant decrease in corticosteroid clearance.</p>
<p>5442,Anticholinesterases : Concomitant use of anticholinesterase_agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.</p>
<p>5443,Anticholinesterases : Concomitant use of anticholinesterase_agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.</p>
<p>5444,Anticholinesterases : Concomitant use of anticholinesterase_agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.</p>
<p>5445,"If possible, anticholinesterase_agents should be withdrawn at least # hours before initiating corticosteroid therapy."</p>
<p>5446,"Anticoagulants , oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin , although there have been some conflicting reports."</p>
<p>5447,"Anticoagulants , oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin , although there have been some conflicting reports."</p>
<p>5448,"Anticoagulants , oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin , although there have been some conflicting reports."</p>
<p>5449,"Anticoagulants , oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin , although there have been some conflicting reports."</p>
<p>5450,"Anticoagulants , oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin , although there have been some conflicting reports."</p>
<p>5451,"Antidiabetics : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic_agents may be required."</p>
<p>5452,Cholestyramine : Cholestyramine may increase the clearance of corticosteroids .</p>
<p>5453,Cyclosporine : Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.</p>
<p>5454,Cyclosporine : Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.</p>
<p>5455,"Ephedrine : Ephedrine may enhance the metabolic clearance of corticosteroids , resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage."</p>
<p>5456,"Ephedrine : Ephedrine may enhance the metabolic clearance of corticosteroids , resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage."</p>
<p>5457,"Estrogens , including oral contraceptives : Estrogens may decrease the hepatic metabolism of certain corticosteroids , thereby increasing their effect."</p>
<p>5458,"Estrogens , including oral contraceptives : Estrogens may decrease the hepatic metabolism of certain corticosteroids , thereby increasing their effect."</p>
<p>5459,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e,g,, barbiturates , phenytoin , carbamazepine , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."</p>
<p>5460,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e,g,, barbiturates , phenytoin , carbamazepine , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."</p>
<p>5461,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e,g,, barbiturates , phenytoin , carbamazepine , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."</p>
<p>5462,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e,g,, barbiturates , phenytoin , carbamazepine , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."</p>
<p>5463,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e,g,, barbiturates , phenytoin , carbamazepine , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."</p>
<p>5464,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e,g,, barbiturates , phenytoin , carbamazepine , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."</p>
<p>5465,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e,g,, barbiturates , phenytoin , carbamazepine , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."</p>
<p>5466,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e,g,, barbiturates , phenytoin , carbamazepine , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."</p>
<p>5467,"Drugs which inhibit CYP 3A4 (e,g,, ketoconazole , macrolide_antibiotics such as erythromycin ) have the potential to result in increased plasma concentrations of corticosteroids ."</p>
<p>5468,"Drugs which inhibit CYP 3A4 (e,g,, ketoconazole , macrolide_antibiotics such as erythromycin ) have the potential to result in increased plasma concentrations of corticosteroids ."</p>
<p>5469,"Drugs which inhibit CYP 3A4 (e,g,, ketoconazole , macrolide_antibiotics such as erythromycin ) have the potential to result in increased plasma concentrations of corticosteroids ."</p>
<p>5470,"Drugs which inhibit CYP 3A4 (e,g,, ketoconazole , macrolide_antibiotics such as erythromycin ) have the potential to result in increased plasma concentrations of corticosteroids ."</p>
<p>5471,"Drugs which inhibit CYP 3A4 (e,g,, ketoconazole , macrolide_antibiotics such as erythromycin ) have the potential to result in increased plasma concentrations of corticosteroids ."</p>
<p>5472,"Drugs which inhibit CYP 3A4 (e,g,, ketoconazole , macrolide_antibiotics such as erythromycin ) have the potential to result in increased plasma concentrations of corticosteroids ."</p>
<p>5473,"Ketoconazole : Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects."</p>
<p>5474,"Ketoconazole : Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects."</p>
<p>5475,"In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal."</p>
<p>5476,Nonsteroidal_anti-inflammatory_agents ( NSAIDS ): Concomitant use of aspirin (or other nonsteroidal_antiinflammatory_agents ) and corticosteroids increases the risk of gastrointestinal side effects.</p>
<p>5477,Nonsteroidal_anti-inflammatory_agents ( NSAIDS ): Concomitant use of aspirin (or other nonsteroidal_antiinflammatory_agents ) and corticosteroids increases the risk of gastrointestinal side effects.</p>
<p>5478,Nonsteroidal_anti-inflammatory_agents ( NSAIDS ): Concomitant use of aspirin (or other nonsteroidal_antiinflammatory_agents ) and corticosteroids increases the risk of gastrointestinal side effects.</p>
<p>5479,Nonsteroidal_anti-inflammatory_agents ( NSAIDS ): Concomitant use of aspirin (or other nonsteroidal_antiinflammatory_agents ) and corticosteroids increases the risk of gastrointestinal side effects.</p>
<p>5480,Nonsteroidal_anti-inflammatory_agents ( NSAIDS ): Concomitant use of aspirin (or other nonsteroidal_antiinflammatory_agents ) and corticosteroids increases the risk of gastrointestinal side effects.</p>
<p>5481,Nonsteroidal_anti-inflammatory_agents ( NSAIDS ): Concomitant use of aspirin (or other nonsteroidal_antiinflammatory_agents ) and corticosteroids increases the risk of gastrointestinal side effects.</p>
<p>5482,Nonsteroidal_anti-inflammatory_agents ( NSAIDS ): Concomitant use of aspirin (or other nonsteroidal_antiinflammatory_agents ) and corticosteroids increases the risk of gastrointestinal side effects.</p>
<p>5483,Nonsteroidal_anti-inflammatory_agents ( NSAIDS ): Concomitant use of aspirin (or other nonsteroidal_antiinflammatory_agents ) and corticosteroids increases the risk of gastrointestinal side effects.</p>
<p>5484,Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.</p>
<p>5485,The clearance of salicylates may be increased with concurrent use of corticosteroids .</p>
<p>5486,"Phenytoin : In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control."</p>
<p>5487,"Phenytoin : In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control."</p>
<p>5488,Vaccines : Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live_vaccines or inactivated_vaccines due to inhibition of antibody response.</p>
<p>5489,Vaccines : Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live_vaccines or inactivated_vaccines due to inhibition of antibody response.</p>
<p>5490,Vaccines : Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live_vaccines or inactivated_vaccines due to inhibition of antibody response.</p>
<p>5491,Corticosteroids may also potentiate the replication of some organisms contained in live_attenuated_vaccines .</p>
<p>5492,Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.</p>
<p>5493,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5494,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5495,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5496,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5497,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5498,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5499,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5500,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5501,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5502,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5503,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5504,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5505,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5506,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5507,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5508,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5509,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5510,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5511,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5512,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5513,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5514,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5515,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5516,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5517,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5518,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5519,"Dexbrompheniramine can interact with alcohol or other CNS_depressants (may potentiate the CNS depressant effects of either these medications or antihistamines ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ), and monoamine_oxidase_(MAO)_inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines )."</p>
<p>5520,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5521,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5522,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5523,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5524,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5525,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5526,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5527,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5528,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5529,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5530,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5531,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5532,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5533,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5534,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5535,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5536,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5537,"In patients receiving nonselective monoamine_oxidase_inhibitors ( MAOIs ) (e,g,, selegiline_hydrochloride ) in combination with serotoninergic_agents (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline , venlafaxine ), there have been reports of serious, sometimes fatal, reactions."</p>
<p>5538,"Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO_inhibitor ."</p>
<p>5539,"Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO_inhibitor ."</p>
<p>5540,At least # days should elapse between discontinuation of a MAO_inhibitor and initiation of treatment with dexfenfluramine .</p>
<p>5541,At least # weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO_inhibitor .</p>
<p>5542,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective_serotonin_reuptake_inhibitors ( SSRIs ) and agents for migraine therapy, such as Imitrex ( sumatriptan_succinate ) and dihydroergotamine ."</p>
<p>5543,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective_serotonin_reuptake_inhibitors ( SSRIs ) and agents for migraine therapy, such as Imitrex ( sumatriptan_succinate ) and dihydroergotamine ."</p>
<p>5544,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective_serotonin_reuptake_inhibitors ( SSRIs ) and agents for migraine therapy, such as Imitrex ( sumatriptan_succinate ) and dihydroergotamine ."</p>
<p>5545,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective_serotonin_reuptake_inhibitors ( SSRIs ) and agents for migraine therapy, such as Imitrex ( sumatriptan_succinate ) and dihydroergotamine ."</p>
<p>5546,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective_serotonin_reuptake_inhibitors ( SSRIs ) and agents for migraine therapy, such as Imitrex ( sumatriptan_succinate ) and dihydroergotamine ."</p>
<p>5547,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective_serotonin_reuptake_inhibitors ( SSRIs ) and agents for migraine therapy, such as Imitrex ( sumatriptan_succinate ) and dihydroergotamine ."</p>
<p>5548,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective_serotonin_reuptake_inhibitors ( SSRIs ) and agents for migraine therapy, such as Imitrex ( sumatriptan_succinate ) and dihydroergotamine ."</p>
<p>5549,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective_serotonin_reuptake_inhibitors ( SSRIs ) and agents for migraine therapy, such as Imitrex ( sumatriptan_succinate ) and dihydroergotamine ."</p>
<p>5550,Dexfenfluramine should not be administered with other serotoninergic_agents .</p>
<p>5551,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5552,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5553,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5554,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5555,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5556,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5557,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5558,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5559,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5560,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5561,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5562,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5563,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5564,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5565,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5566,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5567,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5568,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5569,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5570,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5571,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5572,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5573,"Anesthetics / Sedatives / Hypnotics / Opioids : Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects."</p>
<p>5574,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5575,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5576,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5577,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5578,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5579,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5580,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5581,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5582,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5583,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5584,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5585,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5586,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative , hypnotic or opioid may be required."</p>
<p>5587,"Neuromuscular_Blockers : In one study of # healthy volunteers, administration of PRECEDEX for # minutes at a plasma concentration of # (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration."</p>
<p>5588,ZINECARD does not influence the pharmacokinetics of doxorubicin .</p>
<p>5589,"Acidifying_agents : Gastrointestinal_acidifying_agents ( guanethidine , reserpine , glutamic_acid_HCl , ascorbic_acid , fruit juices, etc,) lower absorption of amphetamines ."</p>
<p>5590,"Acidifying_agents : Gastrointestinal_acidifying_agents ( guanethidine , reserpine , glutamic_acid_HCl , ascorbic_acid , fruit juices, etc,) lower absorption of amphetamines ."</p>
<p>5591,"Acidifying_agents : Gastrointestinal_acidifying_agents ( guanethidine , reserpine , glutamic_acid_HCl , ascorbic_acid , fruit juices, etc,) lower absorption of amphetamines ."</p>
<p>5592,"Acidifying_agents : Gastrointestinal_acidifying_agents ( guanethidine , reserpine , glutamic_acid_HCl , ascorbic_acid , fruit juices, etc,) lower absorption of amphetamines ."</p>
<p>5593,"Acidifying_agents : Gastrointestinal_acidifying_agents ( guanethidine , reserpine , glutamic_acid_HCl , ascorbic_acid , fruit juices, etc,) lower absorption of amphetamines ."</p>
<p>5594,"Acidifying_agents : Gastrointestinal_acidifying_agents ( guanethidine , reserpine , glutamic_acid_HCl , ascorbic_acid , fruit juices, etc,) lower absorption of amphetamines ."</p>
<p>5595,"Acidifying_agents : Gastrointestinal_acidifying_agents ( guanethidine , reserpine , glutamic_acid_HCl , ascorbic_acid , fruit juices, etc,) lower absorption of amphetamines ."</p>
<p>5596,"Acidifying_agents : Gastrointestinal_acidifying_agents ( guanethidine , reserpine , glutamic_acid_HCl , ascorbic_acid , fruit juices, etc,) lower absorption of amphetamines ."</p>
<p>5597,"Acidifying_agents : Gastrointestinal_acidifying_agents ( guanethidine , reserpine , glutamic_acid_HCl , ascorbic_acid , fruit juices, etc,) lower absorption of amphetamines ."</p>
<p>5598,"Urinary_acidifying_agents ( ammonium_chloride , sodium_acid_phosphate , etc,) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion."</p>
<p>5599,"Urinary_acidifying_agents ( ammonium_chloride , sodium_acid_phosphate , etc,) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion."</p>
<p>5600,"Urinary_acidifying_agents ( ammonium_chloride , sodium_acid_phosphate , etc,) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion."</p>
<p>5601,Adrenergic_blockers : Adrenergic_blockers are inhibited by amphetamines .</p>
<p>5602,"Alkalinizing agents: Gastrointestinal alkalinizing agents ( sodium_bicarbonate , etc,) increase absorption of amphetamines ."</p>
<p>5603,"Urinary alkalinizing agents ( acetazolamide , some thiazides ) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion."</p>
<p>5604,"Urinary alkalinizing agents ( acetazolamide , some thiazides ) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion."</p>
<p>5605,"Antidepressants , tricyclic : Amphetamines may enhance the activity of tricyclic or sympathomimetic_agents ;"</p>
<p>5606,"Antidepressants , tricyclic : Amphetamines may enhance the activity of tricyclic or sympathomimetic_agents ;"</p>
<p>5607,"Antidepressants , tricyclic : Amphetamines may enhance the activity of tricyclic or sympathomimetic_agents ;"</p>
<p>5608,"Antidepressants , tricyclic : Amphetamines may enhance the activity of tricyclic or sympathomimetic_agents ;"</p>
<p>5609,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>5610,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>5611,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>5612,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>5613,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>5614,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>5615,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>5616,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>5617,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;</p>
<p>5618,"MAO_inhibitors : MAOI_antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism."</p>
<p>5619,"MAO_inhibitors : MAOI_antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism."</p>
<p>5620,"MAO_inhibitors : MAOI_antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism."</p>
<p>5621,"MAO_inhibitors : MAOI_antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism."</p>
<p>5622,"MAO_inhibitors : MAOI_antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism."</p>
<p>5623,"MAO_inhibitors : MAOI_antidepressants , as well as a metabolite of furazolidone , slow amphetamine metabolism."</p>
<p>5624,Antihistamines : Amphetamines may counteract the sedative effect of antihistamines .</p>
<p>5625,Antihypertensives : Amphetamines may antagonize the hypotensive effects of antihypertensives .</p>
<p>5626,"Chlorpromazine : Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines , and can be used to treat amphetamine poisoning."</p>
<p>5627,"Chlorpromazine : Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines , and can be used to treat amphetamine poisoning."</p>
<p>5628,Ethosuximide : Amphetamines may delay intestinal absorption of ethosuximide .</p>
<p>5629,"Haloperidol : Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines ."</p>
<p>5630,Lithium_carbonate : The stimulatory effects of amphetamines may be inhibited by lithium_carbonate .</p>
<p>5631,Meperidine : Amphetamines potentiate the analgesic effect of meperidine .</p>
<p>5632,"Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying_agents used in methenamine therapy."</p>
<p>5633,"Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying_agents used in methenamine therapy."</p>
<p>5634,"Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying_agents used in methenamine therapy."</p>
<p>5635,Norepinephrine : Amphetamines enhance the adrenergic effect of norepinephrine .</p>
<p>5636,Phenobarbital : Amphetamines may delay intestinal absorption of phenobarbital ;</p>
<p>5637,Phenytoin : Amphetamines may delay intestinal absorption of phenytoin ;</p>
<p>5638,"Propoxyphene : In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur."</p>
<p>5639,Veratrum_alkaloids : Amphetamines inhibit the hypotensive effect of veratrum_alkaloids .</p>
<p>5640,"Additive depressant effect when used with general anesthetics , sedatives , antianxiety_drugs , hypnotics , alcohol , and other opiate_analgesics ."</p>
<p>5641,"Additive depressant effect when used with general anesthetics , sedatives , antianxiety_drugs , hypnotics , alcohol , and other opiate_analgesics ."</p>
<p>5642,"Additive depressant effect when used with general anesthetics , sedatives , antianxiety_drugs , hypnotics , alcohol , and other opiate_analgesics ."</p>
<p>5643,"Additive depressant effect when used with general anesthetics , sedatives , antianxiety_drugs , hypnotics , alcohol , and other opiate_analgesics ."</p>
<p>5644,"Additive depressant effect when used with general anesthetics , sedatives , antianxiety_drugs , hypnotics , alcohol , and other opiate_analgesics ."</p>
<p>5645,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5646,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5647,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5648,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5649,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5650,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5651,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5652,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5653,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5654,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5655,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5656,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5657,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5658,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5659,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5660,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5661,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5662,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5663,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5664,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5665,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5666,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5667,"May interact with thyroid medication (e,g,, levothyroxine ), iodine -containing products, antacids , H2-antagonists (e,g,, famotidine , ranitidine ), and proton_pump_inhibitors (e,g,, lansoprazole , omeprazole )."</p>
<p>5668,"Caution is advised in patients receiving concomitant high-dose aspirin and carbonic_anhydrase_inhibitors , as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction."</p>
<p>5669,"Aspirin : Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations, peak plasma levels, and AUC values."</p>
<p>5670,"Aspirin : Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations, peak plasma levels, and AUC values."</p>
<p>5671,"Aspirin : Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations, peak plasma levels, and AUC values."</p>
<p>5672,"Aspirin : Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations, peak plasma levels, and AUC values."</p>
<p>5673,"Aspirin : Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations, peak plasma levels, and AUC values."</p>
<p>5674,"Aspirin : Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations, peak plasma levels, and AUC values."</p>
<p>5675,"Anticoagulants : While studies have not shown diclofenac to interact with anticoagulants_of_the_warfarin_type , caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs ."</p>
<p>5676,"Anticoagulants : While studies have not shown diclofenac to interact with anticoagulants_of_the_warfarin_type , caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs ."</p>
<p>5677,"Anticoagulants : While studies have not shown diclofenac to interact with anticoagulants_of_the_warfarin_type , caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs ."</p>
<p>5678,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs , including diclofenac , and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required."</p>
<p>5679,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs , including diclofenac , and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required."</p>
<p>5680,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs , including diclofenac , and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required."</p>
<p>5681,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs , including diclofenac , and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required."</p>
<p>5682,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs , including diclofenac , and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required."</p>
<p>5683,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs , including diclofenac , and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required."</p>
<p>5684,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs , including diclofenac , and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required."</p>
<p>5685,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs , including diclofenac , and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required."</p>
<p>5686,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs , including diclofenac , and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required."</p>
<p>5687,"Digoxin , Methotrexate , Cyclosporine : Diclofenac , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs."</p>
<p>5688,"Digoxin , Methotrexate , Cyclosporine : Diclofenac , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs."</p>
<p>5689,"Digoxin , Methotrexate , Cyclosporine : Diclofenac , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs."</p>
<p>5690,"Digoxin , Methotrexate , Cyclosporine : Diclofenac , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs."</p>
<p>5691,"Digoxin , Methotrexate , Cyclosporine : Diclofenac , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs."</p>
<p>5692,"Digoxin , Methotrexate , Cyclosporine : Diclofenac , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs."</p>
<p>5693,"Digoxin , Methotrexate , Cyclosporine : Diclofenac , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs."</p>
<p>5694,"Digoxin , Methotrexate , Cyclosporine : Diclofenac , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs."</p>
<p>5695,"Digoxin , Methotrexate , Cyclosporine : Diclofenac , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs."</p>
<p>5696,"Digoxin , Methotrexate , Cyclosporine : Diclofenac , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs."</p>
<p>5697,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.</p>
<p>5698,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.</p>
<p>5699,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.</p>
<p>5700,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.</p>
<p>5701,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.</p>
<p>5702,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.</p>
<p>5703,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs."</p>
<p>5704,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs."</p>
<p>5705,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs."</p>
<p>5706,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs."</p>
<p>5707,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs."</p>
<p>5708,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs."</p>
<p>5709,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs."</p>
<p>5710,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs."</p>
<p>5711,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs."</p>
<p>5712,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs."</p>
<p>5713,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs."</p>
<p>5714,Lithium : Diclofenac decreases lithium renal clearance and increases lithium plasma levels.</p>
<p>5715,Lithium : Diclofenac decreases lithium renal clearance and increases lithium plasma levels.</p>
<p>5716,"In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop."</p>
<p>5717,"In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop."</p>
<p>5718,Oral Hypoglycemics : Diclofenac does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic_agents .</p>
<p>5719,"There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic_agents in the presence of diclofenac that necessitated changes in the doses of such agents."</p>
<p>5720,"There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic_agents in the presence of diclofenac that necessitated changes in the doses of such agents."</p>
<p>5721,"There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic_agents in the presence of diclofenac that necessitated changes in the doses of such agents."</p>
<p>5722,"A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic_agents ."</p>
<p>5723,"A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic_agents ."</p>
<p>5724,"A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic_agents ."</p>
<p>5725,Diuretics : Diclofenac and other NSAIDs can inhibit the activity of diuretics .</p>
<p>5726,Diuretics : Diclofenac and other NSAIDs can inhibit the activity of diuretics .</p>
<p>5727,Diuretics : Diclofenac and other NSAIDs can inhibit the activity of diuretics .</p>
<p>5728,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine , gold , chloroquine , D-penicillamine , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac ."</p>
<p>5729,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine , gold , chloroquine , D-penicillamine , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac ."</p>
<p>5730,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine , gold , chloroquine , D-penicillamine , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac ."</p>
<p>5731,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine , gold , chloroquine , D-penicillamine , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac ."</p>
<p>5732,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine , gold , chloroquine , D-penicillamine , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac ."</p>
<p>5733,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine , gold , chloroquine , D-penicillamine , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac ."</p>
<p>5734,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine , gold , chloroquine , D-penicillamine , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac ."</p>
<p>5735,Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.</p>
<p>5736,Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.</p>
<p>5737,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic_acid (20% decrease in binding), tolbutamide , prednisolone (10% decrease in binding), or warfarin ."</p>
<p>5738,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic_acid (20% decrease in binding), tolbutamide , prednisolone (10% decrease in binding), or warfarin ."</p>
<p>5739,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic_acid (20% decrease in binding), tolbutamide , prednisolone (10% decrease in binding), or warfarin ."</p>
<p>5740,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic_acid (20% decrease in binding), tolbutamide , prednisolone (10% decrease in binding), or warfarin ."</p>
<p>5741,"Benzylpenicillin , ampicillin , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum."</p>
<p>5742,"Benzylpenicillin , ampicillin , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum."</p>
<p>5743,"Benzylpenicillin , ampicillin , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum."</p>
<p>5744,"Benzylpenicillin , ampicillin , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum."</p>
<p>5745,"Benzylpenicillin , ampicillin , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum."</p>
<p>5746,"Benzylpenicillin , ampicillin , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum."</p>
<p>5747,"Benzylpenicillin , ampicillin , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum."</p>
<p>5748,"Benzylpenicillin , ampicillin , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum."</p>
<p>5749,"Tetracycline , a bacteriostatic_antibiotic , may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided."</p>
<p>5750,"Tetracycline , a bacteriostatic_antibiotic , may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided."</p>
<p>5751,"Tetracycline , a bacteriostatic_antibiotic , may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided."</p>
<p>5752,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5753,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5754,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5755,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5756,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5757,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5758,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5759,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5760,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5761,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5762,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5763,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5764,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5765,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5766,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5767,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5768,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5769,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5770,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5771,"The following agents may increase certain actions or side effects of anticholinergic_drugs , amantadine  antiarrhythmic_agents of class (e,g, quinidine ), antihistamines  antipsychotic_agents (e,g, phenothiazines ), benzodiazepines ."</p>
<p>5772,Anticholinergics antagonize the effects of antiglaucoma_agents .</p>
<p>5773,"Anticholinergic_agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin ;"</p>
<p>5774,"Anticholinergic_drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide ."</p>
<p>5775,"Because antacids may interfere with the absorption of anticholinergic_agents , simultaneous use of these drugs should be avoided."</p>
<p>5776,"Neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy, including stavudine , and these patients may be at increased risk of neuropathy during VIDEX therapy (see ADVERSE REACTIONS)."</p>
<p>5777,Allopurinol : The AUC of didanosine was increased about 4-fold when allopurinol at # mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and # mL/min).</p>
<p>5778,Allopurinol : The AUC of didanosine was increased about 4-fold when allopurinol at # mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and # mL/min).</p>
<p>5779,Allopurinol : The AUC of didanosine was increased about 4-fold when allopurinol at # mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and # mL/min).</p>
<p>5780,The effects of allopurinol on didanosine pharmacokinetics in subjects with normal renal function are not known.</p>
<p>5781,Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.</p>
<p>5782,Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.</p>
<p>5783,Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.</p>
<p>5784,Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.</p>
<p>5785,Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.</p>
<p>5786,Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.</p>
<p>5787,Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.</p>
<p>5788,Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.</p>
<p>5789,Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.</p>
<p>5790,Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.</p>
<p>5791,Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.</p>
<p>5792,Antacids : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.</p>
<p>5793,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least # hours prior to dosing with VIDEX .</p>
<p>5794,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least # hours prior to dosing with VIDEX .</p>
<p>5795,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least # hours prior to dosing with VIDEX .</p>
<p>5796,Ganciclovir : Administration of VIDEX # hours prior to or concurrent with oral ganciclovir was associated with a # (114)% increase in the steady-state AUC of didanosine (n = 12).</p>
<p>5797,Ganciclovir : Administration of VIDEX # hours prior to or concurrent with oral ganciclovir was associated with a # (114)% increase in the steady-state AUC of didanosine (n = 12).</p>
<p>5798,Ganciclovir : Administration of VIDEX # hours prior to or concurrent with oral ganciclovir was associated with a # (114)% increase in the steady-state AUC of didanosine (n = 12).</p>
<p>5799,Ganciclovir : Administration of VIDEX # hours prior to or concurrent with oral ganciclovir was associated with a # (114)% increase in the steady-state AUC of didanosine (n = 12).</p>
<p>5800,Ganciclovir : Administration of VIDEX # hours prior to or concurrent with oral ganciclovir was associated with a # (114)% increase in the steady-state AUC of didanosine (n = 12).</p>
<p>5801,"A # (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered # hours prior to ganciclovir , but not when the two drugs were administered simultaneously (n = 12)."</p>
<p>5802,"A # (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered # hours prior to ganciclovir , but not when the two drugs were administered simultaneously (n = 12)."</p>
<p>5803,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5804,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5805,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5806,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5807,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5808,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5809,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5810,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5811,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5812,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5813,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5814,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5815,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5816,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5817,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5818,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5819,"Quinolone_Antibiotic s: VIDEX should be administered at least # hours after or # hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5820,"In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered # hours prior to a marketed chewable/dispersible tablet formulation of VIDEX ."</p>
<p>5821,"In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered # hours prior to a marketed chewable/dispersible tablet formulation of VIDEX ."</p>
<p>5822,The AUC of ciprofloxacin was decreased an average of 15-fold in # healthy subjects given ciprofloxacin and didanosine -placebo tablets concurrently.</p>
<p>5823,The AUC of ciprofloxacin was decreased an average of 15-fold in # healthy subjects given ciprofloxacin and didanosine -placebo tablets concurrently.</p>
<p>5824,"In a single subject given one dose of ciprofloxacin # hours after a dose of didanosine -placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed."</p>
<p>5825,"In a single subject given one dose of ciprofloxacin # hours after a dose of didanosine -placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed."</p>
<p>5826,"Plasma concentrations of quinolone_antibiotics are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5827,"Plasma concentrations of quinolone_antibiotics are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5828,"Plasma concentrations of quinolone_antibiotics are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5829,"Plasma concentrations of quinolone_antibiotics are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5830,"Plasma concentrations of quinolone_antibiotics are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5831,"Plasma concentrations of quinolone_antibiotics are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5832,"Plasma concentrations of quinolone_antibiotics are decreased when administered with antacids containing magnesium , calcium , or aluminum ."</p>
<p>5833,The optimal dosing interval for coadministration with VIDEX should be determined by consulting the appropriate quinolone package insert.</p>
<p>5834,Interactions with Other Antiretroviral_Drugs : Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX .</p>
<p>5835,Interactions with Other Antiretroviral_Drugs : Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX .</p>
<p>5836,Interactions with Other Antiretroviral_Drugs : Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX .</p>
<p>5837,"To avoid this interaction, delavirdine or indinavir should be given # hour prior to dosing with VIDEX ."</p>
<p>5838,"To avoid this interaction, delavirdine or indinavir should be given # hour prior to dosing with VIDEX ."</p>
<p>5839,"To avoid this interaction, delavirdine or indinavir should be given # hour prior to dosing with VIDEX ."</p>
<p>5840,The pharmacokinetics of nelfinavir are not altered to a clinically significant degree when it is administered with a light meal # hour after VIDEX .</p>
<p>5841,Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen -containing oral contraceptives .</p>
<p>5842,"Antidiabetic_drug requirements (i,e,, insulin ) may be altered."</p>
<p>5843,"conversely, diethylpropion may interfere with antihypertensive_drugs (i,e,, guanethidine , a-methyldopa )."</p>
<p>5844,"conversely, diethylpropion may interfere with antihypertensive_drugs (i,e,, guanethidine , a-methyldopa )."</p>
<p>5845,"conversely, diethylpropion may interfere with antihypertensive_drugs (i,e,, guanethidine , a-methyldopa )."</p>
<p>5846,Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion .</p>
<p>5847,"May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids )."</p>
<p>5848,"May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids )."</p>
<p>5849,"May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids )."</p>
<p>5850,"May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids )."</p>
<p>5851,"May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids )."</p>
<p>5852,"May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids )."</p>
<p>5853,"May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids )."</p>
<p>5854,"May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids )."</p>
<p>5855,"May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids )."</p>
<p>5856,"May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids )."</p>
<p>5857,"May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids )."</p>
<p>5858,"Oral Anticoagulants : In some normal volunteers, the concomitant administration of diflunisal and warfarin , acenocoumarol , or phenprocoumon resulted in prolongation of prothrombin time."</p>
<p>5859,"Oral Anticoagulants : In some normal volunteers, the concomitant administration of diflunisal and warfarin , acenocoumarol , or phenprocoumon resulted in prolongation of prothrombin time."</p>
<p>5860,"Oral Anticoagulants : In some normal volunteers, the concomitant administration of diflunisal and warfarin , acenocoumarol , or phenprocoumon resulted in prolongation of prothrombin time."</p>
<p>5861,"Oral Anticoagulants : In some normal volunteers, the concomitant administration of diflunisal and warfarin , acenocoumarol , or phenprocoumon resulted in prolongation of prothrombin time."</p>
<p>5862,This may occur because diflunisal competitively displaces coumarins from protein binding sites.</p>
<p>5863,"Accordingly, when diflunisal is administered with oral anticoagulants , the prothrombin time should be closely monitored during and for several days after concomitant drug administration."</p>
<p>5864,"Tolbutamide : In diabetic patients receiving diflunisal and tolbutamide , no significant effects were seen on tolbutamide plasma levels or fasting blood glucose."</p>
<p>5865,"Tolbutamide : In diabetic patients receiving diflunisal and tolbutamide , no significant effects were seen on tolbutamide plasma levels or fasting blood glucose."</p>
<p>5866,"Hydrochlorothiazide : In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide ."</p>
<p>5867,"Hydrochlorothiazide : In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide ."</p>
<p>5868,"Hydrochlorothiazide : In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide ."</p>
<p>5869,Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide .</p>
<p>5870,"Furosemide : In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide ."</p>
<p>5871,"Furosemide : In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide ."</p>
<p>5872,"Furosemide : In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide ."</p>
<p>5873,Diflunisal decreased the hyperuricemic effect of furosemide .</p>
<p>5874,Antacids : Concomitant administration of antacids may reduce plasma levels of diflunisal .</p>
<p>5875,Antacids : Concomitant administration of antacids may reduce plasma levels of diflunisal .</p>
<p>5876,"Acetaminophen : In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen ."</p>
<p>5877,"Acetaminophen : In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen ."</p>
<p>5878,"Acetaminophen : In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen ."</p>
<p>5879,Acetaminophen had no effect on plasma levels of diflunisal .</p>
<p>5880,"Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients."</p>
<p>5881,"Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients."</p>
<p>5882,"Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately # times the recommended maximum human therapeutic dose of each (40 to # mg/kg/day of diflunisal / acetaminophen ) resulted in greater gastrointestinal toxicity than when either drug was administered alone."</p>
<p>5883,"Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately # times the recommended maximum human therapeutic dose of each (40 to # mg/kg/day of diflunisal / acetaminophen ) resulted in greater gastrointestinal toxicity than when either drug was administered alone."</p>
<p>5884,"Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately # times the recommended maximum human therapeutic dose of each (40 to # mg/kg/day of diflunisal / acetaminophen ) resulted in greater gastrointestinal toxicity than when either drug was administered alone."</p>
<p>5885,Methotrexate : Caution should be used if diflunisal is administered concomitantly with methotrexate .</p>
<p>5886,Methotrexate : Caution should be used if diflunisal is administered concomitantly with methotrexate .</p>
<p>5887,Nonsteroidal_anti-inflammatory_drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.</p>
<p>5888,"Cyclosporine : Administration of nonsteroidal_anti-inflammatory_drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine -induced toxicity, possibly due to decreased synthesis of renal prostacyclin."</p>
<p>5889,"Cyclosporine : Administration of nonsteroidal_anti-inflammatory_drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine -induced toxicity, possibly due to decreased synthesis of renal prostacyclin."</p>
<p>5890,"Cyclosporine : Administration of nonsteroidal_anti-inflammatory_drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine -induced toxicity, possibly due to decreased synthesis of renal prostacyclin."</p>
<p>5891,"NSAIDs should be used with caution in patients taking cyclosporine , and renal function should be carefully monitored."</p>
<p>5892,Nonsteroidal_Anti-Inflammatory_Drugs : The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin .</p>
<p>5893,Nonsteroidal_Anti-Inflammatory_Drugs : The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin .</p>
<p>5894,In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.</p>
<p>5895,"Therefore, indomethacin and diflunisal should not be used concomitantly."</p>
<p>5896,"The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy."</p>
<p>5897,"Aspirin : In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly."</p>
<p>5898,"Aspirin : In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly."</p>
<p>5899,"Aspirin : In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly."</p>
<p>5900,"Aspirin : In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly."</p>
<p>5901,Sulindac : The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.</p>
<p>5902,"Naproxen : The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite."</p>
<p>5903,"Naproxen : The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite."</p>
<p>5904,"Naproxen : The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite."</p>
<p>5905,Naproxen had no effect on plasma levels of diflunisal .</p>
<p>5906,Potassium-depleting_diuretics are a major contributing factor to digitalis toxicity.</p>
<p>5907,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5908,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5909,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5910,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5911,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5912,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5913,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5914,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5915,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5916,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5917,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5918,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5919,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5920,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5921,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5922,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5923,"Quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , alprazolam , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result."</p>
<p>5924,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5925,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5926,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5927,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5928,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5929,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5930,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5931,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5932,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5933,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5934,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5935,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5936,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5937,"Erythromycin and clarithromycin (and possibly other macrolide_antibiotics ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result."</p>
<p>5938,"Propantheline and diphenoxylate , by decreasing gut motility, may increase digoxin absorption."</p>
<p>5939,"Propantheline and diphenoxylate , by decreasing gut motility, may increase digoxin absorption."</p>
<p>5940,"Propantheline and diphenoxylate , by decreasing gut motility, may increase digoxin absorption."</p>
<p>5941,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5942,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5943,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5944,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5945,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5946,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5947,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5948,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5949,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5950,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5951,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5952,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5953,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5954,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5955,"Antacids , kaolin -pectin, sulfasalazine , neomycin , cholestyramine , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations."</p>
<p>5956,"Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin ."</p>
<p>5957,"Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin ."</p>
<p>5958,"There have been inconsistent reports regarding the effects of other drugs (e,g,, quinine , penicillamine ) on serum digoxin concentration."</p>
<p>5959,"There have been inconsistent reports regarding the effects of other drugs (e,g,, quinine , penicillamine ) on serum digoxin concentration."</p>
<p>5960,"Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin ."</p>
<p>5961,Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.</p>
<p>5962,"Vasoconstrictors : D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP should not be used with peripheral_vasoconstrictors because the combination may cause synergistic elevation of blood pressure."</p>
<p>5963,"Vasoconstrictors : D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP should not be used with peripheral_vasoconstrictors because the combination may cause synergistic elevation of blood pressure."</p>
<p>5964,"Vasoconstrictors : D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP should not be used with peripheral_vasoconstrictors because the combination may cause synergistic elevation of blood pressure."</p>
<p>5965,"Vasoconstrictors : D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP should not be used with peripheral_vasoconstrictors because the combination may cause synergistic elevation of blood pressure."</p>
<p>5966,"Sumatriptan : Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP."</p>
<p>5967,"Sumatriptan : Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP."</p>
<p>5968,"Sumatriptan and D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP should not be taken within # hours of each other,."</p>
<p>5969,"Sumatriptan and D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP should not be taken within # hours of each other,."</p>
<p>5970,"Beta_Blockers : Although the results of a clinical study did not indicate a safe problem associated with the administration of D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP to subjects already receiving propranolol , there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine."</p>
<p>5971,"Beta_Blockers : Although the results of a clinical study did not indicate a safe problem associated with the administration of D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP to subjects already receiving propranolol , there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine."</p>
<p>5972,"Beta_Blockers : Although the results of a clinical study did not indicate a safe problem associated with the administration of D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP to subjects already receiving propranolol , there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine."</p>
<p>5973,"Beta_Blockers : Although the results of a clinical study did not indicate a safe problem associated with the administration of D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP to subjects already receiving propranolol , there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine."</p>
<p>5974,"Beta_Blockers : Although the results of a clinical study did not indicate a safe problem associated with the administration of D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP to subjects already receiving propranolol , there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine."</p>
<p>5975,"Beta_Blockers : Although the results of a clinical study did not indicate a safe problem associated with the administration of D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP to subjects already receiving propranolol , there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine."</p>
<p>5976,"Beta_Blockers : Although the results of a clinical study did not indicate a safe problem associated with the administration of D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP to subjects already receiving propranolol , there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine."</p>
<p>5977,"Nicotine : Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy."</p>
<p>5978,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5979,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5980,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5981,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5982,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5983,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5984,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5985,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5986,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5987,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5988,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5989,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5990,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5991,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5992,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5993,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5994,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5995,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5996,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5997,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5998,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
<p>5999,"Macrolide_Antibiotics (e, g, erythromycin and troleandomycin ): Agents of the ergot_alkaloid_class , of which D,H,E,_45  ( dihydroergotamine_mesylate ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide_class , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction."</p>
